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This project utilized synthesis and in vitro assays to generate antagonist SARs at 
various nAChR subtypes.  Alkylation of the pyridino nitrogen of the nicotine 
molecule afforded subtype specific antagonists at a4ß2* nAChR subtypes and 
nAChR subtypes that mediate nicotine-evoked dopamine release.  Using this data, a 
series of mono-azaaromatic quaternary salts were produced and evaluated in binding 
and functional assays for a4ß2* and a7* nAChR subtypes and nAChR subtypes that 
mediate nicotine-evoked dopamine release.  Additionally, bis-azaaromatic quaternary 
salts were synthesized and evaluated in the same assays.  Two potent lead compounds 
were identified.  N-n-dodecylnicotinium iodide (NDDNI) was found to be very potent 
at both a4ß2* nAChR subtypes and nAChR subtypes that mediate nicotine-evoked 
dopamine release.  And the most promising candidate was N-N’-bis-
dodecylpicolinium dibromide (bDDPiB), which was selective for the nAChR 
subtypes that mediate nicotine-evoked dopamine release (IC50 = 9 nM). 
 
Additionally, using the data from the SARs, predictive computer models were 
generated to assist in future compound assessment without in vitro assays.  Three 
self-organizing map (SOMs) models were generated from three different sets of 
compounds.  The groups consisted of the mono-substituted compounds, the bis-
substituted compounds, and both sets combined.  The models were able to 
successfully "bin" the test set of compounds after developing a model from a similar 
set of training compounds.  Additionally, using genetic functional activity (GFA) 
algorithms an evolutionary approach to generating predictive model equations was 
applied to the compounds.  Three separate equations were generated in order to form 
a predictive method for evaluating affinities at the α4β2* receptor subtype.   
 
In addition to the modeling and SAR work of the quaternary ammonium compounds, 
novel synthetic methods were also employed to develop enantiomerically pure 
nicotine analogs.  Efficient enantioselective syntheses of (S)- and R-(+)-nornicotine, 
(S)-and R-(+)-anabasine, and (S)-and R-(+)-anatabine have been developed, affording 
isomers in high enantiomeric excess. 
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Chapter 1: Overview and Research Plan 
 
1.1. Overview 
In order to bring a drug to market, it first must go through two major areas of research: 
drug discovery and drug development.  Drug discovery incorporates both chemical and 
biological methodologies in order to identify a compound or a group of compounds, 
which exhibit favorable in vitro activity in specific pharmacological assays.  After the 
initial identification of a lead compound, the development process then incorporates 
formulation studies and human clinical trials to assess the bioavailability, stability, and 
safety of the drug candidate (Figure 1.1). 
 
Within the discovery process, there are several important issues to assess.  The first is the 
determination of an active compound.  Once a structure is determined to be bioactive in 
in vitro screens, a series of structurally similar compounds are synthesized and evaluated 
and structure-activity relationships (SAR) are defined in an attempt to optimize biological 
activity, since the initial compound “hit” is rarely the most efficacious.  The synthetic 
compounds are prioritized according to their bioactivity, and a lead candidate is then 
identified.  The data obtained can be compiled to form a library of information or an SAR 
database relating the structure of the compounds to their bioactivities.  From this 
information, computer-assisted models of the compound’s interaction with the receptor 
may be developed. 
 
Depending on the system being evaluated, a variety of techniques may be used to 
generate computer models for assessing biological activity.  Those compounds that 
2  
interact with a biological target that previously has been crystallized, e.g. an enzyme or 
protein molecule, can be modeled in the active site using in silico methods involving 
molecular modeling and docking to the crystallized target.  For those biological targets 
that have not been identified crystallographically, e.g. receptors, several methodologies 
can be utilized in order to achieve a three-dimensional model of the molecular 
recognition site from SAR data.  Pharmacophore models (three-dimensional 
approximation of the active binding site) can be generated from large numbers of 
compounds and their activities predicted using comparative molecular field analysis 
(CoMFA).  Additionally, mathematical models, genetic functional approximation 
algorithms (GFAs), and self-organizing maps (SOMs) can be used as methodologies to 
predict activities or trends at a given receptor or enzyme active site. 
 
Further drug development includes the pre-clinical processes associated with toxicity 
screening, formulation, and characterization of the absorption, distribution, metabolism, 
and elimination (ADME) properties of the potential drug molecule.  After full 
characterization of the compound, as well as determination of dosing parameters, drug 
candidates enter human clinical studies.  In order to obtain approval for clinical studies, 
an Investigational New Drug application (IND) must be filed.  This document contains all 
pertinent data to the drug’s safety and efficacy as determined in the studies mentioned 
above.  If accepted, trials in healthy human volunteers (Phase I) may begin followed by 
patient volunteers (Phase II-IV).  After all information on safety, efficacy, and dosage 
regimes is collected, drug approval is sought from the Food and Drug Administration 
(FDA) through a New Drug Application (NDA). 
3  
 
 
In addition to their therapeutic uses, the development of compounds may also be useful 
as diagnostic and pharmacological tools in the analysis of perspective drug candidates.  In 
in vitro binding assays, a test ligand that interacts with the receptor binding site is used as 
a measurement tool in order to assess the relative affinities of the drug candidates for the 
target binding site.  These ligands must be selective and potent at their site of action in 
order to be used as diagnostic tools. 
 
An objective of this research is to involve aspects of the drug discovery process to aid in 
identifying potential drug candidates for therapeutic use or as analytical tools to help 
determine biological functions. 
4  
 
Figure 1.1 Components of the Drug Discovery and Drug Development Process 
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1.2. Molecular Target and Lead Identification 
Nicotinic acetylcholine receptors (nAChRs) belong to a ligand-gated ion channel 
superfamily of receptors located in both the peripheral and central nervous systems.  
Neuronal nAChRs are composed of five subunits that assemble in both heterologous  
(α- and β-subunits) and homologous forms (α-subunits).  Several different nAChR 
combinations, or subtypes, have been identified, with the α4β2* being the most studied 
heterologous subtype and the α7* being the most studied homologous subtype.  Since 
definitive subunit combinations have yet to be determined, an asterisk (*) is used 
following subtype nomenclature to indicate the reported subunit make-up.  In addition to 
the above receptor subtypes, which are thought to produce a pharmacological effect 
without other nAChR subtypes, there are other receptor populations where multiple 
subtypes contribute to one pharmacological response.  While these heterologous subunit 
combinations have not yet been fully assigned, they are referred to by their biological 
function that they initiate (e.g. the nicotinic receptor that facilitates dopamine (DA) 
release.  These subtypes, which have recently begun to be identified as the α4β2*, 
α4α5β2*, α6β2β3*, and α6α4β2β3*, all contributing to nicotine-evoked DA release.  
Research in the field of nAChRs has focused mainly on the development of receptor 
agonists, and to a lesser extent antagonists, that act at specific nicotinic receptor subtypes 
in order to elucidate function, as well as to serve as potential drug therapies in disease 
states such as Alzheimer's and Parkinson's disease, schizophrenia, pain management, and 
nicotine addiction.   
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Previous research in the Crooks and Dwoskin laboratories has focused on the 
development of ligands, specifically antagonists that may be more efficacious and 
specific than the more established “classical” antagonists (e.g. DHßE).  In this respect, 
alkylation of the pyridyl nitrogen of the nicotine (NIC) molecule afforded two lead 
compounds, N-octylnicotinium iodide (NONI), an antagonist at the nAChR subtypes that 
facilitate DA release, and N-decylnicotinium iodide (NDNI), an antagonist at the α4β2* 
receptor subtype (Crooks et al. 1995; Dwoskin et al. 1999).  Thus, quaternary ammonium 
compounds of this type were considered as useful lead candidates for exploring the 
complex biological activities at the molecular level through SAR studies at individual 
nAChR receptor subtypes. 
 
1.3. Hypothesis and Specific Aims of Research 
The nicotinic receptor has been implicated in many disease states, including Alzheimer’s 
and Parkinson’s disease and schizophrenia.  With the diverse subtype architecture of the 
nicotinic receptor, novel selective ligands are needed for both furthering research and use 
as treatments for diseases.  Current research has focused in the development of agonists 
for these purposes.  However, the development of novel antagonists at various nAChR 
subtypes should also give insight into the pharmacology of these receptors.  This research 
will utilize synthesis and in vitro assays to generate antagonist SARs at various nAChR 
subtypes.  These SARs will be used to develop potent and selective antagonists at 
individual nicotinic receptor subtypes.  Additionally, using the data from the SARs, 
predictive computer models will be generated to assist in future compound assessment 
without in vitro assays. 
7  
 
Specific Aim 1 
SARs directed at alteration of the nicotine molecule will result in optimization of the 
potency, activity, and nicotinic receptor subtype selectivity of these novel classes of 
nicotinic receptor ligands.  Alterations will include changing the pyridino head group, 
e.g. pyridinium and picolinium groups, increasing the carbon chain length, and creating 
both mono- and bis-substituted molecules. 
 
Specific Aim 2 
Utilizing the SARs developed in specific aim 1, computer generated models can be 
developed for screening of compounds at α4β2* receptor subtypes.  Modeling techniques 
will include GFA and SOM model generation. 
 
Specific Aim 3 
The synthesis of quaternary ammonium salts outlined in specific aim 1, which utilize 
commercially available pyridine moieties, e.g. pyridine and S-(-)-nicotine, are useful for 
discovering new nAChR antagonists.  In addition to those commercially available 
compounds, new potential nicotinic receptor ligands head groups will be developed.  
Novel enantioselective synthetic procedures of nornicotine, anabasine, and anatabine will 
be developed and optimized. 
 
Copyright © Joshua Thomas Longen Ayers 2006 
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Chapter 2: Background 
 
2.1. Molecular Pharmacology 
Nicotinic acetylcholine receptors (nAChRs) are members of the ligand-gated ion channel 
superfamily of receptors, activated by endogenous acetylcholine (ACh), and are widely 
distributed throughout the body.  Other members of this superfamily include, gamma-
aminobutyric acid (GABAA), serotonin (5-HT), glycine, and several glutamate 
 receptors (e.g. N-methyl-D-aspartate (NMDA), α-amino-3-hydroxy-5-methyl-4-
isoxazolepropionate (AMPA), and kinate).  Members of this family of receptors all share 
a pair of disulphide-bonded cystines in their N-terminus extracellular halves that are 
separated by 13 residues (Kao and Karlin 1986; Karlin and Akabas 1995; Ortells and 
Lunt 1995).  Nicotinic receptors modulate a wide range of physiological areas, including 
the central and peripheral nervous systems and the function of the cardiovascular, 
immune, and neuromuscular systems and are located at the neuromuscular junction in 
autonomic ganglia, and in the central nervous system (CNS) (Sargent 1993; Lloyd and 
Williams 2000).  nAChRs are preferentially located presynaptically, where they play a 
role in neurotransmitter release (McGehee and Role 1995; Wonnacott 1997).  
Postsynaptic nAChRs, however, have also been identified in brain regions, although their 
function and importance is still being investigated (Colquhoun and Patrick 1997). 
 
2.2. Structure of the nAChR 
It is generally accepted that nAChRs are membrane-bound pentameric complexes 
composed of individual protein subunits.  When activated by interaction with 
acetylcholine or other appropriate agonists, the receptor allows passage of cations, e.g. 
 9
Na+, Ca2+, and K+, through the central pore.  These complexes have an approximate 
molecular weight of 300 kDa.  The protein subunits assemble with a 5-fold axis of 
symmetry and form the ion conduction pathway of the receptor (Karlin and Akabas 1995; 
Schmitt 2000) (Figure 2.1A).  Each subunit is composed of a large N-terminus loop 
followed by four transmembrane spanning hydrophobic regions, M1-M4 (Claudio  et al. 
1983; Leonard et al. 1988).  The portions of the M1 and the complete segments of the M3 
and M4 transmembrane regions interact with the lipid bilayer, separating the pore from 
the hydrophobic membrane (Karlin 2002; Miyazawa et al. 2003).  M2 has a high degree 
of segregated hydrophilic and hydrophobic portions of the amino acid helical cylinder 
and forms the inner portion of the ion channel with some sections of the M1 (Leonard et 
al. 1988; Changeux et al. 1998; Grutter and Changeux 2001; Karlin 2002; Miyazawa et 
al. 2003).  Additionally, alterations to the amino acid sequence of the M2 portion affect 
the ion selectivity of the channel (Imoto et al. 1988; Adcock et al. 1998) (Figure 2.1B). 
 
Smit et al. (2001) provided the high-resolution structure of the Acetylcholine Binding 
Protein (AChBP), which provided a number of insights into the structure and function of 
nAChRs.  AChBP is a soluble protein synthesized in snail neuronal glial cells and 
modulates synaptic transmissions (Brejc et al. 2001; Smit et al. 2001).  This protein binds 
many of the same ligands as the peripheral and neuronal nAChRs, including nicotine, 
epibatidine, (+)-tubocurarine, and α-bungarotoxin.  The affinities for these ligands 
closely resemble those found in the α7* subtype, though with higher overall affinities.  
This similarity can be attributed in part to the AChBP’s similar amino acid residues and a 
 10 
significant sequence alignment (20 - 24%, α7 ~ 24%) with the extracellular portions of 
the α subunits (Grutter and Changeux 2001; Karlin 2002; Smit et al. 2003). 
 
As stated above, several of the nAChR subtypes have a conserved 13 residue Cys-loop at 
the N-terminus.  This loop is present in the AChBP; it is only 12 amino acid residues and 
is not conserved.  The nAChR subunits are typically hydrophobic residues that make up 
the loop, while the AChBP’s subunits are mostly hydrophilic (Karlin 2002; Smit et al. 
2003).  It has been proposed that differences in the 13 amino acid sequence of the Cys-
loop are because nAChR subtypes are membrane bound and interacting with the 
transmembrane domain of the receptor.  The AChBP is not membrane bound, therefore, it 
would not need to have the conserved residues in order to function (Karlin 2002; Smit et 
al. 2003).  The AChBP also provided insight into the binding site of the nAChR.  
Examination of the peripheral nAChR ACh-binding site by mutagenesis and 
photoaffinity labeling studies identified the residues involved in ACh-binding (Corringer 
et al. 2000).  When compared to the peripheral nAChR subtype, the AChBP has high 
conservation of residues that line the ACh-binding site (Smit et al. 2001; Karlin 2002).  It 
was originally thought that the position of the binding site was contained within the α-
subunit within the ion channel (Miyazawa et al. 1999).  The binding site of the AChBP, 
however, was found to be at the outside of the complex approximately midway in 
between the top and bottom of the receptor.  Additionally, access to receptor binding site 
was found to be from the outside not through the ion channel (Changeux and Edelstein 
2001; Karlin 2002).  Studies of the AChBP binding site also demonstrated that the site 
was located at the interface of two subunits.  The same binding phenomenon was 
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determined for peripheral and neuronal nAChR subtypes (Corringer et al. 2000).  Luetje 
and Patrick (1991) demonstrated that both the α- and β-subunits are important in agonist, 
as well as antagonist, sensitivity to nAChRs.  The heteropentamer’s interfacial binding 
site was split into two components, the principal (α-subunit) and the complementary (the 
neighboring subunit, e.g. β-subunits in the CNS and γ/δ in the periphery).  
Homopentamer’s binding sites are also split into the principle and complementary 
components but both are contributed by the α-subunits.  The principal component is 
composed of three loops, A (Tyr93, α1-numbering), B (Trp149), and C (Tyr190, Cys 
192, Cys 193, and Tyr 198).  The complementary component is also composed of three 
loops, D (Trp55 and Glu57, γ-numbering), E (Leu109, Tyr111, Tyr117, and Leu119), and 
F (Asp 174 and Glu176) (Smit et al. 2003; Grutter et al. 2004).  Tyr93 (methyl groups), 
Trp149 (ammonium ion), and Loop C (ester moiety) all interact with the binding of ACh 
(Cohen et al. 1991; Zhong et al. 1998; Grutter et al. 2000).  Additionally, Sine et al. 
(2002) have reported that the AChBP binding of HEPES has been crystallized and the 
charged ammonium group was found to interact with the Trp143 (Trp149 in the 
peripheral nAChR) residue, confirming the calculations of Zhong et al. (1998).  Docking 
experiments using models of the extracellular domains of nAChR subtypes based on the 
AChBP structure have been performed with success (Zhong et al. 1998; Fruchart-
Gaillard et al. 2002; Le Novere et al. 2002; Schapira et al. 2002).  The use of such 
experiments may lead to increased understanding of the nAChR; however, without 
crystallized structures of each individual subtype, data collected will not be definitive. 
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2.3. NAChR Subunit Nomenclature and Composition 
Nicotinic receptors have been characterized into two different classes, peripheral and 
neuronal.  The peripheral muscle-type nicotinic receptor has been extensively 
characterized due to the abundance and reproducibility of the receptor.  When various 
toxins were found to bind to the acetylcholine binding site of the muscle nicotinic 
receptor, radiolabeled forms of these toxins were utilized to identify, quantitate, and 
purify these receptors.  From these studies, the major binding subunit of the nicotinic 
receptor has become known as the α subunit.  This subunit is identified by two adjacent 
cysteine residues (residues 192 and 193) (Figure 2.1A), as well as a highly conserved 
binding domain possessing aromatic amino acids involved in π-interactions (Grutter and 
Changeux 2001; Sharpless and Wonnacott 2001).  From the information gathered using 
these criteria, ten such subunits have been identified, α1-α10, in various peripheral and 
central nervous systems (Sargent 1993; Elgoyhen et al. 2001).   
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Figure 2.1 Subunit designation and composition 
Reprinted from Brain Res Bull, 57(2), Tassonyi E. et al., The role of nicotinic acetylcholine receptors 
in the mechanisms of anesthesia, 133-150, Copyright (2002), with permission from Elsevier 
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The α subunit has been found in combination with other subunits, β , γ, ε, and δ, in the 
periphery.  These other subunits were initially identified as structural subunits.  Similarly, 
α subunits in the central nervous system were found with subunits that lacked the 
disulfide bridge.  These non-alpha or β  subunits have been identified as β1-β4 for 
heterologolously expressed neuronal receptors (Sargent 1993).  Additionally, 
homologolously expressed neuronal receptors that only contain the α subunit have also 
been discovered.  The various subunits found have been further organized into four 
subfamilies, I-IV.  Subfamilies I and II contain the homologously expressed subunits, α9 
and α10 (subfamily I) and α7 and α8 (subfamily II).  The peripheral muscle-type 
receptor subunits (α1, β1, γ, ε, and δ) compose subfamily IV.  Finally the largest of the 
subfamilies, subfamily III (α2-α6 and β2-β4), has been further subdivided into three 
tribes.  Tribe 1 contains the binding subunits, α2, α3, α4, and α6.  The β  subunits, β2 and 
β4, make up tribe 2.  Tribe 3 is composed of α5 and β3 (Corringer et al. 2000). 
 
Skeletal muscle nicotinic receptors were found to have a subunit composition of 
(α1)2:β1:γ :δ or (α1)2:β1:ε:δ depending on the age of the receptor subtype (Karlin and 
Akabas 1995).  The ε subunit replaces the γ subunit in adult mammalian muscle 
receptors.  The pentameric structure of this subtype is α1:γ :α1:δ :β1 or α1:ε:α1:δ:β1.  
Additionally, contrary to the initial findings of the ACh binding site, the α1, γ or ε, and δ 
all contributing to the binding of acetylcholine, with the majority of the binding sites 
located in the α1 subunit (Adcock et al. 1998) (Figure 2.1C). 
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As stated above, CNS nicotinic receptor subunits tend to associate in two modes, e.g. 
heterologously and homologously.  However, in contrast to the significant amount of 
information on the muscle-type receptors, the subunit make-up and stoichiometries of the 
neuronal nAChRs are not as well characterized.  Members of subfamilies I and IV and 
the α8 subunit (subfamily II) are not expressed in the mammalian brain (Corringer et al. 
2000; Elgoyhen et al. 2001).  A number of researchers have isolated cDNA or gene 
clones of several α subunits, α2, α3, α4, α5, α6, and α7, as well as three β  subunits, β2, 
β3, and β4 (Boulter et al. 1987; Goldman et al. 1987; Deneris et al. 1988; Wada et al. 
1988; Deneris et al. 1989; Boulter et al. 1990; Seguela et al. 1993).  Subunit mRNA for 
different α and β  subunits have been identified in various overlapping brain regions, 
suggesting subunit complexity (Wilkens 2001).  The binding site of the heterologously 
expressed nAChR subtypes is formed from both tribe 1 (α2, α3, α4, and α6) and tribe 2 
(β2 and β4).  Additionally, the function of the receptors requires that at least one subunit 
of α and one of β  be present.  Tribe 3 subunits (α5 and β3) have also been proposed to 
exist in such multi α or β  complexes as modulators of the other paired subunits (Lin and 
Meyer 1998; Girod et al. 1999) (Figure 2.1C).  Therefore, the subunit composition of the 
pentameric system is two binding site pairs and a fifth subunit from tribes 2 or 3 (Luetje 
2004). 
 
Homologously expressed receptor subtypes demonstrated a five α subunit binding site 
structure (suggesting a pentameric structure), each of which may exhibit different 
affinities for nicotinic ligands (Palma et al. 1996; Orr-Urtreger et al. 1997; Rakhilin et al. 
1999).  Only the α7 subunit from the homomeric subfamily II exists in the CNS.  
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Therefore, the only homologously expressed subtype is often referred to as the α7* 
nAChR subtype. 
 
2.4. nAChR Subtype Formation 
It should be noted that before there is any discussion about subunit assembly, there is still 
much to be learned about the composition of naturally expressed nAChR subtypes.  
Although many researchers have presented compelling evidence towards a particular 
subtype combination, other more complex assemblies may exist in vivo, and therefore an 
asterisk (*) follows native subtypes that are putatively assigned, after the convention 
adopted by Lukas et al. (Lukas et al. 1999). 
 
Heterologously expressed nAChR Subtypes 
Affinity labeling, immunoprecipitation, [3H]-nicotine binding, in situ hybridization, and 
constitutive gene knockout studies all demonstrate that the α4β2* receptor subtype is the 
predominant neuronal nicotinic receptor for which nicotine has high affinity (Clarke et al. 
1985; Marks et al. 1986; Whiting et al. 1987; Wada et al. 1989; Flores et al. 1992; 
Picciotto et al. 1998; Zoli et al. 1998).  Xenopus oocytes express α4β2 receptors with a 
stoichiometry of (α4)2(β2)3, with the presumed order being α4:β2:α4:β2:β2 (Anand et al. 
1991; Cooper et al. 1991).  Two identical agonist binding sites exist at the α4 and β2 
subunit interfaces.  It has also been proposed that an α5 subunit may be associated with 
some populations of α4β2* receptors (Conroy et al. 1992; Sharpless and Wonnacott 
2001).  α4β2* nAChR have been associated with anxiety, depression, pain, cognition, 
and neurodegeneration (Lloyd and Williams 2000).  
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Another form of heterologously expressed nAChR subtype is the nicotinic receptors that 
mediate NIC-evoked DA release.  Although not as prevalent in brain tissue as α4β2* 
subtypes (Schulz et al. 1991), these subunit assemblies are very important in regulation 
of dopamine release, as determined from antagonist studies involving several known 
compounds that interact at the nAChR subtype (Schulz and Zigmond 1989; Grady et al. 
1992; Crooks et al. 1995; Cartier et al. 1996).  The existence of DA release facilitating 
nAChR subtypes is further supported by autoradiography studies, where a potent, non-
specific agonist, [3H](+)-epibatidine, is proposed to bind to areas of the brain containing 
α4β2* nAChR subtypes as well as a second receptor class that were also marked by  
[125I]neuronal bungarotoxin, a sensitive ligand to the nAChR subtype facilitating DA 
release (Holladay et al. 1997).  Although, initially defined as one subtype, α3β2*, the 
exact assignment of the subunit composition of these DA releasing nAChR subtypes was 
uncertain for many years.  mRNA of several nAChR subunits were shown to be present 
in areas of the brain associated with dopamine release, including α4, α5, α6, α7, β3, and 
β4 subunits located in the substantia nigra, which projects to the striatum, a known area 
involved in dopamine release (Deneris et al. 1989; Wada et al. 1989; Wonnacott 1997; 
Charpantier et al. 1998).  Additionally, mRNA of the modulatory subunits α6 and β3 had 
high expression levels in the substantia nigra (Deneris et al. 1989; Goldner et al. 1997; 
Charpantier et al. 1998).  Studies involving α5 subunits (closely related structurally to β 
subunits) revealed that the replacement of the non-binding β4 subunit with an α5 subunit 
leads to a change in the pore Ca2+ permeabilities and desensitization rates (Wang et al. 
1996; Gerzanich et al. 1998) (Figure 2.1C).  Moreover, increased agonist potencies were 
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observed when incorporating α5 into the oocyte α3β2 subunit assembly to yield a subunit 
composition of α3:β2:α5:β2:α3 (Gerzanich et al. 1998).  These findings generated 
considerable debate as to the exact subunit composition of nAChR subtypes mediating 
NIC-evoked DA release (Klink et al. 2001; Azam et al. 2002; Champtiaux et al. 2002; 
Whiteaker et al. 2002; Zoli et al. 2002), and there remained a large focus on elucidating 
the specific nAChR subtypes responsible for DA release.  The discovery and use of the 
α-conotoxins (α-ctx), particularly α-ctx MII, has greatly increased understanding of this 
receptor class.  Two receptor classes, α-ctx MII sensitive and α-ctx MII resistant, have 
been determined using α-ctx MII.  The α-ctx MII sensitive receptors were identified as 
an α3β2* subtype due to α-ctx MII sensitivity for oocytes expressing the α3β2 subtype.  
However, α3 knockout mice studies did not eliminate [125I]α-ctx MII binding in the brain 
(Whiteaker et al. 2002).  Further studies found that deletion of α6 and β3 subunits led to 
a loss of [125I]α-ctx MII binding (Champtiaux et al. 2003; Cui et al. 2003).  α6 
containing receptors were found to be sensitive to α-ctx MII, neuronal bungarotoxin, and 
α-ctx PnIa, all reported α3β2* subtype antagonists (Kuryatov et al. 2000; Dowell et al. 
2003; Everhart et al. 2003).  In addition to the α6 subunit investigations, knockout mice 
have been used to determine which individual subunits are responsible for functional 
receptor subtypes.  Loss of function was demonstrated for α4-, α5-, α6-, β2-, and β3-null 
mutant mice, implicating their role modulating NIC-evoked DA release (Grady et al. 
2001; Champtiaux et al. 2003; Cui et al. 2003; Salminen et al. 2004).  Salminen et al. 
(2004) also determined that β4- and α7-null mutant mice have no loss of receptor 
function.  By coupling the knockout mice data with the α-ctx MII data, Luetje (2004) has 
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identified four distinct DA releasing subtypes: α-ctx MII sensitive subtypes, α6β2β3 and 
α6α4β2β3, where α6 and α4 form with the β2 subunit to form the binding sites and α-
ctx MII resistant subtypes consisting of α4β2 and α4α5β2 with the α4 and β2 subunits 
forming the agonist binding sites (Luetje 2004).  For purposes of this publication, this 
family of receptors will be referred to by its functional designation, e.g. the receptors that 
mediate NIC-evoked DA release. 
 
Homologously expressed nAChR Subtypes 
In addition to heterologously expressed nAChR subtypes, there exists a second class of 
homologously expressed receptor subtypes.  Originally, these homomers were identified 
using the same methods utilized in identifying muscle-type nAChRs.  Using radiolabeled 
α-bungarotoxin, a known α1β1γδ ligand (Lee 1972), researchers found a receptor 
population which demonstrated a high affinity for the compound (Marks et al. 1986).  
Using α7 mRNA brain distributions as well as the autoradiographic binding data, this 
receptor subtype was identified as an α7 homomer (Clarke et al. 1985; Wada et al. 1989; 
Seguela et al. 1993; Chen and Patrick 1997).  This class of homomeric receptor subtype 
is almost as prevalent as the α4β2* population of nAChRs in the brain.  However, these 
receptors are expressed differently in different brain regions (Holladay et al. 1997).  The 
α7* receptor subtypes are highly permeable to Ca2+ ions (Seguela et al. 1993; de Fiebre 
et al. 1995), and rapidly desensitize in the presence of agonists (Castro and Albuquerque 
1993).  Synapse formation, mediation of nicotine-induced seizures, and modulation of 
neurotransmitter release are some functions potentially regulated by the α7* nAChR 
(Orr-Urtreger et al. 1997). 
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2.5. Pharmacology of Nicotine at the nAChR 
As stated above, nicotinic receptors mediate a wide variety of effects on many systems in 
the body.  Nicotine, the principal alkaloid and active compound in tobacco, has been 
found to interact with the acetylcholine binding site on nicotinic receptor subtypes.  
Nicotine exposure has been shown to enhance memory and attention, increase arousal, 
decrease anxiety, and cause weight loss (Arneric and Brioni 1999).  Additionally, 
nicotine has been shown to be highly addictive due to its ability to affect the modulation 
of dopamine release.  Like acetylcholine and other agonists, nicotine has been shown to 
first activate the opening of the receptor ion channel.  After activation, nicotine exposure 
causes a second conformational change in which the receptor becomes refractory or 
desensitized (Corringer et al. 1998).  In its desensitized state, the ion channel is closed, 
and the receptor is in a resting state.  Before activation by an agonist, the receptor has a 
high affinity for binding nicotine or other agonist molecules.  Interestingly, after binding 
of nicotine, the subsequent desensitized state also has an increased affinity for nicotine, 
even though it is unable to function (Sharpless and Wonnacott 2001).  Additionally, at the 
binding site, the ß-subunit may control the extent of desensitization or inactivation of the 
receptor after long-term agonist exposure (Fenster et al. 1997; Kuryatov et al. 2000; Kuo  
et al. 2005).  Concentrations needed to desensitize the receptor are also much less then 
those required to activate the receptor (Rowell and Hillebrand 1994; Fenster et al. 1997; 
Grady et al. 1997).  An increase in receptor number, or up-regulation, also occurs when 
a4ß2* receptors are exposed to chronic nicotine treatments (Wonnacott et al. 1990).  
However, this upregulation is not due to an increase in receptor mRNA production, and 
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may be due to a recruitment of nicotinic receptors from a reserve pool (Marks et al. 1992; 
Bencherif et al. 1995).  It should also be noted that different nAChR subtypes respond to 
agonists differently, and their desensitization rates and function can vary when exposed 
long term to NIC (Nguyen et al. 2004; Grilli et al. 2005).  As stated above, α7 receptors 
are characterized by their very rapid desensitization, whereas receptors modulating DA 
release are more resistant to desensitization (Castro and Albuquerque 1993; Gray et al. 
1996; Yu et al. 1996).  Interestingly, the opposite is true for regulation of these receptor 
subtypes using chronic NIC infusion.  a7* receptor subtypes are more resistant to 
regulation by NIC, where as a6* containing receptors (DA mediating nAChR subtypes) 
are down-regulated when exposed to chronic NIC (Collins et al. 1994; Lai et al. 2005).  
Desensitization, as well as up-regulation, has allowed researchers not only to search for 
agonists that are selective for various subtypes, but also to explore subtype-selective 
antagonists as therapeutic agents (Arneric and Brioni 1999). 
 
2.6. Existing Assays for Evaluating Affinity and Functional Responses at 
nAChRs 
Radioligand Binding Studies 
Only a limited number of pharmacological tools are available to evaluate affinity and 
function at the various nicotinic receptors.  Radioligand binding assays are often used as 
the first step in determining ligand affinity for individual nAChRs, due to methodological 
ease and the capacity for rapid screening.  These assays are carried out using native 
tissue, or utilizing receptors expressed in Xenopus oocytes or other stably-transfected cell 
lines. 
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Ligand binding assays developed for the α4β2* receptor subtype are performed using 
several different ligands, including [3H]S-(-)-nicotine (NIC), [3H]cytisine, [3H](+)-
epibatidine, and [3H]ACh.  Several different brain regions may be used to obtain native 
tissue nAChRs, including the thalamus, cortex, and striatum.  Cell line K-177, a line of 
human embryonic kidney (HEK) 293 cells that stably express the human α4β2 nAChR, 
has also been utilized in binding assays (Gopalakrishnan et al. 1996).  α7* nAChR 
subtypes are also assayed via radioligand binding methods; the most widely used ligands 
for these studies have been [3H]-α-bungarotoxin and [3H]-methyllycaconitine.  Native 
tissue receptors, as well as stable cell lines expressing a7 receptors have been used in 
these binding assays (Gopalakrishnan et al. 1995; Quik et al. 1996; Whiteaker et al. 
1999).  A third class of neuronal nAChRs, the subtypes that mediate NIC-evoked DA 
release, has primarily utilized [3H]-(+)-epibatidine as the radioligand in the binding assay.  
However, due to its non-specificity (α4β2 activity), this radioligand must be used in 
conjunction with unlabeled cytisine to block [3H](+)-epibatidine binding to the α4β2* 
subtype (Marks et al. 1998).  Cloned cell lines have revealed several possible candidates 
for these studies.  α3α5β2, α3β2, and α3β4 nAChR clones have all shown an affinity for 
n-bungarotoxin and epibatidine (Lin and Meyer 1998).  [125I]-α-ctx MII has also been 
used as a ligand for the nAChR subtype mediating NIC-evoked DA release (Holladay et 
al. 1997). 
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Functional Assays 
In order to differentiate between agonists and antagonist at nAChR subtypes, functional 
studies must be utilized in addition to the binding studies.  These functional assays must 
also be used to assess what is occurring at the actual receptor site.  Binding studies only 
represent the affinity of ligands for the desensitized form of the receptor and may not 
give an accurate indication of the ligand’s interaction with a functional receptor (e.g. the 
non-desensitized form).  As in the binding studies, functional assays must be subtype 
specific.  Current approaches incorporate the use of slices or synaptosomes from various 
brain regions, as well as recombinant receptors expressed in Xenopus oocytes, or in 
stably-transfected cell lines.  α4β2* subtypes have traditionally been assayed using ion 
flux assays involving the radioactive ion [86Rb+].  86Rb+ is an ion considered to be 
equivalent to the endogenous cation K+.  Rodent brain synaptosomes or stably transfected 
cell lines (K177 cells or IMR-32 cells) are preloaded with 86Rb+ and superfusion systems 
in the presence of agonist are used to efflux the radiolabel through the ion channel.  
Functional response is designated once the compound either elicits efflux (agonist), or 
inhibits efflux when NIC is introduced into the system as an agonist (antagonist).  Data 
from 86Rb+ efflux and [3H]-nicotine binding assays have shown correlative EC50 and IC50 
values for agonist- induced efflux, respectively, as well as correlation of similar sites of 
action within brain regions.  It is important to note that α7 [125I]-α-bungarotoxin binding 
data does not correlate with 86Rb+ efflux brain regions, offering further proof that 86Rb+ 
efflux is a functional assay for α4β2* nAChRs (Marks et al. 1998).   
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Generally, ion flux functional assays for α7 subunits have proven to be unsuccessful, due 
to rapid α7* receptor desensitization, which has been reported to occur over several 
milliseconds (Seguela et al. 1993).  Consequently, electrophysiology studies have been 
used to characterize these homomeric receptor subtypes.  Whole-cell voltage clamp 
experiments using either hippocampal interneurons or Xenopus oocytes expressing α7 
subtypes have been shown to be useful in determining functional activity before the 
receptor is desensitized (Frazier et al. 1998; Papke and Thinschmidt 1998; Papke et al. 
2000). 
 
As mentioned above, the nAChR has been implicated in the mediation of NIC-evoked 
dopamine release.  Therefore, nAChR subtypes that mediate NIC-evoked DA release 
have been assayed utilizing neurotransmitter (NT) release methodologies.  These assays, 
usually utilize brain slices or synaptosomes, oocytes, or stably-transfected cell lines, 
which are preloaded with [3H]-dopamine and superfused to monitor the efflux of the 
radiolabel in the presence of agonist.  Drug candidates can be added to the system to 
measure their intrinsic (agonist) activity, and compounds can also be tested against a 
known agonist (e.g. NIC) to determine the ability of the compound to inhibit agonist-
evoked dopamine response (antagonist response).  Native tissues, such as striatum, as 
well as cell lines, including IMR-32 human neuroblastoma cells and rat PC12 cells, both 
of which are ganglionic in nature and express an α3-containing subtype (possibly α3β4), 
have been employed using this assay method (Lukas 1993; Donnelly-Roberts et al. 
1998).  Although this assay does not differentiate between the four possible subtypes that 
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mediate DA release, it has been invaluable in identifying non-α4β2 and non-α7 selective 
ligands. 
 
Researchers may choose to use several types of tissues when conducting any of the 
assays outlined above.  However, both native tissue and expressed cells have benefits and 
limitations.  Using neuronal tissue affords a more accurate representation of the native 
receptor but limits the effective determination of nAChR subtype compositions, due to 
the complexity of the neuronal tissue, as well as the limitations of the pharmacological 
assays.  Additionally, the rodent brain (e.g. rat or mouse) is small, and large amounts of 
tissue may be needed in order to fully assess a series of compounds, adding a high cost to 
the process.  Expressed cells, in contrast, can be grown in large quantities, are quite easy 
to manipulate, and provide an accurate determination of subunit composition.  These cells 
are also cost-effective, when screening large numbers of compounds.  However, 
perceived strengths of homogeneity and basic cell function are also weaknesses for these 
tissue preparations.  In addition, while the subunit composition of nAChRs is known in 
both Xenopus oocytes and transfected cells, they are not necessarily identical to the 
corresponding native receptor subtypes, with regard to subunit combination, 
stoichiometry, post-translational modification, and placement within the brain regions. 
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2.7. Nicotinic Ligands of the nAChR 
 
2.7.1. Agonists 
Alkaloids  
The tobacco plant, Nicotinia tobacum, contains many different naturally occurring 
alkaloids.  The most abundant, NIC (1), has a varied pharmacological profile, as 
discussed above, throughout the body, both peripherally and centrally.  R-(+)-Nicotine 
(R-NIC, 2), the enantiomer of NIC, which is formed during pyrolysis of tobacco products 
and is present in tobacco smoke, also has activity at nAChRs.  In addition to NIC, N. 
tobacum contains several other alkaloids, including, S-(-)-nornicotine (3), S-(-)-cotinine 
(4), S-(-)-anabasine (5), and S-(-)-anatabine (6).  R-NIC has lower affinity for the α4β2* 
receptor subtype than that reported for (1), as determined by inhibition of [3H]-NIC 
binding (Ki = 46 and 2 nM, respectively) (Crooks et al. 1995).  Stimulation of DA release 
in striatal tissue with (2) afforded an equivalent efficacy but a lower potency than (1) 
(Garvey et al. 1994).  Compounds 3 and 4 have been evaluated in the NIC-evoked [3H]-
DA release assay and both evoked [3H]-DA release but neither was as potent as NIC.  S-
(-)-Nornicotine (EC50 = 1.0 µM) was more potent than S-(-)-cotinine (EC50 = 30.0 µM) 
(Teng et al. 1997; Dwoskin et al. 1999).  [3H]-NIC binding affinities for (3) and (4) were 
also determined in comparison to that of NIC and were 259-fold and 3900-fold lower in 
affinity, respectively (Garvey et al. 1994; Lin and Meyer 1998).  Compound 5 exhibits a 
30-fold decrease in affinity when compared to NIC in the [3H]-NIC binding assay, a 40% 
efficacy in the 86Rb+ efflux assay compared to NIC, and an EC50 value of 15.4 µM in the 
NIC-evoked [3H]-DA release assay  (Marks et al. 1993; Dwoskin et al. 1995). 
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Figure 2.2 Structures of Alkaloid Molecules and Pyridine Ring Modified NIC Molecules  
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Anabaseine and Anabaseine Analogs 
Anabaseine (7) is a 1’, 2’-dehydroanabasine analog.  It is found in cured tobacco and in 
the marine worm Hoponemetines hydrobiologia.  Compound 7 affords about a 20-fold 
decrease in rat brain [3H]-NIC binding affinity when compared to NIC, and has a similar 
selectivity for α4β2* nAChR subtypes (Ki = 32 nM) over α7* nAChR subtypes (Ki = 58 
nM) (de Fiebre et al. 1995; Kem et al. 1997).  However, intrinsic α7 activity is 200% 
higher for (7) over NIC in expressed oocytes.  A 3’-substituted anabaseine analog, GTS-
21 (8), exhibits partial agonist activity at rat α7 receptors expressed in Xenopus oocytes 
(ca. 28% of the ACh response) and low activities at α4β2 oocyte-expressed receptors.  In 
contrast, human α7 receptor activity elicited by (8), when compared to that elicited at rat 
α7 nAChRs, was less efficacious (Briggs et al. 1997; Meyer et al. 1998).  4-OH-GTS-21 
(9), a GTS-21 metabolite, showed a similar increase in affinity for the α7 receptor 
subtype when compared to (8) in rat oocyte PC-12 cells utilizing the [125I]α-Btx binding 
assay [e.g. Ki = 45 nM (4-OH-GTS-21) and 31 nM (GTS-21)].  Additionally, the 4-OH 
metabolite had more affinity for the binding sites of human SK-N-SH cells when assayed 
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in the [125I]α-Btx binding assay (Ki = 170 nM (9) and 23 µM (8)) (Meyer et al. 1998; 
Papke et al. 2000). 
 
Figure 2.3 Structures of Anabaseine and Modified Anabaseine Molecules 
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Two series of restricted nicotine analogs (10-12) have affinities for nAChRs.  A syn-
rotamers of NIC (10a) elicited antinociceptive effects in the tail flick assay (a purported 
α4β2* mediated effect), with the (+)-enantiomer having a 12-fold greater effect over the 
(-)-enantiomer (Sabey et al. 1999; Sarkar et al. 2004).  Interestingly, affinity values of 
these enantiomers in the [3H]-NIC binding assay were reversed; the (+)- and (-)-
enantiomers of 10) having Ki values of >10,000 and 605 nM, respectively.  The racemic 
desmethyl analog (10b) had a higher affinity for α4β2* nAChRs (Ki = 167 nM) when 
compared to the N-methyl enantiomers (Chavadarian et al. 1983; Glassco et al. 1993).  
Xu et al. (2001) obtained similar values for the syn-rotamer compounds 10a and 10b (Ki 
= 400 and 220 nM, respectively) in the [3H]-NIC binding assay, and these compounds 
demonstrated different affinities in the [3H]-MLA binding assay, Ki = 590 nM (10a) and 
20.2 µM (9b).  Binding affinities for the anti- rotameric analogs (11a and 11b) of NIC and 
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nornicotine indicated no appreciable affinity of these compounds at the α7 receptor 
subtype (Ki >100 µM for both compounds) and only weak micromolar affinity in the 
[3H]-NIC binding assay (Ki = 12.2 and 10.5 µM, respectively) (Xu et al. 2001).  
Compound 12, a racemic 6-methoxy substituted analog of (10b), had a much lower 
affinity (Ki = 1.9 µM) than that of NIC in the [3H]-NIC binding assay using rat brain 
homogenate, but exhibited strong antinociceptive effects in the rat tail flick assay 
(McDonald et al. 1996).   
 
Figure 2.4 Structures of Conformationally Restricted NIC Analogs 
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Cytisine  
Cytisine (Cyt, 13), an alkaloid found in laburnum of the Leguminosae family, has 
exhibited selectivity for neuronal nAChR subtypes over those in the periphery (Astles et 
al. 2002).  Cyt has demonstrated high affinity and activity at α4β2* nAChRs.  In [3H]-
NIC binding assays, Ki values ranging from 0.14-2.7 nM for Cyt have been reported 
(Marks et al. 1993; Court et al. 1994; Whiteaker et al. 1998).  Cyt has been shown to 
favor α4-containg subtypes over the a7* nAChR subtype (Astles et al. 2002).  Functional 
studies have revealed that Cyt elicits ion flux in both brain thalamic synaptosomes, as 
well as in cells expressing α4β2* nicotinic receptors (EC50 = 0.019 – 71.4 nM) (Marks et 
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al. 1993; Peng et al. 1994; Marks et al. 1996).  Cyt has low µM affinity (Ki = 1.6 µM) in 
the [125I]-α-Btx binding assay using rat brain preparations (α7* nAChRs) (Marks et al. 
1993).  In the [3H]-DA release assay from rat striatal slices, Cyt was a partial agonist 
(Sacaan et al. 1995).  However, Grady et al. (1992) reported that Cyt was a full agonist 
when evaluating DA release from mouse striatal synaptosomes (Grady et al. 1992).  Cyt 
is also able to distinguish between the β4 and β2 subunits using oocyte-expressed cells 
systems, with the α4β4 nAChR subtype eliciting a much larger agonist response than the 
α4β2 subtype (Luetje and Patrick 1991). 
 
Epibatidine  
Epibatidine (Epi, 14), an alkaloid originally isolated from Epipedobates tricolour (an 
Ecuadorian poisonous frog), was first structurally determined by Daly et al. (1991) to be 
an azabicycloheptane (Daly et al. 1991; Spande et al. 1992; Badio and Daly 1994).  To 
date, Epi is the most potent natural agonist at nAChRs.  Epi has demonstrated very little 
enantioselectivity at various nAChRs (Badio and Daly 1994; Gerzanich et al. 1995).  In 
rat homogenate binding assays using various specific radiolabeled ligands, Epi had 
picomolar affinities at α4β2* receptor subtypes (Ki = 70 pM), low nanomolar affinities at 
α7* (Ki = 21 nM), and low micromolar affinities at α1βγδ receptor subtypes (2.7 µM, 
respectively) (Gopalakrishnan et al. 1996; Sullivan and Bannon 1996).  Cell expressed 
nAChRs demonstrated similar α4β2 affinities (Ki =19 pM) and slightly weaker α7 
affinities (Ki = 200 nM).  Affinities for α3β2 and α3β4 nAChRs were determined to be 
over 10-fold lower than for α4β2 nAChRs (Ki = 230 and 380 pM, respectively) 
(Gerzanich et al. 1995; Xiao et al. 1998).  In functional assays, Epi has been evaluated in 
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the NIC-evoked [86Rb+] efflux assay using K177 cells expressing the α4β2* nAChR 
(EC50 = 17 nM), as well as oocyte-expressed α7 nAChRs (EC50 = 1.3 µM) 
(Gopalakrishnan et al. 1996; Sullivan and Bannon 1996).  Epi was also 150-fold more 
potent (EC50 = 0.4 nM) than nicotine (EC50 = 60 nM) in evoking DA release from rat 
striatal slices, and 40% more efficacious (Sullivan et al. 1994). 
 
Figure 2.5 Structures of Cytisine, Epibatidine, Anatoxin-a 
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Anatoxin-a 
(+)-Anatoxin-a (Atx, 15), isolated from the freshwater blue-green algae Anabaena flos-
aquae, has an azabicyclononene skeleton and exhibits a wide variety of nAChR activities.  
Atx has a similar affinity to NIC (Atx, Ki = 3.5 nM; NIC, Ki = 1-3 nM) in the [3H]-NIC 
binding assay using rat brain homogenate (Wonnacott et al. 1991).  Binding studies using 
rat α7* native receptors and [125I]-α-Btx revealed that (+)-Atx had a 60-fold higher 
binding affinity than NIC at this receptor subtype.  Using mouse thalamic synaptosomes 
and M10 cells, 15 has been shown to be more efficacious than NIC in the NIC-evoked 
[86Rb+] efflux assay (EC50 = 48 - 93 nM and 180 - 2500 nM, respectively) (Thomas et al. 
1993; Marks et al. 1996).  Using α7 receptors expressed in Xenopus oocyte cells, ion flux 
assays demonstrated a 50-fold increase in potency for Atx over NIC (Thomas et al. 
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1993).  Additionally, (+)-anatoxin is 10-fold more potent than NIC in PC-12 cells 
expressing a ganglionic-type receptor (Daly et al. 1991).  The (-)-Atx enantiomer has 
1000-fold less affinity for α4β2* receptors and 50-fold less affinity for α7* receptors, 
compared to (+)-Atx, when assaying rat brain tissue (Macallan et al. 1988).  Reduction of 
the olefinic bond in the octene ring of (+)-Atx causes a 20-fold decrease in affinity at 
both [3H]-NIC (α4β2*) and α-Btx (α7*) binding sites in rat brain tissue. 
 
2.7.2. Antagonists 
Competitive Antagonists 
d-Tubocurarine (d-TC, 16) is a classical nAChR antagonist isolated from the South 
American bush Chondodendron tomentosum.  Originally used as a poison on the tips of 
arrows, d-TC was found to be a potent antagonist at muscle type nAChR [(α1)2βγδ or 
(α1)2βεδ] (Sharpless and Wonnacott 2001).  d-TC binds to many different peripheral and 
neuronal nicotinic receptor subtypes with a low micromolar affinity, and is able to 
antagonize several different functional responses of nicotinic receptors at micromolar 
concentrations in Xenopus oocytes (Chiappinelli et al. 1993; Cachelin and Rust 1995; 
Chavez-Noriega et al. 1997).  Similar activities were seen in native neuronal receptor 
assays for α4β2* nAChR subtypes and receptor subtypes mediating DA release (Grady et 
al. 1992), further supporting the observation that d-TC is not a selective ligand at nAChR 
subtypes.  It should also be noted that, while d-TC does exhibit competitive antagonistic 
properties in the systems mentioned above, it also may have a non-competitive 
component to its receptor inhibition profile (Cachelin and Rust 1994; Chavez-Noriega et 
al. 1997). 
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Dihydro-β-erythroidine (DHβE, 17), an alkaloid isolated from Erythrina seeds, 
competitively binds to nAChRs, with affinities in the nanomolar range, at both α4β2* 
nAChR subtypes and receptor subtypes mediating DA release (Crooks et al. 1995; 
Khiroug et al. 2004).  Characterization of DHβE in a number of oocyte expression 
systems demonstrated selectivity between nAChR subtypes.  A 3-fold selectivity α4β2 
receptor subtype over the α2β2 receptor subtype and a 10-fold selectivity for the α4β4 
receptor subtype over the α4β2 receptor subtype.  Additionally, an approximate 100-fold 
increase in selectivity for α4β4 receptors over α3β4 receptors was observed (Harvey and 
Luetje 1996; Chavez-Noriega et al. 1997; Khiroug et al. 2004).  DHβE binds similarly to 
NIC, and the receptor blockade can be overcome with high concentrations of NIC or 
another agonist.  DHβE does not act as an antagonist at α7* receptor subtypes 
(McQuinston and Madison 1999).  Erysodine (18), a structurally related DHβE analog, 
also isolated from Erythrina seeds, has also been investigated.  Erysodine is more active 
at α4β2* receptor subtypes than DHβE, but like DHβE has relatively weak affinity for 
α7* nAChRs (Decker et al. 1995).  Erysodine also exhibits antagonistic properties 
similar to those of DHβE at nAChR subtypes mediating DA release. 
 
Methyllycaconitine (MLA, 19) isolated from Delphinium brownii, is a tertiary 
diterpenoid alkaloid.  It is a potent and competitive antagonist at the homologously 
expressed and native α7* nAChR subtypes with a low nanomolar affinity (Ki =1 nM).  
MLA also has the ability to block α7 mediated currents recorded from Xenopus oocytes 
or hippocampal neurons (Alkondon et al. 1992; Palma et al. 1996; Davies et al. 1999).  In 
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addition to the homomeric α7* nAChR subtypes, MLA has been shown to inhibit a 
population of α7-like nAChR subtypes which are not labeled by other α7 antagonists 
(Yum et al. 1995; Davies et al. 1999).  When compared to other receptor subtypes, both 
muscle and α4β2* subtypes require micromolar concentrations of MLA to achieve 
inhibition of nAChR function (Wonnacott et al. 1993).  Early studies have shown MLA 
has little antagonistic activity in the nicotine-evoked dopamine release assay (Drasdo et 
al. 1992).  However, more recent studies have demonstrated that MLA may antagonize 
α6-containing nAChR subtypes, one of the purported nAChR subtypes involved in 
mediating DA release (Mogg et al. 2002; Karadsheh et al. 2004).  SAR on the MLA 
molecule reveals the ring E moiety is an important feature for activity, specifically the 
succinimide moiety of the multi-ring structure.  Removal of various portions of the 
succinimide moiety significantly decreases binding affinity 20- to 2000-fold (Hardick et 
al. 1995).  In addition, Ring E racemic analogs of MLA exhibited moderate to equivalent 
activity compared to that of MLA, and demonstrates the importance of the methyl group 
in the succinimide moiety (Jacyno et al. 1996; Bergmeier et al. 1999). 
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Figure 2.6 Structures of Competitive nAChR Antagonists and Neurotoxins 
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Neurotoxins  
Several small peptide antagonists have been identified from the venom of Bungarus 
multicinctus, the Formosan banded krait.  α-Bungarotoxin (α-Btx), the most studied of 
these peptides, is an 8kDa protein that was found to have high affinity at neuronal α7* 
homomeric nAChR subtypes (Ki = 1 nM) (Marks et al. 1986; Davies et al. 1999).  
Homomeric avian α8* nAChRs and α9* nAChRs of cochlear hair cells are also inhibited 
with low nanomolar concentrations of α-Btx (Gotti et al. 1994; Elgoyhen et al. 2001).  α-
 36 
Btx does not seem to antagonize any neuronal heteromeric nAChR assemblies (McGehee 
and Role 1995). 
 
A minor component of the venom of Bungarus multicinctus, is neuronal bungarotoxin (n-
Btx or κ-Btx).  n-Btx has been shown to inhibit some α3*- and α6*- containing neuronal 
nicotinic receptor subtypes, as well as α7* subtypes (Chiappinelli 1983; Luetje et al. 
1998; Luetje 2004).  n-Btx inhibits nicotine-evoked dopamine release, as well as 
inhibiting [3H]-(+)-epibatidine non-α4β2* binding sites (Grady et al. 1992; Houghtling et 
al. 1995).  Due to its limited availability and non-selective pharmacological profile, n-Btx 
is not as widely utilized in research as other nAChR antagonists. 
 
Other neurotoxins exist in nature that act at various nAChRs, including neosurugatoxin 
(NSTX, 20) from the Japanese mollusk Babylonia japonica, which exhibits non-
competitive antagonism at several different nAChR subtypes and lophotoxin (LTX, 21) 
and its analog LTX-1 are cyclic diterpenes isolated from coral, which block 
neurotransmission of muscle type and ganglionic nAChRs (Abramson et al. 1988; 
Groebe and Abramson 1995).  Additionally, other toxins identified, include α-cobratoxin 
(α-CBT), erabutoxin-a (ETX-a) and erabutoxin-b (ETX-b), and  histrionicotoxin, all of 
which have been isolated from various species of snake (Luetje et al. 1990; Adams and 
Olivera 1994).  ETX-a has been identified as an inhibitor of NIC-evoked DA release in 
rat striatal tissue, while α-CBT had no inhibitory effect in the same system (Dajas-
Bailador et al. 1998). 
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a-Conotoxins  
Venoms from the Conus marine snails have been isolated and found to target various 
nAChR subtypes.  The α-conotoxin compounds are peptides of 12-19 amino acids in 
length and contain key disulphide bonds integral to maintaining their structure (Janes 
2005).  α-Conotoxin MII (22a) has been shown to potently and selectively antagonize 
α3β2 nAChRs expressed in Xenopus oocytes at concentrations of 100 nM, which was 2 
to 4 orders of magnitude higher than any other subtype tested (Harvey et al. 1997; Kaiser 
et al. 1998).  Partial inhibition of nicotine-evoked dopamine release was observed when 
rat striatal synaptosomes were exposed to α-conotoxin MII (Kaiser et al. 1998).  This 
partial inhibition was due to the presence of two classes of nAChR subtypes involved in 
mediating DA release.  The α6-containing α-ctx MII sensitive receptor subtypes are 
blocked by α-ctx MII (Salminen et al. 2004).  Related α-conotoxins, α-conotoxin ImI 
(22b) and α-conotoxin AuBI (22c), were shown to be selective for α7 and α3β4 
receptors, respectively (Johnson et al. 1995; Grady et al. 2001).  However, recent 
evaluation of a-ImI and a close analog, a-ImII (75% homology), both demonstrate 
activity at a3ß2 (IC50 = 40.8 nM and 9.61 µM, respectively) and a7 (IC50 = 595 nM and 
571 nM, respectively) receptor subtypes expressed in Xenopus oocytes.  Therefore, the 
evaluation of the selectivity of a-ImI is undecided at this time.  a-ImII did act at a 
different a7 binding region than traditional a7 antagonists, including a-ImI.  This a-
conotoxin could act as a potential probe for a novel a7 binding site (Ellison et al. 2003; 
Ellison et al. 2004).  a-Conotoxin BuIA (22d), isolated from Conus bullatus, 
demonstrated a broad spectrum of activity at several nAChR subtypes expressed in 
Xenopus oocytes.  BuIA was most active in the inhibiting a6/a3ß2 nAChRs (IC50 = 0.258 
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nM) followed by a6/a3ß4 nAChRs (IC50 = 1.54 nM).  a7 and a4ß2 nAChR subtypes 
were not as active with IC50 values of 272 nM and 10.4 µM, respectively.  Additionally, 
BuIA was able to differentiate between ß2- and ß4-containing subtypes due to different 
dissociation rates when a common a-subunit was used (Azam et al. 2005). 
 
Nicotinium Salts 
N-n-alkylnicotinium iodide salts have been prepared by regioselective N-alkylation of the 
S-(-)-nicotine pyridino-N moiety (Crooks et al. 1995; Dwoskin et al. 1999).  These 
compounds exhibited a range of inhibitory potency at various nAChR subtypes.  
Compounds 23a-d were the most potent inhibitors.  In [3H]-NIC binding experiments 
utilizing rat striatal slices, NDNI (Ki = 93 nM) and NDDNI (140 nM) had similar 
affinities for the α4β2* receptor subtype, with NNNI (840 nM) having moderate affinity, 
and NONI (20 µM) demonstrating weaker affinity for this receptor subtype.  Functional 
responses (IC50) were also determined in NIC-evoked 86Rb+ efflux assays, IC50 values 
obtained were: NDNI (14 nM) = NNNI (9 nM) > NDDNI (40 nM) > NONI (10 µM).  
Nicotine-evoked [3H]-DA release assays, these N-alkylnicotinium salts exhibited a 
different inhibitory profile than that observed in the 86Rb+ efflux assays, with inhibitory 
potencies (IC50) ranging from the low nanomolar to high micromolar range; IC50 values 
were as follows: NDDNI (9 nM) > NNNI (140 nM) > NONI (620 nM) > NDNI (>100 
µM).  From the functional and binding data, it can be concluded that NNNI and NDDNI 
are nonselective antagonists at α4β2* nAChR subtypes and at nAChR subtypes 
mediating NIC-evoked DA release, while NDNI and NONI, due to their functional 
profiles, are selective and competitive receptor antagonists at α4β2* nAChR subtypes 
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and at nAChR subtypes mediating NIC-evoked DA release, respectively.  In addition, 
none of the N-alkylated compounds 23a-d had any affinity for α7 [3H]-MLA binding 
sites (Wilkins et al. 2003).  When unsaturation was introduced to the alkyl chains of the 
N-n-alkylnicotinium salts, the NONI analogs gained affinity for α4β2* nAChR subtypes 
(0.08 – 4.49 µM), while maintaining or increasing their activity at nAChR subtypes 
mediating NIC-evoked DA release (80 – 250 nM).  Additionally, the NDNI analogs 
maintained or lost affinity for α4β2* nAChR subtypes (0.05 – 7.47 µM), but 
demonstrated antagonist activity at nAChR subtypes mediating NIC-evoked DA release 
(20 – 140 nM) (Sumarithan et al. 2005). 
 
Figure 2.7 Structures of Nicotinium and Structurally Modified Nicotinium Salts 
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A second series of conformationally restricted nicotinium analogs (24 and 25) were 
alkylated with various long carbon chain lengths (Crooks et al. 2000).  Restriction of the 
pyrrolidine ring rotation about the pyridine moiety caused complete loss of affinity for 
the α4β2* nAChR subtype, and none of these compounds had any activity in the [3H]-
MLA binding assay.  However, analysis of these compounds in the [3H]-nicotine-evoked 
dopamine release assay demonstrated that a general increase in carbon chain length from 
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C8 to C12 produced a nearly 100-fold increase in antagonism at the nAChR mediating DA 
release (IC50 = 30 – 660 nM).  The sole exception was the dodecyl analog BCDD, which 
was devoid of inhibitory activity at this receptor, although interestingly the isomeric 
analog ACDD exhibited an IC50 of 220 nm. 
 
Other Antagonists 
Lobeline (LOB, 26), an alkaloid found in Lobelia inflata plants is the active ingredient in 
what is referred to as “Indian tobacco”.  LOB has many pharmacological effects related 
to those of nicotine, and has historically been regarded as an agonist at nicotinic 
receptors; however, it may bind to the nicotinic receptor in a novel manner (Decker et al. 
1995; Damaj et al. 1997).  Both LOB and nicotine bind to the α4β2* nAChR with low 
nanomolar affinity (Ki = 4 - 30 nM), while exhibiting little or no α7 affinity (>10,000 
nM) (Abood et al. 1988; Reavill et al. 1990; Bhat et al. 1991; Court et al. 1994; Brioni et 
al. 1997).  LOB has recently been shown to competitively inhibit NIC-evoked 
[3H]dopamine overflow (IC50 = 300 nM), as well as inhibiting NIC-evoked 86Rb+ efflux 
(IC50 = 700 nM) in rat striatal slices and in rat thalamus synaptosomes, respectively 
(Miller et al. 2000).  It should be noted that at concentrations greater than 1 µM, LOB 
potently releases dopamine from rat striatal slices in a manner that is not nAChR 
mediated, since the release cannot be inhibited by mecamylamine (Teng et al. 1997).  
These data lead to the classification of LOB as a competitive, nonselective antagonist at 
α4β2* nAChR subtypes and at nAChR subtypes mediating NIC-evoked DA release. 
 
 41 
Strychnine (27) has been shown to competitively inhibit the α7* nAChR subtype, in 
addition to its original use as an antagonist at the glycine-gated chloride channel 
(Matsubayashi et al. 1998).  In Xenopus oocytes expressing nAChRs individually 
composed of homomeric α7, α8, and α9 nAChR subtypes, strychnine acts as an inhibitor 
at toxicologically relevant concentrations (Gerzanich et al. 1994; Peng et al. 1994).  
Additionally, strychnine has also been found to block α4β2* nAChRs non-competitively 
(Matsubayashi et al. 1998). 
 
bis-Isoquinolines, tetrandrine, hernandezine and E6-berbamine were evaluated as ligands 
to block ACh-evoked currents at α3* and α7 nAChR subtypes endogenously expressed 
in PC12 cells.  Tetrandrine, hernandezine and E6-berbamine exhibited antagonistic 
activity at the α3* nAChR subtypes (IC50 = 8.1, 5.8, and 5.1 µM, respectively).  
[3H]MLA binding studies revealed that all three compounds displaced the radiolabeled 
ligand (IC50 = 8.1 µM (tetrandrine), 5.8 µM (hernandezine), and 5.1 µM (E6-berbamine)).  
Additionally, the functional assay demonstrated that tetrandrine and hernandezine 
inhibited ACh-evoked currents at α7 nAChR subtypes (IC50 = 407 and 372 nM, 
respectively) (Virginio et al. 2005). 
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Figure 2.8 Structures of nAChR Antagonists 
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Prevailing drug discovery endeavors have lead researchers to explore structural 
modifications of tobacco alkaloids in an attempt to find novel agonists that are potent and 
subtype-selective.  More recently, there has been a growing interest in the development 
of novel receptor antagonists that are selective and potent at various nAChR subtypes.  
Abbot laboratories have disclosed several antagonist candidates that have stemmed from 
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their development of a series of pyridyl ether agonists.  Compounds 29-36 have been 
evaluated in the IMR-32 expressed cell assay utilizing the nicotine-evoked 86Rb+ efflux 
assay to determine the extent of α3β4* nAChR antagonist activity.  Compound 29a and  
29b inhibited 50% of the 86Rb+ efflux at concentrations of 1 µM, although 29b had 15% 
intrinsic activity at the same concentration implying that it is a partial agonist.  Under the 
same conditions, compound 30a produced 50% inhibition (1 µM) and 60% inhibition (10 
µM), while compound 30b exhibited 20-90% inhibition over the concentration range 1-
10 µM.  Two compounds in the 3-(2-pyrrolidinylethoxy)pyridine series (31a and 31b)  
produced moderate antagonist activity (IC50 = 75 and 6 µM, respectively), with no 
observed intrinsic activity and compound 32 (1 µM) also exhibited 55% inhibition of 
NIC-evoked 86Rb+ efflux and produced no intrinsic activity.  Therefore, a pyridyl ether 
linkage can demonstrate antagonist activities at the α3β4* nAChR subtype.  The 
substituted pyridyl ethers (33-36) were also assessed using IMR-32 expressed cells in 
nicotine (100 µM)-evoked 86Rb+ efflux assays.  Compound 33a at a 1 µM exhibited 66% 
inhibition of NIC-evoked 86Rb+ efflux, while compound 33b at 10 µM exhibited 100% 
inhibition, indicating potent α3β4* antagonism.  The 5-substituted pyridyl ethers 34a and  
34b were found to inhibit 90% of NIC-evoked 86Rb+ efflux at 10 µM; while 34b 
exhibited an IC50 = 2 µM.  Compounds 35a and 35b, exhibited ~50% inhibition, while 
the R- and S- enantiomers of 35c (only S-(-) shown) had comparable IC50 values of 9 
µM.  Compound 36 (1 µM) produced 50% inhibition of NIC-evoked 86Rb+ efflux.  Taken 
together the substituted pyridyl ethers demonstrate an ability to inhibit α3β4* nAChR 
subtypes at the µM level.  The inclusion of a chlorine molecule on either aromatic ring in 
compounds 33a or 33b resulted in the most potent compounds in this series.  
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Additionally, this series of compounds demonstrates that the 5-position of the pyridine 
ring can be altered with large substituents and still fit into the binding site. 
 
Figure 2.9 Conformationally Restricted Pyridyl Ether Analogs 
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Compounds 37-40 were assayed in the IMR-32 cell assay described above and/or in 
K177 cells expressing the α4β2* nAChR subtype.  A rigid aromatic analog of compound 
30b, compound 37, exhibits nonselective antagonist activity in both the K177 cell assay 
(55% inhibition and 6% intrinsic activity) and the IMR cell assay (38% inhibition and 7% 
intrinsic activity).  This indicates a significant difference in inhibitory capability, since 
30b was assayed in the IMR cell assay at 10 µM (90% inhibition).  The difference in 
IMR cell assay activities between 37 and 30b may be attributed to increased aromatic 
characteristics of 37 as well as the additional flexibility of 30b.  Compounds 38-40 
incorporate an extra degree of conformational rigidity, due to the substitution of a 
hexahydro-1H-pyrrolizine moiety for the N-methyl pyrrolidine ring.  The 7a-substituted 
hexahydro-1H-pyrrolizine analog, 38, was a low-potency antagonist (43% inhibition, 
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with minimal intrinsic activity).  Compound 39 (30 µM), a dehalogenated, rigid analog of 
37, exhibited no intrinsic activity, while exhibiting 50% inhibition in the IMR cell assay.  
The 55% inhibition produced by compound 40 is not significantly different from that 
afforded by its stereoisomer 39 in the IMR cell assay. 
 
Figure 2.10 Structural Analogs of Anabaseine and NIC 
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In addition to the structural modifications of the agonist molecules listed above, other 
researchers have attempted to structurally modify the minor tobacco alkaloids, 
anabaseine and anabasine, in order to identify possible new nAChR antagonists.  The 
partial agonist GTS-21 (7; also known as DMXB) is a structural analog of anabaseine and 
has been discussed previously in this chapter (de Fiebre et al. 1995; Meyer et al. 1997; 
Meyer et al. 1998).   3-Trans-cinnamylidene analogs have been developed to alter the 
agonist/antagonist profile of GTS-21 in an attempt to create antagonists that are more 
potent.  Using an Xenopus oocyte α7 expression system, compounds 41a, 41b, and 41c 
were shown to exhibit nanomolar affinities for [125I]-α-Btx binding sites (IC50 = 8-80 
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nM), and cause activation of α7 receptor channels (EC50 = 3.2 – 15.9 µM).  These 
compounds also inhibited acetylcholine-elicited electrical responses after incubation for 
five minutes with various concentrations of the analog.  The following order of potencies 
(IC50) was obtained: 2-MeOCA (41b) (2.3 µM) > 4-MeOCA (41c) (5.0 µM) > 3-CA 
(41a) (15 µM).  Due to the similar concentration ranges for both IC50 and EC50 values, 
these compounds have antagonist characteristics but are viewed as partial agonists, rather 
than antagonists (Meyer et al. 1998). 
 
Conformationally restricted piperidine ring analogs of anabasine have been shown to be 
potent antagonists at α4β2* nAChRs.  Compound 42 has high affinity for the [3H]-
nicotine binding site (Ki = 1 nM) in rat brain membranes, and blocks nicotine (10µM)-
evoked 86Rb+ efflux in rat thalamic synaptosomes (IC50 = 154 nM) (Crooks et al. 1998).  
However, in the nicotine-evoked [3H]-dopamine release assay using rat striatal 
synaptosomes, compound 42 had an EC50 of 2 nM, Emax = 40%, and this compound 
activated α3β4* (EC50 = 1100 nM) and muscle-type (EC50 = 59 nM) nAChRs (Bencherif 
et al. 1998).  Therefore, 42 is potent antagonist at α4β2* nAChRs and an agonist at other 
nAChR subtypes.  The R-isomer appears to be the more active of the two enantiomers, 
with a Ki value of 0.5 µM at α4β2* nAChRs, and an EC50 value of 9 nM, Emax = 55% at 
nAChR subtypes mediating NIC-evoked DA release (Dwoskin and Crooks 2001).  
Compounds 43a and 43b are adamantane analogs of anabasine, developed by R. J. 
Reynolds (Co. 1999, 1999, 1999, 2000).  Compound 43b was found to antagonize NIC 
(100 µM)-evoked 86Rb+ efflux in rat thalamic synaptosomes with an IC50 value of 630 
nM.  Additionally, both 43a and 43b were found to inhibit NIC-evoked [3H]-DA release 
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using rat striatal synaptosomes with values in the high nanomolar range (IC50 =659 and 
846 µM respectively) and were devoid of intrinsic activity.  Thus, these 1-aza-2-(5-
ethoxy-(3-pyridyl))tricyclo-[3.3.1.13,7]decanes appear to be nonselective and potent 
antagonist at α4β2* nAChR subtypes and nAChR subtypes mediating NIC-evoked DA 
release.  Compounds 44 and 45 are methylene bridged analogs of 2-(3-pyridyl-)-1-
azabicyclo[2.2.2]octane (42) and have high affinity for the [3H]-NIC binding site in rat 
cortical membranes (Ki = 37 and 73 nM respectively).  Although no functional 
antagonism has been reported in the 86Rb+ efflux assay, no agonist activity was observed 
in the 86Rb+ efflux assay, using rat thalamic synaptosomes.  Also, no agonist activity was 
observed in either muscle-type (α1β1γδ) or α3β4* nAChRs (Dwoskin et al. 2000; 
Dwoskin and Crooks 2001). 
 
2.8. Channel Blockers  
One of the first nAChR open channel blockers (OCB) was identified as hexamethonium 
(HEX, 46), a six-carbon bis-trimethylammonium alkyl compound, which acts within the 
pores of nAChR subtypes on autonomic ganglia (Paton and Zaimis 1951; Blackman et al. 
1963; Ascher et al. 1979).  HEX is considered a prototypical OCB, since it meets the 
following criteria: (1) it causes a voltage dependent blocking effect, (2) it displays a use-
dependent mode of action, and (3) it produces a more pronounced inhibitory effect when 
there is an increase in agonist concentrations (Ascher et al. 1979; Buisson and Bertrand 
1998).  Compound 46 has also been shown to exhibit antagonist effects on reconstituted 
chick and rat α4β2* nAChRs (Bertrand et al. 1990; Charnet et al. 1992). 
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Figure 2.11 Structures of Open Channel Blockers of the nAChR 
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Mecamylamine (MEC, 47) has become one of the most utilized nAChR blockers due to 
its ability to block the physiological, behavioral, and reinforcing effects of nicotine 
(Papke et al. 2001).  MEC, a neuronal and peripheral OCB, has been shown to block 
several neuronal nAChR subtypes at low micromolar affinities, but has lower activities at 
muscle- like nAChRs (Cachelin and Rust 1995; Briggs and McKenna 1996).  Moderate 
nanomolar inhibition (IC50 = 150 – 190 nM) of rat and Xenopus oocyte-expressed α3β4 
nAChRs has been observed (Cachelin and Rust 1995; Webster et al. 1999).  Separation of 
the R- and S-enantiomers of MEC demonstrated very little pharmacological benefit.  
However, S-(+)-MEC enantiomer appears to dissociate more slowly than R-(-)-MEC at 
α4β3* and α4β2* nAChRs (Papke et al. 2001).  Suchocki et al. (1991) prepared a series 
of C1, C2, C3, and C7 analogs of MEC and showed that compounds with methyl 
substituents at the C3 position were important for channel blockage activity (Suchocki et 
al. 1991).  Creasy et al. (1996) determined that substitutions on the C2 amino 
functionality with large groupings were detrimental to antinociception and hypomotility 
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activities (Creasy et al. 1996).  Webster et al. (1999) found that point mutations of the 
M2 region of the β4 subunit in Xenopus oocytes expressing ganglionic (α4β3) neuronal 
nAChRs, caused a decrease in sensitivity to MEC, indicating a possible binding location 
of MEC.  Another well studied OCB is the bis-quaternary antagonist, chlorisondamine 
(48).  This compound has no effect on [3H]-ACh or [3H]-NIC binding to rat brain 
(Schwartz et al. 1982).  However, chlorisondamine does block NIC-evoked DA release 
from rat striatal synaptosomes both in vitro and when administered over a period of 
weeks in vivo (10 mg/kg/day) (el-Bizri and Clarke 1994, 1994).  This suggests that the 
quaternary ammonium molecule is able to pass the blood brain barrier, although the exact 
mechanism is not known.  In addition, it is not known if metabolic changes could account 
for its CNS activity.  Central nervous system accumulation of chlorisondamine has been 
suggested to explain the blockade effects; however, this cannot provide a complete 
explanation of the long-term blockade effects of the drug (el-Bizri and Clarke 1994; 
Reuben et al. 1998).  Buisson and Bertrand have demonstrated that several OCBs have 
activity at human α4β2* receptors.  Classical NMDA OCBs, amantadine (49), 
memantine (50), and dizocilipine ((+)-MK-801, 51), as well as, the Ca2+ channel 
antagonist 8-(N,N-diethylamino)-octyl 3,4,5,-trimethoxybenzoate (TMB-8, 52) were 
evaluated using stably expressed α4β2* receptors from embryonic kidney 293 cells.  
ACh-elicited electrophysiological current blockade was measured in the presence of 
various concentrations of each of a number of antagonist molecules.  Potency values 
(IC50) were as follows: amantadine (3 µM) > memantine (7 µM) > TMB-8 (15 µM) ~ 
MK-801 (15 µM).  These studies demonstrated that OCBs tested non-competitively 
antagonized α4β2* nAChRs and were supported by a mechanism of action mathematical 
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model detailing the interaction between the nAChR and OCBs (Buisson and Bertrand 
1998).  TMB-8 has also been shown to potently inhibit agonist- induced flux through 
muscle-type and ganglionic type nAChRs (IC50 ~400 nM), as well as, exhibiting potent 
inhibition (IC50 ~500 nM) in NIC-evoked [3H]DA release assays using rat brain 
synaptosomes (Bencherif et al. 1995).  However, all nAChR binding affinities for TMB-8 
were in the moderate to high micromolar range (IC50 = 30 - 200 µM).  Additionally, in 
the muscle-type nAChR ion flux assay, in the presence of TMB-8, increased agonist 
(ACh) concentration caused a more potent blockade of the receptor.  MK-801 was also 
examined in human α7 nAChRs expressed in Xenopus oocytes, and exhibited a non-
competitive inhibition of ACh elicited currents (IC50 = 14 - 15 µM).  Stereoselectivity 
was not a criteria for blockade since both the (+)- and (-)-MK-801 isomers had similar 
activities and the blockade observed was dependent on cell potential, a hallmark of 
channel blockade (Briggs and McKenna 1996). 
 
2.9. The Nicotinic Pharmacophore  
The nicotinic pharmacophore has been studied for over fifty years.  Theories in the early 
1950s and 60s suggested a positive center located near an onium site (e.g. N+) (Hey 1952; 
Sekul and Holland 1961).  In the late sixties, the theory was revised to include a partially 
negative site near (4.85 Å) an onium site (Kier 1968).  Beers and Reich proposed a model 
that is considered to be the first for the nicotinic pharmacophore.  They proposed a two 
element system using both agonist and antagonist molecules: element 1- a protonated 
nitrogen, and element 2- an electronegative atom that can act as a hydrogen bond 
acceptor.  They also proposed a specific distance of 5.9 Å as the optimum length between 
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the center of the charged moiety and a van derWaals interaction area in the receptor 
binding site (Beers and Reich 1970).  Sheridan et al. (1986) suggested that a third 
element, an aryl centroid moiety, was needed for binding site recognition, a point or atom 
that was close to the H-bond acceptor site and that was in-line with the acceptor atom, in 
addition to altering the Beers-Reich distance to 4.8 Å (See Figure 2.12A) (Sheridan et al. 
1986).  Over the last decade, several nAChR ligands have been identified and 
modifications to the Sheridan model have been necessary.  One major issue was some 
compounds with affinity for the nAChR were not in accordance the Sheridan distance.  
Therefore, a model had to be developed for “long” and “short” ligands.  It is also 
important to note that stereochemistry plays an important part in receptor recognition, 
and since several enantiomerically pure ligands have dramatically different affinities 
compared to their optical isomers (Hacksell and Mellin 1989).  Tonder et al. (2001) 
proposed the following nAChR pharmacophore: 1- interaction between the protonated 
atom of the ligand (N+) with an anionic site (a) located on the receptor, 2- a hydrogen 
bond acceptor moiety (X) on the ligand that is paired with a H-bond donator (b) on the 
receptor surface, 3- π-system interaction of the ligand with π-systems (or positively 
charged residues) of the receptor (aryl centroid, c), 4- interactions between a protonated 
N-atom in the ligand and π-systems of the receptor (possibly Trp-149), and steric 
interactions around the aliphatic and heteroaromatic portions of the molecule (Figure 
2.12b) (Tonder and Olesen 2001; Tonder et al. 2001; Glennon and Dukat 2004).  Another 
model proposed involved the use of a water molecule to change “short” ligands into 
“long” ligands.  This water molecule may interact with the protonated atom or the 
hydrogen bonding acceptor (Glennon et al. 2004).  Many ligands, however, have shown 
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different affinities and activities at various nAChRs.  Therefore, different pharmacophore 
models may need to be developed for each individual receptor subtype, and maybe even 
for the assays as well, due to the varied characteristics of the pharmacological tools used. 
 
Figure 2.12  Pharmacophore models proposed for the α4β2* receptor subtype 
 
Reprinted from Bioorg Med Chem Lett, 14, Glennon and Dukat, a4ß2 nACh Receptor pharmacophore 
models, 1841-1844, Copyright (2004), with permission from Elsevier 
 
The pharmacological tools themselves pose a challenge as it is unclear which molecular 
species is interacting with the binding site.  Huang et al. (2005) modeled multiple free 
base and protonation states of NIC and (R)-descholoroepibatidine (DCEH) using a 
variety of molecular modeling and docking techniques to explore a general strategy of 
“from-microscopic-to-phenomenological” approach.  This procedure involved prediction 
of binding energies to each of the different states of NIC and DCEH.  Furthermore, 
hydrogen-bonding and cation-π  interactions were found to be the dominant forces that 
differentiated the binding strengths of the molecular states of NIC and DCEH.  These 
types of studies increase modeling ability beyond a static structure to a more dynamic 
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approach that can correlate binding energies with multiple states of molecule (Huang et 
al. 2005). 
 
2.10. Disease States 
Alzheimer’s Disease 
Alzheimer’s disease (AD) is diagnosed as the loss of ability to learn by memory and 
attention deficits and usually affect the population over the age of 65 years and older 
(Lindstrom 1997; Tuppo and Arias 2005).  As mentioned above, NIC improves cognitive 
function in healthy humans.  Additionally, treatment of Alzheimer’s patients with 
nicotine has attenuated the decline of cognitive deficits (Everitt and Robbins 1997; 
Lawrence and Sahakian 1998).  Diagnosed Alzheimer’s patients also had a decreased 
number of high affinity [3H]-NIC binding sites in various brain regions (Flynn and Mash 
1986; Whitehouse et al. 1988; Sugaya et al. 1990; Nordberg et al. 1995; Rusted et al. 
2000).  On a genetic level, β2 knockout mice (e.g. mice unable to express β2 subunits) 
lack high affinity nicotine binding sites.  In addition, these knockout mice demonstrated 
learning and memory abnormalities, implicating the α4β2* receptor subtype as playing a 
key role in cognitive function (Picciotto et al. 1995; Zoli et al. 1999).  
Neuroinflammation has also been linked to the onset of Alzheimer’s disease, although the 
role it plays is not fully understood (Tuppo and Arias 2005).  α7* binding sites are 
unaffected in Alzheimer’s patients; however, a high concentration of Ca2+ ions may 
implicate this receptor subtype in neurodegeneration, due to the high Ca2+ permeability of 
the α7* nAChR (Sugaya et al. 1990; Perry et al. 2000).  Additionally, strong correlations 
have been found between expression of α7* nAChR subtypes and the presence and rate 
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of accumulation of amyloid beta (1-42), the predominant Aβ  species in amyloid plaques.  
The two proteins strongly interact and interference in this interaction may lead to the 
neurodegeneration.  With this information, α7* nAChR subtypes may be targets for the 
treatment of Alzheimer’s disease (D'Andrea et al. 2002; D'Andrea and Nagele 2006).  To 
date, several subtype selective nAChR ligands are being investigated for their potential 
therapeutic value.  Among them are ABT-418 (Abbott Laboratories), RJR-2403 (R. J. 
Reynolds/Targacept), and GTS-21 (Decker et al. 1994; Lippiello et al. 1996; Kem 1997; 
Gotti et al. 2000).  Administration of the nAChR channel blocker, mecamylamine, 
decreased cognitive function in all populations tested.  This blockade of the channel is 
over come by administration of NIC.  Interestingly, younger healthy volunteers had a 
decreased sensitivity to the mecamylamine induced cognitive deficits, while AD patients 
had the highest sensitivity (Rusted et al. 2000) 
 
Parkinson’s Disease 
Parkinson’s disease (PD) has been closely associated with Alzheimer’s disease in that 
patients in both disease states are found to have deficiencies in neurotransmitter systems, 
as well as decreased nAChR expression within the CNS.  Parkinsonian patients suffer 
from an inability to control hyper-motor function.  This is manifested as difficulties in 
initiating and sustaining motions (Lloyd et al. 1975; Olanow 2004; Samii et al. 2004).  
These motor control problems occur due to loss of dopaminergic neurons in the 
substantia nigra (German et al. 1989).  L-Dihydroxyphenylanine (L-DOPA), a dopamine 
prodrug, treatments have been used as a form of dopamine substitute therapy, after 
conversion of L-DOPA to dopamine in the CNS.  Although not a cure for the disease, L-
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DOPA treatments can retard the degenerative effects for three to five years before 
peripheral side effects prevent it use.  Nicotine has also been linked to the treatment of 
Parkinson’s disease.  Monkeys given NIC with L-DOPA experienced a synergistic effect 
to reverse parkinsonian symptoms (Schneider et al. 1998; Domino et al. 1999).  An 
inverse relationship exists between smoking cigarettes and staving off the effects of PD.  
The occurrence of PD was decreased in smokers and non-smokers were two times as 
likely to contract PD (Fratiglioni and Wang 2000).  Studies suggest that targeting 
heterologously expressed receptors, non-α7, may be a valuable treatment for PD (Quik  et 
al. 2005).  α6* nAChR subtypes involved in mediating DA release have recently been 
suggested as a therapeutic target for PD.  Stimulation of these nAChR subtypes may 
result in relief from the PD symptoms without the side effects (O'Neill et al. 2002; Quik  
et al. 2004; Quik and McIntosh 2006).  Nicotine is thought to be acting as a protective 
agent in the CNS (Morens et al. 1995; Baron 1996).  SIB-1508Y (Sibia) has entered 
Phase 2 trials as a possible drug treatment for PD, due to its lower toxicity and increased 
potency for various nicotinic receptors (Sacaan et al. 1997; Arneric and Brioni 1999). 
 
Schizophrenia 
An excess of dopamine in the CNS has been hypothesized to cause Schizophrenia.  
Symptoms of this disease include delusions, hallucinations, blunt affect, and chaotic 
thinking and speech (Arnold and Trojanowski 1996).  Schizophrenics have sensory 
imbalances, thereby making it difficult to regulate auditory and visual stimuli.  Smoking 
is pervasive among the schizophrenic community (Lohr and Flynn 1992).  It is postulated 
that those suffering from this disease smoke cigarettes in order to self-medicate 
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themselves with nicotine (Freedman et al. 1997; Sacco et al. 2005).  Nicotine normalizes 
the gating deficit seen in patients participating in the P50 auditory-evoked response test 
(Adler et al. 1993; Bencherif and Schmitt 2002).  Due to this finding, it has been 
suggested that nAChRs may be involved in schizophrenia.  α7* receptors are decreased 
in schizophrenics (Freedman et al. 1995).  Additionally, α7* antagonists impair auditory 
gating in rodents, indicating a possible loss, or reduced function of α7* nAChRs in 
schizophrenics’ gating response (Luntz-Leybman et al. 1992; Lena and Changeux 1997).  
A genetic polymorphism in the a7* nicotinic receptor D15S1360 has been linked to a 
deficiency in the normal inhibition of the P50 auditory-evoked response (Freedman et al. 
1997).  De Luca et al. (2004) demonstrated a genetic difference in the D15S1360 marker 
between Parkinson’s patients who smoke and those that do not, though larger studies are 
still needed to determine the relevance of these findings (De Luca et al. 2004). 
 
Pain Management 
Pain therapies have traditionally centered around two classes of compounds, nonsteroidal 
anti- inflammatory drugs (NSAIDs) and opioids.  Nicotine in higher doses, however, 
affords a moderate and short-lived antinociceptive effect (Sahley and Berntson 1979; 
Tripathi et al. 1982).  The discovery of the non-selective nAChR agonist, epibatidine, 
stimulated interest in the pain management aspect of nicotinic receptors.  Epibatidine has 
demonstrated a potent mecamylamine-sensitive antinociceptive effect in animals (Badio 
and Daly 1994; Sullivan et al. 1994).  However, due to its non-selectivity, epibatidine is 
not considered a drug candidate for the treatment of pain (Decker and Meyer 1999).  
Specific nAChR subtypes involved in analgesia have yet to be identified, although α4β2* 
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and α3β4* ganglionic receptor subtypes have been implicated (Badio et al. 1997; Badio  
et al. 1997; Marubio et al. 1999).  Additionally, nicotinic agonist- induced antinociceptive 
behavior is most likely resulting from involvement of the α4β2* subtype causing or 
mediating neurotransmitter release in the spinal cord (Hogg and Bertrand 2004).  Affinity 
for the α4β2* subtype, however, does not necessarily denote antinociceptive activity in a 
compound (Meyer et al. 2000).  Studies assessing the possible role of α7* nAChRs in 
pain therapy have had mixed results.  MLA and α-Btx were unable to block the 
antinociceptive effects of nicotine, cytosine, and other nAChR agonists in the tail- flick 
latency test (Rao et al. 1996; Damaj et al. 1998).  When choline, an α7-specific agonist, 
was used to elicit the effect of analgesia, MLA and α-Btx were able to block the 
antinociceptive effect (Damaj et al. 2000). 
 
Tourette’s Syndrome 
Tourette’s syndrome is a hyperkinetic motor disorder characterized by involuntary 
movements and vocalizations.  Although the exact mechanism of action is unknown, 
antipsychotics (e.g. haloperidol) are used to attenuate the symptoms of the condition.  
However, this treatment is not effective in ~30% of the cases and the drug causes some 
side effects (Erenberg et al. 1987; Shapiro et al. 1989).  Nicotine reduces the symptoms 
of Tourette’s syndrome in animal models, as well as in human subjects (Moss et al. 1989; 
Sanberg et al. 1989; Sanberg et al. 1997).  Presently, the nicotinic mechanism of these 
therapies is thought to be the  inactivation of α4β2* or α7* receptor subtypes, as well as a 
prolonged desensitization period (Lindstrom 1997; Sanberg et al. 1997).  Mecamylamine 
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has also been used as a potential therapy for the attenuation of the tics associated with 
this disease (Silver et al. 2000; Young et al. 2001). 
 
Smoking Cessation 
Due to the addictive properties of NIC, the active alkaloid in tobacco products, smoking 
cessation has long been associated with the nicotinic receptors (Benowitz 1996; Rose 
1996).  Nicotine replacement therapy has been employed via nicotine gums, patches, and 
nasal sprays in order to achieve abatement of smoking (Hajek et al. 1999).  Further 
research has also shown that the combination of the channel blocker mecamylamine with 
nicotine patches decreases cravings for cigarettes (Rose et al. 1994; Rose et al. 1998; 
Rose et al. 2001).  Researchers uses the Rose et al. studies as the basis for using a partial 
agonist, which combines agonist and antagonist properties, to provide relief to smoking 
cessation patients.  Cystine analogs, including varenicline, a α4β2* nicotinic receptor 
subtype partial agonist, have been evaluated as agents for smoking cessation by Pfizer 
Laboratories (Coe et al. 2005; Coe et al. 2005).  The alkaloid (-)- lobeline was in clinical 
trials as treatment for smoking cessation (Schneider and Olsson 1996).  However, further 
study revealed that lobeline use in patient groups was not statistically different than those 
of the placebo group, though one of three sites did demonstrate significant improvements 
(Glover et al. 1998).  Therefore, the use of lobeline as a smoking cessation agent is not 
fully understood and not a viable option currently (Dwoskin and Crooks 2002).  
Bupropion, a phenylaminoketone atypical antidepressant, has been utilized as a sustained 
release therapy for smoking cessation (George and O'Malley 2004).  The mechanism of 
action is not known but Bupropion is a nicotinic antagonist at a3ß2, a4ß2, and a7 
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receptor subtypes expressed in Xenopus oocytes (IC50 = 1.3, 8.0, and 60 µM, 
respectively) (Slemmer et al. 2000).  However, given its limited effectiveness and cost, 
Bupropion is not considered a long term solution (Sweet 2003). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Copyright © Joshua Thomas Longen Ayers 2006 
 60 
Chapter 3: Synthesis and Evaluation of mono- and bis-Alkylated Quaternary 
Ammonium Salts  
 
3.1. Introduction 
The neuronal nicotinic acetylcholine receptor (nAChR) belongs to a superfamily of 
ligand gated ion channel receptors, and has several diverse and complicated 
substructures.  Each receptor is composed of five individual subtypes either 
heterologously or homologously expressed.  Selected heterogeneous subtypes include 
combinations of α3, α4, α5, α6 and β2 or β4 (e.g. α4β2*) subunits, while the 
predominant homologous subtype is composed of α7 subunits (α7*) (Holladay et al. 
1997).  The endogenous ligand, acetylcholine (ACh), as well as NIC are agonists at the 
receptor binding site.  NIC has been studied as a potential treatment in several 
pathologies (e.g. Alzheimer’s and Parkinson’s disease, schizophrenia, and analgesia) and 
has been used as a treatment in smoking cessation programs (Lindstrom 1997).  
However, NIC is a nonspecific agonist interacting with several receptor subtypes, both in 
the periphery, as well as in the central nervous system (CNS).  Therefore, a large amount 
of research has been devoted to the discovery of agonists that may increase the potential 
beneficial therapeutic effects and decrease the side effects of NIC (Holladay et al. 1997).  
These efforts have afforded a number of agonist compounds that are both potent and 
selective for nAChR subtypes.  Surprisingly, very little research has focused on structure 
activity relationships (SARs) involving nAChR antagonists that are subtype selective 
(Dwoskin et al. 2000; Dwoskin and Crooks 2001). 
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mono-Substituted Quaternary Ammonium Molecules 
Crooks et al. (1995) synthesized a small series of N-alkylated nicotinium compounds that 
demonstrated selective antagonist activities at different neuronal nAChR subtypes.  
Alkylating the pyridino N-atom of the NIC molecule with an n-octyl carbon chain 
afforded a compound that was both potent and selective for the nAChRs mediating 
dopamine (DA) release, a purported α6 containing receptor (Crooks et al. 1995).  
Incorporating an n-decyl carbon chain was later shown to afford an analog that was a 
selective antagonist at the α4β2* receptor subtype (Dwoskin et al. 1999).  Thus, subtle 
changes in the alkyl chain length of these N-n-alkylnicotinium analogs produced a 
surprising difference in the antagonist activities of the compounds.  Conformationally 
restricted analogs of the NIC molecule were also N-n-alkylated and these compounds 
retained antagonist activity at the nAChRs mediating DA release, with chain lengths of 8-
12 carbons in the syn-conformation (24a-e) and 8-11 carbons in the anti-conformation 
(25a-d) affording various degrees of antagonist activity (Xu et al. 2001).  Unlike the N-n-
alkylnicotinium analogs, none of these conformationally restricted molecules antagonized 
the α4β2* nAChR subtype.  Therefore, structural modification of the nicotine molecule 
can result in compounds with potent and selective nAChR antagonist characteristics. 
 
bis-Substituted Quaternary Ammonium Molecules 
bis-Quaternary ammonium salts have also been used as ligands in several receptor 
systems.  For example, bis-quinolinium cyclophans have been used to block Apamin-
sensitive Ca2+-activated K+ channels (Chen et al. 2000).  Investigators determined that 
altering the chain lengths of alkane spacers between the quaternary ammonium centers 
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could effectively afford analogs that inhibit receptor function.  Additionally, like the 
mono-substituted N-alkyl quaternized ammonium salts, bis-substituted quaternized 
ammonium salts have demonstrated selective inhibition of peripheral nicotinic 
acetylcholine receptor subtypes.  Peripheral nicotinic receptor antagonists, such as 
hexamethonium (HEX, 46) and decamethonium (DEC), were originally prepared as 
simple analogs of the neuromuscular blocking agent, d-tubocurarine (d-Tub, 16).  The ten 
carbon analog, DEC, demonstrated competitive inhibition of nicotinic receptors at the 
neuromuscular junction, while HEX primarily antagonized nerve-nerve terminals 
(ganglionic receptors).  These two bis-quaternary ammonium compounds were among 
the first to be used to differentiate between the different subtypes of peripheral nicotinic 
receptors, muscle and ganglionic.  Although their mechanisms of action are quite 
different, DEC and HEX have been shown to have the optimum chain lengths for binding 
to their respective receptor subtypes in the periphery.  In the CNS, HEX and DEC have 
been evaluated for NIC binding at a4ß2* receptors and found to exhibit weak affinities 
(Ki = 31.9 and 4.27, respectively) for the receptor subtype (Ayers et al. 2005).  d-Tub, a 
more complex bis-quaternary structure, also has activity at the muscle-type peripheral 
nAChR subtype, but it also has activities at the ganglionic receptor subtypes and at a4ß2* 
subtypes (Ascher et al. 1979; Colquhoun et al. 1979; Ogden and Colquhoun 1985; 
Bertrand et al. 1990).  Therefore, bis-quaternary ammonium structures have been used 
mainly as antagonists peripherally, and have the potential to differentiate between these 
nAChR subtypes by both altering the chain length and the quaternary ammonium 
headgroup. 
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In order to assess the pyrrolidine moiety’s importance to the antagonist activity of these 
interesting series of compounds, a series of quaternized aza-aromatic compounds (e.g. 
pyridine, 3-picoline, nicotinamide, and NIC) were evaluated (53-56).  In addition to the 
assessment of the importance of the pyrrolidine ring, alkyl chain lengths of between one 
to twenty carbon units were attached to the pyridino functionality to evaluate the 
relationship between alkyl chain length and inhibition of and selectivity for various 
nAChR subtypes. 
 
Figure 3.1 mono-Alkylated Quaternary Ammonium Salts 
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Additionally, bis-quaternary ammonium salts (57-61) were evaluated for their effect on 
various nAChR subtypes as analogs of the existing peripheral antagonists HEX, DEC, 
and d-Tub to determine if such analogs antagonized neuronal nicotine receptors.  Varying 
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chain lengths and different pyridinium moieties (e.g. pyridinium, 3-picolinium, 
quinolinium, isoquinolinium, and nicotinium) were utilized to determine if selective 
nicotinic receptor subtype antagonism could be achieved. 
 
Figure 3.2 bis-Alkylated Quaternary Ammonium Salts 
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3.2. Experimental 
3.2.1. Chemicals 
S-(-)-Nicotine, pyridine, 3-picoline, nicotinamide, quinoline, isoquinoline, iodomethane, 
iodoethane, 1- iodopropane, 1- iodobutane, 1-iodopentane, 1- iodohexane, 1-iodoheptane, 
1-iodooctane, 1-iodononane, 1- iododecane, 1- iodoundecane, 1-iodododecane, 1-
bromopentadecane, 1-bromoecosane, 1,5-diiodopentane, 1,6-diiodohexane, 1,8-
diiodooctane, 1,9-dibromononane, 1,10-diiododecane, 1,11-dibromoundecane, 1,12-
dibromododecane, diethylether, chloroform, deuterium oxide (100% atom D), deuterium 
chloride solution (20% W/W solution in D2O, 99.5% atom D), 3-(trimethylsilyl)-2,2,3,3-
d4-propionate, and α-D-glucose were purchased from Aldrich Chemical Company Inc. 
(Milwaukee, WI).  Acetic acid, was obtained from Fisher Scientific (Pittsburgh, PA).  S-
(-)-Nicotine ditartrate, nomifensine maleate, and mecamylamine hydrochloride (MEC) 
were purchased from Research Biochemicals, Inc. (Natick, MA).  S-(-)-Cytisine, 
pargyline hydrochloride, N-[2-hydroxyethyl]piperazine-N’-[2-ethanesulfonic acid] 
(HEPES), Tris[hydroxymethyl]-aminomethane hydrochloride (Trizma HCl), 
Tris[hydroxymethyl]aminomethane (Trizma base), polyethylenimine (PEI), and 
dihydroxy-β-erythroidine hydrobromide (DHβE) were purchased from Sigma Chemical 
Co. (St. Louis, MO).  Ascorbic acid, and TS-2 tissue solubilizer were purchased from 
Fluka (Ronkonkona, NY), AnalaR (BHD Ltd., Poole, U.K.), and Research Products 
International (Mount Prospect, IL), respectively.  [3H]Dopamine ([3H]DA); 3,4-ethyl-2-
[N-3H]dihydroxyphenylethylamine;  specific activity, 25.6 Ci/mmol) and [3H]nicotine (L-
(−)-[N-methyl-3H];  specific activity, 78.4 Ci/mmol) were obtained from New England 
Nuclear (Boston, MA). 
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3.2.2. Synthetic Procedures 
3.2.3. Synthetic Procedures for the Preparation of mono-Substituted Pyridinium 
Derivatives 
 
3.2.3.1. Pyridinium Salts 
The appropriate 1- iodoalkane or 1-bromoalkane (5.01-16.1 mmol) was added to a 
solution (30 mL) of dry pyridine and the solution was heated for 24 h at 65°C.  The 
resulting solid precipitates were filtered and washed five times with dry diethyl ether.  
For liquid products, the excess pyridine was decanted off, the resulting liquid precipitates 
were washed with diethyl ether five times, and the remaining liquid was dried under 
vacuum.  The resulting solids or liquids were isolated in 56-95% yields. 
 
N-Methylpyridinium Iodide (NMPI, 53a) 
1H NMR (300 MHz, DMSO-D6), δ 9.01 (2H, d, C2&C6-H), 8.58 (1H, t, C4-H), 8.13 
(2H, t, C3&C5-H), 4.37 (3H, s, C’1-CH3); 13C NMR (75 MHz, DMSO-D6), δ 145.3, 
144.8, 127.5, 48.0.  The resulting tan solid was isolated in 95% yield, with a melting 
point of 117°C.  Combustion Analysis: calculated for C6H8IN, C, 32.60; H, 3.65; N, 6.35.  
Found: C, 32.51; H, 3.62; N, 6.34. 
 
N-Ethylpyridinium Iodide (NEPI, 53b) 
1H NMR (300 MHz, DMSO-D6), δ 9.14 (2H, d, C2&C6-H), 8.60 (1H, t, C4-H), 8.16 
(2H, t, C3&C5-H), 4.67 (2H, q, C’1-CH2), 1.53 (3H, t, C’2-CH3); 13C NMR (75 MHz, 
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DMSO-D6), δ 145.5, 144.0, 127.8, 56.0, 16.0.  The resulting yellow solid was isolated in 
92% yield, with a melting point of 88-89°C.  Combustion Analysis: calculated for 
C7H10IN, C, 35.77; H, 4.29; N, 5.96.  Found: C, 35.86; H, 4.33; N, 5.94. 
 
N-n-Propylpyridinium Iodide (NPrPI, 53c) 
1H NMR (300 MHz, DMSO-D6), δ 9.19 (2H, d, C2&C6-H), 8.63 (1H, t, C4-H), 8.17 
(2H, t, C3&C5-H), 4.64 (2H, t, C’1-CH2), 1.89 (2H, m, C’2-CH2), 0.80 (3H, t, C’3-CH3); 
13C NMR (75 MHz, DMSO-D6), δ 144.7, 143.8, 127.1, 61.1, 23.4, 9.4.  The resulting 
brown liquid was isolated in 87% yield.  Combustion Analysis: calculated for C8H12IN, 
C, 38.57; H, 4.86; N, 5.62.  Found: C, 38.73; H, 4.92; N, 5.61. 
 
N-n-Butylpyridinium Iodide (NBuPI, 53d) 
1H NMR (300 MHz, DMSO-D6), δ 9.19 (2H, d, C2&C6-H), 8.64 (1H, t, C4-H), 8.18 
(2H, t, C3&C5-H), 4.67 (2H, t, C’1-CH2), 1.90 (2H, p, C’2-CH2), 1.25 (2H, m, C’3-CH2), 
0.86 (3H, t, C’4-CH3); 13C NMR (75 MHz, DMSO-D6), δ 146.2, 144.5, 127.9, 60.4, 32.4, 
18.4, 13.1.  The resulting orange liquid was isolated in 90% yield, with a melting point of 
59-62°C.  Combustion Analysis: calculated for C9H14IN, C, 41.08; H, 5.36; N, 5.32.  
Found: C, 41.14; H, 5.41; N, 5.32. 
 
N-n-Pentylpyridinium Iodide (NPePI, 53e) 
1H NMR (300 MHz, DMSO-D6), δ 9.16 (2H, d, C2&C6-H), 8.62 (1H, t, C4-H), 8.17 
(2H, t, C3&C5-H), 4.83 (2H, t, C’1-CH2), 1.89 (2H, p, C’2-CH2), 1.23 (4H, m, C’3&C’4-
CH2), 0.80 (3H, t, C’5-CH3); 13C NMR (75 MHz, DMSO-D6), δ 146.2, 144.5, 127.9, 
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60.4, 30.0, 27.2, 21.3, 13.7.  The resulting orange solid was isolated in 93% yield, with a 
melting point of 62°C.  Combustion Analysis: calculated for C10H16IN, C, 43.34; H, 5.82; 
N, 5.05.  Found: C, 43.47; H, 5.87; N, 5.04. 
 
N-n-Hexylpyridinium Iodide (NHxPI, 53f) 
1H NMR (300 MHz, DMSO-D6), δ 9.17 (2H, d, C2&C6-H), 8.63 (1H, t, C4-H), 8.19 
(2H, t, C3&C5-H), 4.85 (2H, t, C’1-CH2), 2.00 (2H, p, C’2-CH2), 1.24 (6H, m, C’3-C’5-
CH2), 0.80 (3H, t, C’6-CH3); 13C NMR (75 MHz, DMSO-D6), δ 145.5, 144.6, 128.1, 
60.6, 30.6, 30.4, 24.9, 21.8, 13.8.  The resulting yellow solid was isolated in 94% yield, 
with a melting point of 62°C.  Combustion Analysis: calculated for C11H18IN, C, 45.37; 
H, 6.23; N, 4.81.  Found: C, 45.30; H, 6.20; N, 4.85. 
 
N-n-Heptylpyridinium Iodide (NHpPI, 53g) 
1H NMR (300 MHz, DMSO-D6), δ 9.17 (2H, d, C2&C6-H), 8.63 (1H, t, C4-H), 8.18 
(2H, t, C3&C5-H), 4.65 (2H, t, C’1-CH2), 1.90 (2H, p, C’2-CH2), 1.22 (8H, m, C’3-C’6-
CH2), 0.80 (3H, t, C’7-CH3); 13C NMR (75 MHz, DMSO-D6), δ 145.5, 144.6, 128.1, 
60.6, 31.1, 30.6, 27.9, 25.2, 21.8, 13.9.  The resulting yellow solid was isolated in 89% 
yield, with a melting point of 63°C.  Combustion Analysis: calculated for C12H20IN, C, 
47.22; H, 6.61; N, 4.59.  Found: C, 47.40; H, 6.72; N, 4.58. 
 
N-n-Octylpyridinium Iodide (NOPI, 53h) 
1H NMR (300 MHz, DMSO-D6), δ 9.16 (2H, d, C2&C6-H), 8.62 (1H, t, C4-H), 8.17 
(2H, t, C3&C5-H), 4.83 (2H, t, C’1-CH2), 1.89 (2H, p, C’2-CH2), 1.22 (10H, m, C’3-C’7-
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CH2), 0.80 (3H, t, C’8-CH3); 13C NMR (75 MHz, DMSO-D6), δ 145.0, 144.2, 127.6, 
60.1, 30.6, 30.2, 27.9, 27.8, 24.8, 21.4, 13.4.  The resulting brown liquid was isolated in 
87% yield.  Combustion Analysis: calculated for C13H22IN, C, 48.91; H, 6.95; N, 4.39.  
Found: C, 49.01; H, 7.08; N, 4.39. 
 
N-n-Nonylpyridinium Iodide (NNPI, 53i) 
1H NMR (300 MHz, DMSO-D6), δ 9.14 (2H, d, C2&C6-H), 8.62 (1H, t, C4-H), 8.17 
(2H, t, C3&C5-H), 4.62 (2H, t, C’1-CH2), 1.90 (2H, p, C’2-CH2), 1.22 (12H, m, C’3-C’8-
CH2), 0.82 (3H, t, C’9-CH3); 13C NMR (75 MHz, DMSO-D6), δ 145.5, 144.6, 128.1, 
60.7, 31.3, 30.6, 28.6, 28.5, 28.3, 25.3, 22.0, 13.9.  The resulting yellow solid was 
isolated in 88% yield, with a melting point of 76°C.  Combustion Analysis: calculated for 
C14H24IN, C, 50.46; H, 7.26; N, 4.20.  Found: C, 50.42; H, 7.34; N, 4.21. 
 
N-n-Decylpyridinium Iodide (NDPI, 53j) 
1H NMR (300 MHz, DMSO-D6), δ 9.15 (2H, d, C2&C6-H), 8.62 (1H, t, C4-H), 8.17 
(2H, t, C3&C5-H), 4.82 (2H, t, C’1-CH2), 1.92 (2H, p, C’2-CH2), 1.22 (14H, m, C’3-C’9-
CH2), 0.82 (3H, t, C’10-CH3); 13C NMR (75 MHz, DMSO-D6), δ 145.5, 144.7, 128.1, 
60.8, 31.2, 30.7, 28.8, 28.7, 28,6, 28.4, 25.3, 22.0, 13.9.  The resulting pale yellow solid 
was isolated in 84% yield, with a melting point of 71°C.  Combustion Analysis: 
calculated for C15H26IN, C, 51.88; H, 7.55; N, 4.03.  Found: C, 51.91; H, 7.54; N, 4.00. 
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N-n-Undecylpyridinium Iodide (NUPI, 53k) 
1H NMR (300 MHz, DMSO-D6), δ 9.12 (2H, d, C2&C6-H), 8.61 (1H, t, C4-H), 8.17 
(2H, t, C3&C5-H), 4.61 (2H, t, C’1-CH2), 2.00 (2H, p, C’2-CH2), 1.24 (16H, m, C’3-
C’10-CH2), 0.83 (3H, t, C’11-CH3); 13C NMR (75 MHz, DMSO-D6), δ 145.2, 144.4, 
127.8, 60.1, 31.0, 30.3, 28.6 (x2), 28.4, 28,3, 28.1, 25.0, 21.7, 13.6.  The resulting pale 
yellow solid was isolated in 82% yield, with a melting point of 91°C.  Combustion 
Analysis: calculated for C16H28IN, C, 53.19; H, 7.81; N, 3.88.  Found: C, 53.24; H, 7.80; 
N, 3.89. 
 
N-n-Dodecylpyridinium Iodide (NDDPI, 53l) 
1H NMR (300 MHz, DMSO-D6), δ 9.13 (2H, d, C2&C6-H), 8.62 (1H, t, C4-H), 8.18 
(2H, t, C3&C5-H), 4.73 (2H, t, C’1-CH2), 1.89 (2H, p, C’2-CH2), 1.24 (18H, m, C’3-
C’11-CH2), 0.84 (3H, t, C’12-CH3); 13C NMR (75 MHz, DMSO-D6), δ 145.4, 144.6, 
128.0, 60.7, 31.2, 30.8, 28.9 (x3), 28.8, 28,7, 28.6, 25.4, 22.0, 13.9.  The resulting yellow 
solid was isolated in 85% yield, with a melting point of 84°C.  Combustion Analysis: 
calculated for C17H30IN, C, 54.40; H, 8.06; N, 3.73.  Found: C, 54.59; H, 7.97; N, 3.73. 
 
N-n-Pentadecylpyridinium Bromide (NPeDPB, 53m) 
1H NMR (300 MHz, CDCl3), δ 9.44 (2H, d, C2&C6-H), 8.49 (1H, t, C4-H), 8.11 (2H, t, 
C3&C5-H), 5.02 (2H, t, C’1-CH2), 2.01 (2H, p, C’2-CH2), 1.35 (24H, m, C’3-C’14-CH2), 
0.86 (3H, t, C’15-CH3); 13C NMR (75 MHz, CDCl3), δ 145.2, 145.1, 128.4, 62.6, 32.3, 
32.2, 30.0, 29.9(x3), 29.8, 29.7, 29.6, 29.3, 26.4, 22.1, 14.5.  The resulting tan solid was 
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isolated in 65% yield, with a melting point of 76°C.  Combustion Analysis: calculated for 
C20H36BrN. 1.0 H2O, C, 61.84; H, 9.86; N, 3.61.  Found: C, 61.73; H, 9.62; N, 3.60. 
 
N-Ecosylpyridinium Bromide (NEcPB, 53n) 
1H NMR (300 MHz, DMSO-D6), δ 9.13 (2H, d, C2&C6-H), 8.62 (1H, t, C4-H), 8.17 
(2H, t, C3&C5-H), 4.61 (2H, t, C’1-CH2), 1.80 (2H, p, C’2-CH2), 1.25 (34H, m, C’3-
C’19-CH2), 0.85 (3H, t, C’20-CH3); 13C NMR (75 MHz, DMSO-D6), δ 145.3, 144.6, 
127.9, 60.7, 31.3, 30.7, 29.0 (x10), 28.9, 28.8, 28.7, 28.4, 25.4, 22.1, 14.0.  The resulting 
white solid was isolated in 56% yield, with a melting point of 73°C.  Combustion 
Analysis: calculated for C25H46BrN. 1.75 H2O, C, 63.61; H, 10.57; N, 2.97.  Found: C, 
63.45; H, 10.27; N, 3.00. 
 
3.2.3.2. Picolinium Salts 
The appropriate 1-iodoalkane (5.01-16.1 mmol) was added to a solution (30 mL) of 3-
picoline, and the solution heated for 24 h at 65°C.  The resulting liquid precipitates had 
the excess picoline decanted off and the resulting oil precipitates were washed with 
diethyl ether five times, and the remaining oil was dried under vacuum.  The resulting oil 
was isolated in yields ranging from 89-94%. 
 
N-n-Octylpicolinium Iodide (NOPiI, 54a) 
1H NMR (300 MHz, DMSO-D6), δ 9.04 (1H, s, C2 -H), 8.94 (1H, s, C6-H), 8.45 (1H, d, 
C4-H), 8.06 (1H, t, C5-H), 4.55 (2H, t, C’1-CH2), 2.50 (3H, s, C3-CH3), 1.91 (2H, p, 
C’2-CH2), 1.25 (10H, m, C’3-C’7-CH2), 0.85 (3H, t, C’8-CH3); 13C NMR (75 MHz, 
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DMSO-D6), δ 145.5, 144.0, 141.8, 138.5, 127.2, 60.5, 31.1, 30.6, 28.4 (x2), 25.4, 22.1, 
17.9, 14.0.  The resulting dark brown oil was isolated in 92% yield.  Combustion 
Analysis: calculated for C14H24IN, C, 50.46; H, 7.26; N, 4.20.  Found: C, 50.26; H, 7.28; 
N, 4.18. 
 
N-n-Nonylpicolinium Iodide (NNPiI, 54b) 
1H NMR (300 MHz, DMSO-D6), δ 9.00 (1H, s, C2 -H), 8.94 (1H, s, C6-H), 8.45 (1H, d, 
C4-H), 8.06 (H, t, C5-H), 4.55 (2H, t, C’1-CH2), 2.50 (3H, s, C3-CH3), 1.91 (2H, p, C’2-
CH2), 1.25 (10H, m, C’3-C’7-CH2), 0.85 (3H, t, C’8-CH3); 13C NMR (75 MHz, DMSO-
D6), δ 145.5, 144.0, 141.8, 138.5, 127.2, 60.5, 31.2, 30.6, 28.7, 28.6, 28.4, 25.4, 22.1, 
17.9, 14.0.  The resulting dark brown oil was isolated in 94% yield.  Combustion 
Analysis: calculated for C15H26IN, C, 51.88; H, 7.55; N, 4.03.  Found: C, 51.99; H, 7.54; 
N, 4.04. 
 
N-n-Decylpicolinium Iodide (NDPiI, 54c) 
1H NMR (300 MHz, DMSO-D6), δ 9.02 (1H, s, C2 -H), 8.93 (1H, s, C6-H), 8.45 (1H, d, 
C4-H), 8.06 (1H, t, C5-H), 4.53 (2H, t, C’1-CH2), 2.50 (3H, s, C3-CH3), 1.91 (2H, p, 
C’2-CH2), 1.23 (14H, m, C’3-C’9-CH2), 0.84 (3H, t, C’10-CH3); 13C NMR (75 MHz, 
DMSO-D6), δ 145.5, 144.0, 141.8, 138.5, 127.2, 60.5, 31.3, 30.6, 28.9, 28.8, 28.7, 28.4, 
25.4, 22.1, 17.9, 14.0.  The resulting dark brown oil was isolated in 90% yield.  
Combustion Analysis: calculated for C16H28IN, C, 53.19; H, 7.81; N, 3.88.  Found: C, 
53.24; H, 7.79; N, 3.89. 
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N-n-Undecylpicolinium Iodide (NUPiI, 54d)  
1H NMR (300 MHz, DMSO-D6), δ 9.04 (1H, s, C2 -H), 8.94 (1H, s, C6-H), 8.46 (1H, d, 
C4-H), 8.07 (1H, t, C5-H), 4.55 (2H, t, C’1-CH2), 2.50 (3H, s, C3-CH3), 1.91 (2H, p, 
C’2-CH2), 1.24 (18H, m, C’3-C’11-CH2), 0.85 (3H, t, C’12-CH3); 13C NMR (75 MHz, 
DMSO-D6), δ 145.5, 144.0, 141.7, 138.5, 127.2, 60.5, 31.3, 30.6, 29.0, 28.9, 28.8, 28.7, 
28.4, 25.4, 22.1, 17.9, 14.0.  The resulting dark brown oil was isolated in 89% yield.  
Combustion Analysis: calculated for C17H30IN, C, 54.40; H, 8.06; N, 3.73.  Found: C, 
54.53; H, 7.99; N, 3.75. 
 
N-n-Dodecylpicolinium Iodide (NDDPiI, 54e) 
1H NMR (300 MHz, DMSO-D6), δ 9.03 (1H, s, C2 -H), 8.94 (1H, s, C6-H), 8.46 (1H, d, 
C4-H), 8.17 (1H, t, C5-H), 4.54 (2H, t, C’1-CH2), 2.50 (3H, s, C3-CH3), 1.92 (2H, p, 
C’2-CH2), 1.25 (18H, m, C’3-C’11-CH2), 0.86 (3H, t, C’12-CH3); 13C NMR (75 MHz, 
DMSO-D6), δ 145.7, 144.1, 141.9, 138.7, 127.3, 60.6, 31.2, 30.5, 28.9 (x2), 28.8, 28.7, 
28.6, 28.3, 25.3,22.0, 17.8, 13.9.  The resulting dark brown oil was isolated in 91% yield.  
Combustion Analysis: calculated for C18H32IN, C, 55.53; H, 8.28; N, 3.60.  Found: C, 
55.70; H, 8.20; N, 3.59. 
 
3.2.3.3. N-Alkylated Nicotinamide Salts 
The appropriate 1-iodoalkane (5.01-16.1 mmol) was added to a solution (30 mL) of 
nicotinamide (40.94 mmol) in methanol.  The solution was heated for 24 h at 65°C.  The 
resulting precipitate was filtered, and the product washed five times with dry diethyl 
ether.  The remaining solid was then dissolved in water and extracted with chloroform (3 
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x 25 mL).  The organic layer was dried over anhydrous magnesium sulfate, filtered, and 
the solvent removed.  The resulting solid was isolated in yields ranging from 70-83%. 
 
N-n-Octylnicotinamide Iodide (NONAI, 55a) 
1H NMR (300 MHz, DMSO-D6), δ 9.47 (1H, s, C2 -H), 9.20 (1H, d, C6-H), 8.92 (1H, d, 
C4-H), 8.54 (1H, s, N1’-H), 8.27 (2H, t, C5-H), 8.18 (1H, s, N1’-H), 4.64 (2H, t, C’1-
CH2), 1.93 (2H, p, C’2-CH2), 1.27 (10H, m, C’3-C’7-CH2), 0.87 (3H, t, C’8-CH3); 13C 
NMR (75 MHz, DMSO-D6), δ 162.6, 146.2, 144.6, 143.0, 133.7, 127.7, 61.1, 31.1, 30.6, 
28.4 (x2), 25.4, 22.1, 14.0.  The resulting golden solid was isolated in 83% yield, with a 
melting point of 154-155°C.  Combustion Analysis: calculated for C14H23IN2O 0.25 H2O, 
C, 45.85; H, 6.46; N, 7.64.  Found: C, 45.60; H, 6.36; N, 7.71. 
 
N-n-Nonylnicotinamide Iodide (NNNAI, 55b) 
1H NMR (300 MHz, DMSO-D6), δ 9.48 (1H, s, C2 -H), 9.22 (1H, d, C6-H), 8.92 (1H, d, 
C4-H), 8.54 (1H, s, N1’-H), 8.28 (2H, t, C5-H), 8.17 (1H, s, N1’-H), 4.63 (2H, t, C’1-
CH2), 1.93 (2H, p, C’2-CH2), 1.25 (12H, m, C’3-C’8-CH2), 0.85 (3H, t, C’9-CH3); 13C 
NMR (75 MHz, DMSO-D6), δ 162.6, 146.2, 144.6, 143.0, 133.7, 127.7, 61.1, 31.2, 30.6, 
28.7, 28.6, 28.4, 25.4, 22.1, 14.0.  The resulting yellow solid was isolated in 80% yield, 
with a melting point of 164°C.  Combustion Analysis: calculated for C15H25IN2O 0.5 
H2O, C, 46.76; H, 6.80; N, 7.27.  Found: C, 46.55; H, 6.69; N, 7.30. 
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N-n-Decylnicotinamide Iodide (NDNAI, 55c) 
1H NMR (300 MHz, DMSO-D6), δ 9.48 (1H, s, C2 -H), 9.22 (1H, d, C6-H), 8.92 (1H, d, 
C4-H), 8.54 (1H, s, N1’-H), 8.28 (2H, t, C5-H), 8.18 (1H, s, N1’-H), 4.65 (2H, t, C’1-
CH2), 1.92 (2H, p, C’2-CH2), 1.24 (14H, m, C’3-C’9-CH2), 0.86 (3H, t, C’10-CH3); 13C 
NMR (75 MHz, DMSO-D6), δ 162.6, 146.1, 144.5, 143.1, 133.7, 127.7, 61.1, 31.3, 30.6, 
28.9, 28.8, 28.7, 28.4, 25.4, 22.1, 14.0.  The resulting yellow solid was isolated in 77% 
yield, with a melting point of 170°C.  Combustion Analysis: calculated for C16H27IN2O 
0.33 H2O, C, 48.49; H, 7.04; N, 7.07.  Found: C, 48.38; H, 6.85; N, 6.95. 
 
N-n-Undecylnicotinamide Iodide (NUNAI, 55d) 
1H NMR (300 MHz, DMSO-D6), δ 9.48 (1H, s, C2 -H), 9.21 (1H, d, C6-H), 8.92 (1H, d, 
C4-H), 8.54 (1H, s, N1’-H), 8.28 (2H, t, C5-H), 8.18 (1H, s, N1’-H), 4.64 (2H, t, C’1-
CH2), 1.93 (2H, p, C’2-CH2), 1.25 (16H, m, C’3-C’10-CH2), 0.85 (3H, t, C’11-CH3); 13C 
NMR (75 MHz, DMSO-D6), δ 162.6, 146.1, 144.6, 143.0, 133.7, 127.7, 61.1, 31.3, 30.6, 
29.0, 28.9, 28.8, 28.7, 28.4, 25.4, 22.1, 14.0.  The resulting dark yellow solid was isolated 
in 70% yield, with a melting point of 175°C.  Combustion Analysis: calculated for 
C17H29IN2O 0.25 H2O, C, 49.94; H, 7.27; N, 6.85.  Found: C, 49.81; H, 7.33; N, 6.83. 
 
N-n-Dodecylnicotinamide Iodide (NDDNAI, 55e) 
1H NMR (300 MHz, DMSO-D6), δ 9.47 (1H, s, C2 -H), 9.21 (1H, d, C6-H), 8.92 (1H, d, 
C4-H), 8.54 (1H, s, N1’-H), 8.27 (2H, t, C5-H), 8.18 (1H, s, N1’-H), 4.64 (2H, t, C’1-
CH2), 1.92 (2H, p, C’2-CH2), 1.23 (18H, m, C’3-C’11-CH2), 0.84 (3H, t, C’12-CH3); 13C 
NMR (75 MHz, DMSO-D6), δ 162.6, 146.1, 144.5, 143.1, 133.7, 127.7, 61.2, 31.3, 30.6, 
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29.0 (x2), 28.9, 28.8, 28.7, 28.4, 25.4, 22.1, 14.0.  The resulting golden solid was isolated 
in 72% yield, with a melting point of 181°C.  Combustion Analysis: calculated for 
C18H31IN2O 0.33 H2O, C, 50.95; H, 7.52; N, 6.60.  Found: C, 50.73; H, 7.48; N, 6.43. 
 
3.2.3.4. Nicotinium Salts 
S-(-)-Nicotine (30.8 mmol) was dissolved in glacial acetic acid (35 mL) and the solution 
was stirred at ambient temperature for five minutes.  The appropriate 1-iodoalkane (30.8 
mmol) was added to the solution, and the mixture was refluxed for three days.  The 
mixture was then evaporated under reduced pressure to remove the solvent, and the 
resulting oil was treated with an aqueous solution of sodium bicarbonate.  Diethyl ether 
(3 x 50 mL) and chloroform (3 x 50 mL) were added successively to the resulting mixture 
to extract the unreacted NIC and quaternized analog, respectively.  The chloroform layers 
were collected, combined, and dried over magnesium sulfate.  The chloroform was then 
filtered and evaporated to dryness on a rotary evaporator.  The resulting oil was triturated 
with dry diethyl ether as needed, and the ether washings discarded.  The remaining 
residue was utilized as a homogenous viscous oil in the pharmacological assays.  The 
resulting oil was isolated in yields ranging from 60-72%. 
N-n-Butylnicotinium Iodide (NnBNI, 56d) 
1H NMR (300 MHz, DMSO-D6),δ 9.05 (1H, s, C2-H), 8.99 (1H, d, C6-H), 8.54 (1H, d, 
C4-H), 8.12 (1H, t, C3-H), 4.61 (2H, t, C’’1-CH2), 3.43 (1H, t, pyrrolidine CH2), 3.18 
(1H, t, pyrrolidine CH2), 2.34 (2H, m, C’’2-CH2), 2.15 (3H, s, pyrrolidine N-CH3), 1.88 
(4H, m, pyrrolidine CH2CH2), 1.65 (1H, m, pyrrolidine CH), 1.30 (2H, m, C’’3-CH2), 
0.92 (3H, t, C”-CH3); 13C NMR (75 MHz, DMSO-D6) δ 144.3, 143.9, 143.3, 127.8, 66.5, 
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60.5, 56.3, 34.7, 32.8 (x2), 22.6, 18.8, 13.4.  The resulting dark brown oil was isolated in 
60% yield.  Combustion Analysis: calculated for C14H23IN2 0.125 H2O, C, 48.25; H, 
6.72; N, 8.04.  Found: C, 48.02; H, 6.58; N, 8.02. 
 
N-n-Pentylnicotinium Iodide (NPeNI, 56e) 
1H NMR (300 MHz, CDCl3) δ 9.37 (1H, d, C6-H), 9.18 (1H, s, C2-H), 8.50 (1H, d, C4-
H), 8.11 (1H, t, C3-H), 4.92 (2H, t, C’’1-CH2), 3.64 (1H, t, pyrrolidine CH2), 3.25 (1H, t, 
pyrrolidine CH2), 2.46 (2H, m, C’’2-CH2), 2.25 (3H, s, pyrrolidine N-CH3), 1.80- 2.02 
(4H, m, pyrrolidine CH2CH2), 1.67 (1H, m, pyrrolidine CH), 1.36 (4H, m, C’’3&’’4-
CH2), 0.87 (3H, t, C”-CH3); 13C NMR (75 MHz, CDCl3) δ 146.7, 144.3, 143.7, 143.2, 
128.6, 67.1, 62.4, 57.0, 40.9, 36.1, 31.9, 28.4, 23.6, 22.5, 14.2.  The resulting light brown 
oil was isolated in 72% yield.  Combustion Analysis: calculated for C15H25IN2 0.25 H2O, 
C, 45.93; H, 6.49; N, 7.14.  Found: C, 45.76; H, 6.34; N, 7.15. 
 
N-n-Dodecylnicotinium Iodide (NDDNI, 56l) 
1H NMR (300 MHz, CDCl3) δ 9.30 (1H, d, C6-H), 9.08 (1H, s, C2-H), 8.52 (1H, d, C4-
H), 8.11 (1H, t, C5-H), 4.90 (2H, t, C’’1-CH2), 3.69 (1H, t, pyrrolidine CH2), 3.30 (1H, t, 
pyrrolidine CH2), 2.50 (2H, m, C’’2-CH2), 2.30 (3H, s, pyrrolidine N-CH3), 1.65-2.12 
(5H, m, pyrrolidine CH2CH2CH), 1.18-1.50 (18H, m, C’’3-11-CH2), 0.89 (3H, t, C”12-
CH3); 13C NMR (75 MHz, CDCl3) δ 146.7, 144.3, 143.6, 143.0, 128.6, 67.1, 62.6, 56.9, 
40.9, 36.1, 32.1 (x2), 29.8 (x2), 29.7, 29.6 (x2), 29.3, 26.3, 23.5, 23.0, 14.4.  The 
resulting dark brown oil was isolated in 65% yield.  Combustion Analysis: calculated for 
C22H39IN2 0.25 HI, C, 53.88; H, 8.07; N, 5.71.  Found: C, 53.74; H, 8.04; N, 5.58. 
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3.2.4. Synthetic Procedures for the Preparation of bis-Pyridinium Derivatives 
 
3.2.4.1. bis-Pyridinium Salts 
1,X-dihalogenoalkane, where X denotes the appropriate carbon length, (6.09-12.13 
mmol) was added to a solution (30 mL) of dry pyridine, and the solution heated for 24 h 
at 65°C.  The resulting solid precipitates were filtered and washed five times with dry 
diethyl ether.  For liquid products, the excess pyridine was decanted off, the resulting 
liquid precipitates were washed with diethyl ether five times, and the remaining liquid 
was dried under vacuum.  The resulting solid or liquid was isolated yields ranging from 
87-93%. 
 
N,N’-Pentane-1,5-diyl-bis-pyridinium Diiodide (bPPeI, 57a) 
1H NMR (300 MHz, DMSO-D6) δ 9.14 (2H, d, C2&C6-H), 8.62 (1H, t, C4-H), 8.19 (2H, 
t, C3&C5-H), 4.62 (2H, t, C’1-CH2), 1.92 (2H, m, C’2-CH2), 1.25 (1H, m, C’3-CH2); 13C 
NMR (75 MHz, DMSO-D6) δ 145.3, 144.5, 127.9, 60.1, 29.9, 21.7.  The resulting yellow 
solid was isolated in 90% yield, with a melting point of 146-147°C.  Combustion 
Analysis: calculated for C15H20I2N2, C, 37.37; H, 4.18; N, 5.81.  Found: C, 37.51; H, 
4.20; N, 5.73. 
 
N,N’-Hexane-1,6-diyl-bis-pyridinium Diiodide (bPHxI, 57b) 
1H NMR (300 MHz, DMSO-D6) δ 9.13 (2H, d, C2&C6-H), 8.63 (1H, t, C4-H), 8.18 (2H, 
t, C3&C5-H), 4.52 (2H, t, C’1-CH2), 1.93 (2H, m, C’2-CH2), 1.34 (2H, m, C’3-CH2); 13C 
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NMR (75 MHz, DMSO-D6) δ 145.3, 144.5, 127.9, 60.5, 30.7, 24.8.  The resulting pale 
yellow solid was isolated in 92% yield, with a melting point of 242-243°C.  Combustion 
Analysis: calculated for C16H22I2N2, C, 38.73; H, 4.47; N, 5.65.  Found: C, 38.62; H, 
4.53; N, 5.87. 
 
N,N’-Octane-1,8-diyl-bis-pyridinium Diiodide (bPOI, 57c) 
1H NMR (300 MHz, DMSO-D6) δ 9.11 (2H, d, C2&C6-H), 8.63 (1H, t, C4-H), 8.18 (2H, 
t, C3&C5-H), 4.59 (2H, t, C’1-CH2), 1.89 (2H, m, C’2-CH2), 1.28 (4H, m, C’3&4-CH2); 
13C NMR (75 MHz, DMSO-D6) δ 145.3, 144.5, 127.9, 60.5, 30.6, 28.1, 25.2.  The 
resulting pale yellow solid was isolated in 93% yield, with a melting point of 203-204°C.  
Combustion Analysis: calculated for C18H26I2N2, C, 41.24; H, 5.00; N, 5.43.  Found: C, 
41.20; H, 5.08; N, 5.68. 
 
N,N’-Nonane-1,9-diyl-bis-pyridinium Dibromide (bPNB, 57e) 
1H NMR (300 MHz, DMSO-D6) δ 9.17 (2H, d, C2&C6-H), 8.61 (1H, t, C4-H), 8.18 (2H, 
t, C3&C5-H), 4.63 (2H, t, C’1-CH2), 1.89 (2H, m, C’2-CH2), 1.22 (5H, m, C’3-5-CH2); 
13C NMR (75 MHz, DMSO-D6) δ 145.3, 144.5, 127.9, 60.5, 30.7, 28.4, 28.2, 25.3, 
C19H28Br2N2.  The resulting clear liquid was isolated in 87% yield.  Combustion 
Analysis: calculated for C19H28Br2N2, C, 51.37; H, 6.35; N, 6.31.  Found: C, 51.42; H, 
6.31; N, 6.25. 
 
N,N’-Decane-1,10-diyl-bis-pyridinium Diiodide (bPDI, 57f) 
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1H NMR (300 MHz, DMSO-D6) δ 9.10 (2H, d, C2&C6-H), 8.63 (1H, t, C4-H), 8.19 (2H, 
t, C3&C5-H), 4.60 (2H, t, C’1-CH2), 1.89 (2H, m, C’2-CH2), 1.24 (6H, m, C’3-5-CH2); 
13C NMR (75 MHz, DMSO-D6) δ 145.3, 144.5, 127.9, 60.6, 30.6, 28.8, 28.1, 25.2.  The 
resulting pale yellow solid was isolated in 90% yield, with a melting point of 162-163°C.  
Combustion Analysis: calculated for C20H30I2N2, C, 43.50; H, 5.48; N, 5.07.  Found: C, 
43.53; H, 5.67; N, 5.29. 
 
N,N’-Undecane-1,11-diyl-bis-pyridinium Dibromide (bPUB, 57g) 
1H NMR (300 MHz, DMSO-D6) δ 9.18 (2H, d, C2&C6-H), 8.62 (1H, t, C4-H), 8.19 (2H, 
t, C3&C5-H), 4.63 (2H, t, C’1-CH2), 1.88 (2H, m, C’2-CH2), 1.22 (7H, m, C’3-6-CH2); 
13C NMR (75 MHz, DMSO-D6) δ 145.3, 144.6, 127.9, 60.6, 30.8, 28.8 (x2), 28.4, 25.4.  
The resulting amber liquid was isolated in 91% yield.  Combustion Analysis: calculated 
for C21H32Br2N2, C, 53.40; H, 6.83; N, 5.93.  Found: C, 53.39; H, 6.91; N, 5.88. 
 
N,N’-Dodecane-1,12-diyl-bis-pyridinium Dibromide (bPDDB, 57h) 
1H NMR (300 MHz, DMSO-D6) δ 9.15 (2H, d, C2&C6-H), 8.62 (1H, t, C4-H), 8.19 (2H, 
t, C3&C5-H), 4.61 (2H, t, C’1-CH2), 1.88 (2H, m, C’2-CH2), 1.22 (8H, m, C’3-6-CH2); 
13C NMR (75 MHz, DMSO-D6) δ 145.3, 144.6, 127.9, 60.7, 30.8, 28.9, 28.8, 28.5, 25.4.  
The resulting white solid was isolated in 93% yield, with a melting point of 222-223°C.  
Combustion Analysis: calculated for C22H34Br2N2, C, 54.33; H, 7.05; N, 5.76.  Found: C, 
54.40; H, 7.00; N, 5.86. 
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3.2.4.2. bis-Picolinium Salts 
1,X-dihalogenoalkane, where X denotes the appropriate carbon length, (6.09-12.13 
mmol) was added to a solution (30 mL) of 3-picoline, and the solution heated for 24 h at 
65°C.  The resulting precipitate was filtered, and the product washed five times with dry 
diethyl ether.  The precipitate was then dissolved in water (30 mL) and extracted with 
chloroform (3 x 30 mL).  The organic layer was collected and evaporated to dryness on a 
rotary evaporator.  The resulting solid or liquid was isolated in yields ranging from 90-
94%. 
 
N,N’-Hexane-1,6-diyl-bis-picolinium Diiodide (bPiHxI, 58a) 
1H NMR (300 MHz, DMSO-D6) δ 9.06 (1H, s, C2-H), 8.94 (1H, d, C6-H), 8.46 (1H, d, 
C4-H), 8.07 (1H, t, C5-H), 4.56 (2H, t, C’1-CH2), 2.50 (3H, s, C3-CH3), 1.86 (2H, m, 
C’2-CH2), 1.33 (2H, m, C’3-CH2); 13C NMR (75 MHz, DMSO-D6) δ 145.6, 144.0, 141.7, 
138.5, 127.1, 60.3, 30.3, 24.8, 17.9.  The resulting pale yellow solid was isolated in 91% 
yield, with a melting point of 214-215°C.  Combustion Analysis: calculated for 
C18H26I2N2, C, 41.24; H, 5.00; N, 5.34.  Found: 41.03; H, 5.32; N, 5.22. 
 
N,N’-Octane-1,8-diyl-bis-picolinium Diiodide (bPiOI, 58b) 
1H NMR (300 MHz, DMSO-D6) δ 9.18 (1H, s, C2-H), 8.96 (1H, d, C6-H), 8.46 (1H, d, 
C4-H), 8.07 (1H, t, C5-H), 4.62 (2H, t, C’1-CH2), 2.50 (3H, s, C3-CH3), 1.94 (2H, m, 
C’2-CH2), 1.27 (4H, m, C’3&4-CH2); 13C NMR (75 MHz, DMSO-D6) δ 145.5, 143.9, 
141.7, 138.5, 127.1, 60.4, 30.5, 28.1, 25.2, 17.9.  The resulting canary yellow solid was 
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isolated in 94% yield, with a melting point of 161-162°C.  Combustion Analysis: 
calculated for C20H30I2N2, C, 43.50; H, 5.48; N, 5.07.  Found: C, 43.32; H, 5.47; N, 4.98. 
 
N,N’-Nonane-1,9-diyl-bis-picolinium Dibromide (bPiNB, 58c) 
1H NMR (300 MHz, DMSO-D6) δ 9.17 (1H, s, C2-H), 9.04 (1H, d, C6-H), 8.47 (1H, d, 
C4-H), 8.08 (1H, t, C5-H), 4.60 (2H, t, C’1-CH2), 2.50 (3H, s, C3-CH3), 1.92 (2H, m, 
C’2-CH2), 1.27 (5H, m, C’3-5-CH2); 13C NMR (75 MHz, DMSO-D6) δ 145.5, 144.1, 
141.8, 138.5, 127.1, 60.4, 30.7, 28.5, 28.3, 25.4, 17.9.  The resulting tan liquid was 
isolated in 90% yield.  Combustion Analysis: calculated for C21H32Br2N2. 0.5 H2O, C, 
52.40; H, 6.91; N, 5.82.  Found: C, 52.26; H, 6.89; N, 5.70. 
 
N,N’-Decane-1,10-diyl-bis-picolinium Diiodide (bPiDI, 58d) 
1H NMR (300 MHz, CDCl3) δ 9.04 (1H, s, C2-H), 8.94 (1H, d, C6-H), 8.46 (1H, d, C4-
H), 8.06 (1H, t, C5-H), 4.58 (2H, t, C’1-CH2), 2.50 (3H, s, C3-CH3), 1.90 (2H, m, C’2-
CH2), 1.27 (6H, m, C’3-5-CH2) ; 13C NMR (75 MHz, DMSO-D6) δ 145.6, 144.0, 141.7, 
138.6, 127.2, 60.5, 30.6, 28.7, 28.4, 25.4, 18.0.  The resulting tan solid was isolated in 
92% yield, with a melting point of 161-162°C.  Combustion Analysis: calculated for 
C22H34I2N2.  1.5 H2O, C, 43.51; H, 6.14; N, 4.61.  Found: C, 43.82; H, 6.02; N, 4.61. 
 
N,N’-Undecane-1,11-diyl-bis-picolinium Dibromide (bPiUB, 58e) 
1H NMR (300 MHz, DMSO-D6) δ 9.10 (1H, s, C2-H), 8.98 (1H, d, C6-H), 8.46 (1H, d, 
C4-H), 8.07 (1H, t, C5-H), 4.58 (2H, t, C’1-CH2), 2.50 (3H, s, C3-CH3), 1.90 (2H, m, 
C’2-CH2), 1.26 (7H, m, C’3-6-CH2); 13C NMR (75 MHz, DMSO-D6) δ 145.5, 144.0, 
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141.8, 138.5, 127.1, 60.5, 30.7, 28.8, 28.7, 28.4, 25.4, 17.9.  The resulting tan liquid was 
isolated in 90% yield.  Combustion Analysis: calculated for C23H36Br2N2. 0.33 H2O, C, 
54.56; H, 7.30; N, 5.53.  Found: C, 54.23; H, 7.43; N, 5.41. 
 
N,N’-Dodecane-1,12-diyl-bis-picolinium Dibromide (bPiDDB, 58f) 
1H NMR (300 MHz, CDCl3) δ 9.04 (1H, s, C2-H), 8.94 (1H, d, C6-H), 8.46 (1H, d, C4-
H), 8.16 (1H, t, C5-H), 4.55 (2H, t, C’1-CH2), 2.50 (3H, s, C3-CH3), 1.90 (2H, m, C’2-
CH2), 1.25 (8H, m, C’3-6-CH2); 13C NMR (75 MHz, DMSO-D6) δ 145.5, 144.1, 141.8, 
138.5, 127.2, 60.4, 30.7, 28.9, 28.8, 28.4, 25.4, 17.9.  The resulting tan liquid was 
isolated in 92% yield.  Combustion Analysis: calculated for C24H38Br2N2, C, 56.04; H, 
7.45; N, 5.45.  Found: C, 55.89; H, 7.62; N, 5.32. 
 
3.2.4.3. bis-Quinolinium Salts 
1,X-dihalogenoalkane, where X denotes the appropriate carbon length, (6.09-12.13 
mmol) was added to a solution (30 mL) of dry quinoline, and the solution heated for 24 h 
at 65°C.  The resulting precipitate was filtered, and the product washed five times with 
dry diethyl ether.  The resulting solid was isolated in yields ranging from 87-92%. 
 
N,N’-Hexane-1,6-diyl-bis-quinolinium Diiodide (bQHxI, 59a) 
1H NMR (300 MHz, DMSO-D6) δ 9.53 (1H, d, C2-H), 9.29 (1H, d, C3-H), 8.61 (1H, d, 
C8-H), 8.50 (1H, d, C4-H), 8.29 (1H, t, C7-H), 8.18 (1H, t, C5-H), 8.07 (1H, d, C6-H), 
5.09 (2H, t, C’1-CH2), 1.96 (2H, m, C’2-CH2), 1.25 (2H, m, C’3-CH2); 13C NMR (75 
MHz, DMSO-D6) δ 149.4, 147.2, 137.2, 135.5, 130.6, 129.7, 129.6, 122.0, 118.8, 57.2, 
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29.3, 25.3.  The resulting mustard yellow solid was isolated in 89% yield, with a melting 
point of 234-235°C.  Combustion Analysis: calculated for C24H26I2N2, C, 48.34; H, 4.39; 
N, 4.70.  Found: C, 48.29; H, 4.43; N, 4.85. 
 
N,N’-Octane-1,8-diyl-bis-quinolinium Diiodide (bQOI, 59b) 
1H NMR (300 MHz, DMSO-D6) δ 9.53 (1H, d, C2-H), 9.29 (1H, d, C3-H), 8.61 (1H, d, 
C8-H), 8.50 (1H, d, C4-H), 8.29 (1H, t, C7-H), 8.18 (1H, t, C5-H), 8.07 (1H, d, C6-H), 
5.09 (2H, t, C’1-CH2), 1.96 (2H, m, C’2-CH2), 1.25 (4H, m, C’3&4-CH2); 13C NMR (75 
MHz, DMSO-D6) δ 149.5, 147.4, 137.4, 135.6, 130.7, 129.9, 129.7, 122.1, 118.9, 57.3, 
29.5, 28.5, 25.7.  The resulting canary yellow solid was isolated in 89% yield, with a 
melting point of 222-223°C.  Combustion Analysis: calculated for C26H30I2 N2.  0.25 
H2O, C, 49.54; H, 4.90; N, 4.44.  Found: C, 49.41; H, 5.19; N, 4.11. 
 
N,N’-Nonane-1,9-diyl-bis-quinolinium Dibromide (bQNB, 59c) 
1H NMR (300 MHz, DMSO-D6) δ 9.68 (1H, d, C2-H), 9.34 (1H, d, C3-H), 8.67 (1H, d, 
C8-H), 8.55 (1H, d, C4-H), 8.27 (2H, m, C5&C7-H), 8.07 (1H, d, C6-H), 5.09 (2H, t, 
C’1-CH2), 1.95 (2H, m, C’2-CH2), 1.19-1.45 (5H, m, C’3-5-CH2); 13C NMR (75 MHz, 
DMSO-D6) δ 149.5, 147.2, 137.2, 135.5, 130.6, 129.7, 129.5, 122.0, 118.9, 57.2, 29.6, 
28.6, 28.4, 25.7.  The resulting dark purple solid was isolated in 92% yield, with a 
melting point of 185-186°C.  Combustion Analysis: calculated for C27H32Br2N2. 0.25 
H2O, C, 59.08; H, 5.97; N, 5.10.  Found: C, 59.01; H, 6.09; N, 5.05. 
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N,N’-Decane-1,10-diyl-bis-quinolinium Diiodide (bQDI, 59d) 
1H NMR (300 MHz, DMSO-D6) δ 9.53 (1H, d, C2-H), 9.29 (1H, d, C3-H), 8.61 (1H, d, 
C8-H), 8.50 (1H, d, C4-H), 8.29 (1H, t, C7-H), 8.18 (1H, t, C5-H), 8.06 (1H, d, C6-H), 
5.04 (2H, t, C’1-CH2), 1.96 (2H, m, C’2-CH2), 1.32 (6H, m, C’3-5-CH2); 13C NMR (75 
MHz, DMSO-D6) δ 149.5, 147.4, 137.4, 135.6, 130.7, 129.9, 129.7, 122.1, 118.9, 57.3, 
29.5,28.9, 28.5, 25.7.  The resulting canary yellow solid was isolated in 91% yield, with a 
melting point of 235-236°C.  Combustion Analysis: calculated for C28H34I2N2.  0.66 H2O, 
C, 50.62; H, 5.36; N, 4.22.  Found: C, 50.48; H, 5.52; N, 4.19. 
 
N,N’-Undecane-1,11-diyl-bis-quinolinium Dibromide (bQUB, 59e) 
1H NMR (300 MHz, CDCl3) δ 9.54 (1H, d, C2-H), 9.28 (1H, d, C3-H), 8.60 (1H, d, C8-
H), 8.48 (1H, d, C4-H), 8.27 (1H, t, C7-H), 8.16 (1H, t, C5-H), 8.05 (1H, d, C6-H), 5.03 
(2H, t, C’1-CH2), 1.95 (2H, m, C’2-CH2), 1.15-1.48 (7H, m, C’3-6-CH2); 13C NMR (75 
MHz, DMSO-d6) δ 149.5, 147.4, 137.4, 135.6, 130.7, 129.9, 129.7, 122.1, 118.9, 57.3, 
29.5,28.9, 28.8, 28.5, 25.7.  The resulting dark purple solid was isolated in 87% yield, 
with a melting point of 188-189°C.  Combustion Analysis: calculated for C29H36Br2N2. 
1.0 H2O, C, 58.99; H, 6.49; N, 4.75.  Found: C, 59.23; H, 6.56; N, 4.62. 
 
N,N’-Dodecane-1,12-diyl-bis-quinolinium Dibromide (bQDDB, 59f) 
1H NMR (300 MHz, DMSO-D6) δ 9.58 (1H, d, C2-H), 9.29 (1H, d, C3-H), 8.61 (1H, d, 
C8-H), 8.50 (1H, d, C4-H), 8.29 (1H, t, C7-H), 8.18 (1H, t, C5-H), 8.04 (1H, d, C6-H), 
5.04 (2H, t, C’1-CH2), 1.95 (2H, m, C’2-CH2), 1.2-1.4 (8H, m, C’3-6-CH2); 13C NMR 
(75 MHz, DMSO-D6) δ 149.5, 147.4, 137.4, 135.6, 130.7, 129.9, 129.7, 122.1, 118.9, 
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57.3, 29.5,28.9, 28.8, 28.5, 25.7.  The resulting dark purple solid was isolated in 92% 
yield, with a melting point of 187-188°C.  Combustion Analysis: calculated for 
C30H38Br2N2. 0.33 H2O, C, 60.82; H, 6.58; N, 4.73.  Found: C, 61.01; H, 6.63; N, 4.64. 
 
3.2.4.4. bis-Isoquinolinium Salts 
1,X-dihalogenoalkane, where X denotes the appropriate carbon length, (6.09-12.13 
mmol) was added to a solution (30 mL) of isoquinoline, and the solution heated for 24 h 
at 65°C.  The resulting precipitate was filtered, and the product washed five times with 
dry diethyl ether.  The resulting solid was isolated in yields ranging from 89-92%. 
 
N,N’-Hexane-1,6-diyl-bis-isoquinolinium Diiodide (bIQHxI, 60a) 
1H NMR (300 MHz, DMSO-D6) δ 10.09 (1H, d, C1-H), 8.80 (1H, d, C3-H), 8.61 (1H, d, 
C8-H), 8.48 (1H, d, C4-H), 8.36 (1H, d, C7-H), 8.27 (1H, t, C5-H), 8.08 (1H, t, C6-H), 
4.71 (2H, t, C’1-CH2), 2.03 (2H, m, C’2-CH2), 1.40 (4H, m, C’3&4-CH2); 13C NMR (75 
MHz, DMSO-D6) δ 149.7, 136.7 (x2), 134.7, 131.0, 130.1, 127.1, 127.0, 125.7, 60.6, 
30.2, 25.0.  The resulting pale yellow solid was isolated in 87% yield, with a melting 
point of 233°C.  Combustion Analysis: calculated for C24H26I2N2, C, 48.34; H, 4.39; N, 
4.70.  Found: C, 48.46; H, 4.57; N, 4.98. 
 
N,N’-Octane-1,8-diyl-bis-isoquinolinium Diiodide (bIQOI, 60b) 
1H NMR (300 MHz, DMSO-D6) δ 10.05 (1H, d, C1-H), 8.77 (1H, d, C3-H), 8.58 (1H, d, 
C8-H), 8.48 (1H, d, C4-H), 8.35 (1H, d, C7-H), 8.26 (1H, t, C5-H), 8.07 (1H, t, C6-H), 
4.68 (2H, t, C’1-CH2), 2.00 (2H, m, C’2-CH2), 1.30 (4H, m, C’3&4-CH2); 13C NMR (75 
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MHz, DMSO-D6) δ 149.7, 136.9 (x2), 134.8, 131.3, 130.3, 127.3, 127.2, 125.9, 60.9, 
30.6, 28.4, 25.6.  The resulting yellow solid was isolated in 92% yield, with 
decomposition at 250°C.  Combustion Analysis: calculated for C26H30I2N2, C, 50.02; H, 
4.84; N, 4.49.  Found: C, 50.22; H, 4.61; N, 4.53. 
 
N,N’-Nonane-1,9-diyl-bis-isoquinolinium Dibromide (bIQNB, 60c) 
1H NMR (300 MHz, DMSO-D6) δ 10.17 (1H, d, C1-H), 8.85 (1H, d, C3-H), 8.62 (1H, d, 
C8-H), 8.49 (1H, d, C4-H), 8.36 (2H, d, C7-H), 8.26 (2H, t, C5-H), 8.08 (1H, t, C6-H), 
4.72 (2H, t, C’1-CH2), 2.02 (2H, m, C’2-CH2), 1.11-1.45 (5H, m, C’3-5-CH2); 13C NMR 
(75 MHz, DMSO-D6) δ 149.8, 136.7 (x2), 134.8, 131.0, 130.1, 127.1, 127.1, 125.7, 60.7, 
30.5, 28.6, 28.4, 25.5.  The resulting light purple solid was isolated in 92% yield, with a 
melting point of 162°C.  Combustion Analysis: calculated for C27H32Br2N2. 0.33 H2O C, 
58.92; H, 5.98; N, 5.09.  Found: C, 58.76; H, 5.92; N, 4.90. 
 
N,N’-Decane-1,10-diyl-bis-isoquinolinium Diiodide (bIQDI, 60d)  
1H NMR (300 MHz, DMSO-D6) δ 10.07 (1H, d, C1-H), 8.78 (1H, d, C3-H), 8.58 (1H, d, 
C8-H), 8.48 (1H, d, C4-H), 8.36 (1H, d, C7-H), 8.26 (1H, t, C5-H), 8.07 (1H, t, C6-H), 
4.69 (2H, t, C’1-CH2), 2.0 (2H, m, C’2-CH2), 1.15-1.50 (6H, m, C’3-5-CH2); 13C NMR 
(75 MHz, DMSO-D6) δ 149.7, 136.9 (x2), 134.9, 131.2, 130.0, 127.3, 127.2, 125.9, 60.9, 
30.7, 28.9, 28.6, 25.7.  The resulting dark yellow solid was isolated in 92% yield, with a 
melting point of 192°C.  Combustion Analysis: calculated for C28H34I2N2.  0.33 H2O C, 
51.08; H, 5.31; N, 4.25.  Found: C, 50.88; H, 5.42; N, 4.13. 
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N,N’-Undecane-1,11-diyl-bis-isoquinolinium Dibromide (bIQUB, 60e) 
1H NMR (300 MHz, DMSO-D6) δ 10.07 (1H, d, C1-H), 8.78 (1H, d, C3-H), 8.57 (1H, d, 
C8-H), 8.48 (1H, d, C4-H), 8.35 (1H, d, C7-H), 8.25 (1H, t, C5-H), 8.07 (1H, t, C6-H), 
4.69 (2H, t, C’1-CH2), 2.0 (2H, m, C’2-CH2), 1.05-1.45 (7H, m, C’3-6-CH2); 13C NMR 
(75 MHz, DMSO-D6) δ 149.8, 136.7 (x2), 134.8, 131.0, 130.2, 127.1 (x2), 125.7, 60.7, 
30.5, 28.9, 28.8, 28.5, 25.6.  The resulting purple solid was isolated in 89% yield, with a 
melting point of 166°C.  Combustion Analysis: calculated for C29H36Br2N2, C, 60.85; H, 
6.34; N, 4.89.  Found: C, 60.65; H, 6.43; N, 4.92. 
 
N,N’-Dodecane-1,12-diyl-bis-isoquinolinium Dibromide (bIQDDB, 60f) 
1H NMR (300 MHz, DMSO-D6) δ 10.06 (1H, d, C1-H), 8.78 (1H, d, C3-H), 8.58 (1H, d, 
C8-H), 8.48 (1H, d, C4-H), 8.35 (1H, d, C7-H), 8.25 (1H, t, C5-H), 8.07 (1H, t, C6-H), 
4.70 (2H, t, C’1-CH2), 2.0 (2H, m, C’2-CH2), 1.15-1.40 (8H, m, C’3-6-CH2); 13C NMR 
(75 MHz, DMSO-D6) δ 149.8, 136.7 (x2), 134.8, 131.0, 130.1, 127.1 (x2), 125.7, 60.6, 
30.5, 28.9, 28.8, 28.5, 25.5.  The resulting gray-purple solid was isolated in 91% yield, 
with a melting point of 225°C.  Combustion Analysis : calculated for C30H38Br2N2. 0.5 
H2O, C, 60.51; H, 6.60; N, 4.70.  Found: C, 60.75; H, 6.56; N, 4.54. 
 
3.2.4.5. bis-Nicotinium Salts 
S-(-)-Nicotine (30.8 mmol) was dissolved in glacial acetic acid (35 mL) and the solution 
was stirred at ambient temperature for five minutes.  The 1,X-dihalogenoalkane, where X 
denotes the appropriate carbon length, (15.4 mmol) was added to the solution and the 
mixture stirred with refluxing for three days.  The mixture was then evaporated under 
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reduced pressure to remove the solvent, and the resulting oil was treated with an aqueous 
solution of sodium bicarbonate.  The resulting aqueous mixture was extracted with 
diethyl ether (3 x 50 mL), and then chloroform (3 x 50 mL) and the remaining aqueous 
layer separated and evaporated to dryness on a rotary evaporator.  The resulting solid was 
dissolved in chloroform (200 mL) and filtered.  The filtrate was collected and evaporated 
to dryness under pressure.  The resulting oil was isolated in yields ranging from 15-35%. 
 
N,N’-Hexane-1,6-diyl-bis-nicotinium Diiodide (bNHxI, 61a) 
1H NMR (300 MHz, CDCl3),δ 9.44 (1H, s, C2-H), 9.38 (1H, d, C6-H), 8.44 (1H, d, C4-
H), 8.13 (1H, m, C5-H), 4.95 (2H, t, C’’1-CH2), 4.03 (1H, t, pyrrolidine CH2), 3.25 (1H, 
t, pyrrolidine CH2), 2.49 (2H, m, C’’2-CH2), 2.23 (3H, s, pyrrolidine N-CH3), 1.60-2.19 
(5H, m, pyrrolidine CH2CH2), 1.30-1.55 (2H, m, C’’3-CH2); 13C NMR (75 MHz, CDCl3) 
δ 146.8, 143.9, 143.7 (x2), 128.2, 66.8, 61.1, 57.0, 40.8, 36.0, 31.3, 24.7, 23.5.  The 
resulting brown viscous oil was isolated in 25% yield.  Combustion Analysis: calculated 
for C26H40I2N4.  0.75 H2O, C, 46.20; H, 6.19; N, 8.29.  Found: C, 46.08; H, 6.27; N, 8.23. 
 
N,N’-Octane-1,8-diyl-bis-nicotinium Diiodide (bNOI, 61b) 
1H NMR (300 MHz, CDCl3),δ 9.58 (1H, s, C2-H), 9.50 (1H, d, C6-H), 8.47 (1H, d, C4-
H), 8.03 (1H, m, C5-H), 4.96 (2H, t, C’’1-CH2), 3.65 (1H, t, pyrrolidine CH2), 3.24 (1H, 
t, pyrrolidine CH2), 2.49 (2H, m, C’’2-CH2), 2.25 (3H, s, pyrrolidine N-CH3), 1.60-2.19 
(5H, m, pyrrolidine CH2CH2), 1.40-1.60 (4H, m, C’’3&4-CH2); 13C NMR (75 MHz, 
CDCl3) δ 146.9, 143.8, 143.6, 143.5, 128.3, 66.8, 61.7, 57.0, 40.8, 36.1, 32.0, 27.7, 25.2, 
23.5.  The resulting yellow viscous oil was isolated in 15% yield.  Combustion Analysis: 
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calculated for C28H44I2N4.  0.25 H2O, C, 48.39; H, 6.45; N, 8.06.  Found: C, 48.13; H, 
6.61; N, 7.98. 
 
N,N’-Nonane-1,9-diyl-bis-nicotinium Dibromide (bNNB, 61c) 
1H NMR (300 MHz, CDCl3),δ 9.75 (1H, s, C2-H), 9.56 (1H, d, C6-H), 8.49 (1H, d, C4-
H), 8.08 (1H, m, C5-H), 5.05 (2H, t, C’’1-CH2), 3.65 (1H, t, pyrrolidine CH2), 3.25 (1H, 
t, pyrrolidine CH2), 2.48 (2H, m, C’’2-CH2), 2.25 (3H, s, pyrrolidine N-CH3), 1.60-2.23 
(5H, m, pyrrolidine CH2CH2), 1.30-1.60 (5H, m, C’’3-5-CH2); 13C NMR (75 MHz, 
CDCl3) δ 146.5, 144.2, 143.7, 143.6, 128.3, 66.9, 61.7, 56.9, 40.7, 36.0, 32.1, 28.2, 28.0, 
25.5, 23.4.  The resulting yellow viscous oil was isolated in 27% yield.  Combustion 
Analysis: calculated for C29H46Br2N4. 0.33 H2O, C, 56.50; H, 7.63; N, 9.09.  Found: C, 
56.18; H, 7.81; N, 9.01. 
 
N,N’-Decane-1,10-diyl-bis-nicotinium Diiodide (bNDI, 61d) 
1H NMR (300 MHz, CDCl3) δ 9.55 (1H, s, C2-H), 9.44 (1H, d, C6-H), 8.53 (1H, d, C4-
H), 8.09 (1H, m, C5-H), 4.98 (2H, t, C’’1-CH2), 3.74 (1H, t, pyrrolidine CH2), 3.30 (1H, 
t, pyrrolidine CH2, 2.50 (2H, m, C’’2-CH2), 2.29 (3H, s, pyrrolidine N-CH3), 1.65-2.20 
(5H, m, pyrrolidine CH2CH2), 1.30-1.57 (6H, m, C’’3-5-CH2); 13C NMR (75 MHz, 
CDCl3) δ 146.6, 143.9 x 2, 143.4, 128.4, 66.9, 61.9, 57.0, 40.8, 36.1, 32.1, 28.5, 28.2, 
25.8, 23.5.  The resulting yellow viscous oil was isolated in 27% yield.  Combustion 
Analysis: calculated for C30H48I2N4.  1.0 H2O, C, 48.92; H, 6.84; N, 7.61.  Found: C, 
48.64; H, 6.58; N, 7.48. 
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N,N’-Undecane-1,11-diyl-bis-nicotinium Dibromide (bNUB, 61e) 
1H NMR (300 MHz, CDCl3) δ 9.70 (1H, s, C2-H), 9.47 (1H, d, C6-H), 8.49 (1H, d, C4-
H), 8.12 (1H, m, C5-H), 5.02 (2H, t, C’’1-CH2), 3.65 (1H, t, pyrrolidine CH2), 3.26 (1H, 
t, pyrrolidine CH2), 2.49 (2H, m, C’’2-CH2), 2.25 (3H, s, pyrrolidine N-CH3), 1.60-2.20 
(5H, m, pyrrolidine CH2CH2), 1.20-1.50 (8H, m, C’’3-6-CH2); 13C NMR (75 MHz, 
CDCl3) δ 146.5, 144.2, 143.7, 143.5, 128.4, 66.9, 61.9, 56.9, 40.7, 36.1, 32.2, 28.8, 28.7, 
28.6, 25.9, 23.4.  The resulting yellow viscous oil was isolated in 30% yield.  Combustion 
Analysis: calculated for C31H50Br2N4. 0.33 H2O, C, 57.76; H, 7.92; N, 8.69.  Found: C, 
57.55; H, 7.99; N, 8.61. 
 
N,N’-Dodecane-1,12-diyl-bis-nicotinium Dibromide (bNDDB, 61f) 
1H NMR (300 MHz, CDCl3) δ 9.66 (1H, s, C2-H), 9.38 (1H, d, C6-H), 8.46 (1H, d, C4-
H), 8.10 (1H, t, C5-H), 5.01 (2H, t, C’’1-CH2), 3.61 (1H, t, pyrrolidine CH2), 3.25 (1H, t, 
pyrrolidine CH2), 2.45 (2H, m, C’’2-CH2), 2.23 (3H, s, pyrrolidine N-CH3), 1.60-2.19 
(5H, m, pyrrolidine CH2CH2), 1.20-1.50 (8H, m, C’’3-6-CH2); 13C NMR (75 MHz, 
CDCl3) δ 146.6, 144.2, 143.7, 143.4, 128.5, 67.0, 62.0, 60.0, 40.8, 36.1, 32.4, 29.0, 28.8, 
28.7, 26.0, 23.5.  The resulting yellow viscous oil was isolated in 35% yield.  Combustion 
Analysis: calculated for C32H52Br2N4. 0.5 H2O, C, 58.09; H, 8.07; N, 8.47.  Found: C, 
57.86; H, 8.12; N, 8.39. 
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3.2.5. Binding Assays for α4β2* and α7* Nicotinic Receptor Subtypes 
 
[3H]Nicotine Binding Assay (α4β2*) 
The interaction of the compounds with the high affinity [3H]NIC binding site of the 
α4β2* nAChR was studied utilizing a modification of the methodology of Marks et al. 
(1986).  Rat striata were dissected, pooled, and homogenized in 10 vol ice-cold modified 
Krebs-HEPES buffer (in mM: 20 HEPES, 118 NaCl, 4.8 KCl, 2.5 CaCl2, 1.2 MgSO4, 
pH 7.5).  Homogenates were incubated at 37°C for 5 min, and then centrifuged at 27,000 
g for 20 min at 4°C.  The pellets were resuspended in 10 vol ice-cold MilliQ water and 
incubated for 5 min at 37°C, followed by centrifugation at 27,000 g for 20 min at 4°C.  
The second and third pellets were resuspended in 10 vol fresh, ice-cold 10% KRH buffer, 
incubated for 5 min at 37°C, and centrifuged as above.  The final pellets were 
resuspended in 20 vol of ice-cold MilliQ water, which afforded ~200 µg membrane 
protein/100 µL aliquot [Bradford, 1976], using BSA as the protein standard.  Binding 
assays were performed in duplicate in a final vol of 200 µL Krebs-HEPES buffer 
containing 200 mM Tris (pH 7.5 at 4°C).  Assays were initiated by the addition of 100 µL 
of membrane suspension to assay tubes containing final concentrations of 3 nM [3H]-
NIC (50 µL) and one of 9 concentrations of compound being evaluated.  Nonspecific 
binding was defined in the presence of 10 µM NIC.  After a 90 min incubation at 4°C, 
reactions were terminated by dilution with 3 mL ice-cold Krebs-HEPES buffer, followed 
immediately by filtration through Schleicher and Schuell #32 glass fiber filters (pre-
soaked in 0.5% polyethyleneimine) using a Brandel cell harvester (Biomedical Research 
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and Development Laboratories, Inc., Gaithersburg, MD).  Filters were rinsed three times 
with 3 mL of ice-cold Krebs-HEPES buffer and transferred to scintillation vials, 3 mL of 
scintillation cocktail was added, and radioactivity was determined by liquid scintillation 
spectroscopy (Marks et al. 1986). 
 
[3H]MLA Binding Assay (α7*) 
[3H]MLA binding probes the α7 nAChR subtype, and assays were carried out using a 
modification of the method of Davies et al. (1999).  Whole brain minus cortex, striatum 
and cerebellum was homogenized in 20 vol of ice-cold hypotonic buffer (in mM: 2 
HEPES, 14.4 NaCl, 0.15 KCl, 0.2 CaCl2 and 0.1 MgSO4, pH 7.5).  Homogenates were 
incubated at 37°C for 10 min and centrifuged at 29,000 g for 17 minutes at 4°C.  Pellets 
were washed three times by resuspension in 20 vol of the same buffer followed by 
centrifugation as described above.  Final pellets were resuspended in the incubation 
buffer to yield ~150 µg membrane protein/100 µL membrane suspension.  Binding assays 
were performed in duplicate, in a final volume of 250 µL of incubation buffer (in mM: 20 
HEPES, 144 NaCl, 1.5 KCl, 2 CaCl2, and 1 MgSO4, pH 7.5).  Binding assays were 
initiated by the addition of 100 µL of membrane suspension to 150 µL of sample 
containing 2.5 nM [3H]MLA and the desired concentration of the test compound, and 
incubated for 2 hrs at ambient temperature.  Nonspecific binding was determined in the 
presence of 1 mM nicotine.  Assays were terminated by dilution of samples with 3 mL of 
ice-cold incubation buffer, followed by immediate filtration through Schleicher and 
Schuell #32 glass fiber filters (pre-soaked in 0.5% polyethyleneimine) using a Brandel 
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cell harvester (Davies et al. 1999).  Filters were processed as described above for the 
[3H]NIC binding assay. 
 
3.2.6. Functional Assays for the Nicotinic Receptors Modulating DA Release and 
α4β2* Nicotinic Receptor Subtype  
 
[3H]Dopamine Overflow Assay  
Quaternary ammonium analog effects on [3H]overflow from rat striatal slices preloaded 
with [3H]DA, were determined using a modification of a previously published method 
(Dwoskin and Zahniser 1986; Wilkins  et al. 2002).  Briefly, rat striata were dissected and 
coronal slices (500 µm, 6-8 mg) were obtained using a McIlwain tissue chopper.  Slices 
were incubated for 30 min in Krebs buffer (in mM: 118 NaCl, 4.7 KCl, 1.3 CaCl2, 1.2 
MgCl2, 1.0 NaH2PO4, 11.1 α-D-glucose, 25 NaHCO3, 0.11 L-ascorbic acid and 0.004 
disodium EDTA; pH 7.4, saturated with 95% O2 / 5% CO2) at 34°C in a metabolic 
shaker.  Slices were then incubated for an additional 30 min in fresh buffer containing 0.1 
µM [3H]DA, after rinsing, each slice was transferred to a glass superfusion chamber, 
maintained at 34 °C and superfused (1.0 mL/min) with oxygenated Krebs’ buffer 
containing nomifensine (10 µM), a DA reuptake inhibitor), and pargyline (10 µM), a 
monoamine oxidase inhibitor, to ensure that [3H]overflow represented [3H]DA, rather 
than [3H]DA metabolites. 
 
Following superfusion for 60 min, three 5-min samples (5 mL/sample) were collected to 
determine basal [3H]outflow.  After collection of the third basal sample, slices from an 
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individual rat were superfused for 60 min in the absence (0 nM; control) or presence of 
analog (1 nM-10 µM) to determine the intrinsic activity of the analog, e.g., ability of the 
analog to evoke [3H]overflow.  Each slice was exposed to only one concentration of 
analog, which remained in the buffer through the completion of the experiment.  After a 
60 min superfusion in the absence or presence of analog, NIC (10 µM) was added to the 
superfusion buffer and samples were collected for an additional 60 min to determine the 
ability of the analog to inhibit NIC-evoked [3H]DA overflow.  At least one striatal slice in 
each experiment was superfused for 60 min in the absence of analog, followed by 
superfusion with only NIC (10 µM) to determine a NIC control for NIC-evoked [3H]DA 
overflow in the absence of analog.  Using a repeated-measures design, striata from a 
single rat were used to determine the ability of an analog to evoke [3H]DA release 
(intrinsic activity) and to determine analog-induced inhibition of NIC-evoked [3H]DA 
overflow (antagonist activity). 
 
After collection of the superfusate samples, slices were retrieved from the chambers and 
solubilized using 1 mL TS-2 tissue solubilizer.  Scintillation cocktail (10 mL) was added 
to the superfusate samples.  The pH and volume of the solubilized tissue samples were 
adjusted to those of the superfusate samples.  Radioactivity in the superfusate and tissue 
samples was determined by liquid scintillation spectroscopy (Packard model B1600 TR 
Scintillation Counter, Downer’s Grove, IL). 
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86Rb+ Efflux Assay (α4β2*) 
Quaternary ammonium analog effects on 86Rb+ efflux were determined using a 
previously published method (Marks et al. 1995).  Rat thalamus was homogenized and 
centrifuged at 1000xg for 10 min at 4°C.  The supernatant fraction was centrifuged at 
12,000xg for 20 min at 4°C to obtain the synaptosomal fraction.  Synaptosomes were 
incubated for 30 min in 35 µl of uptake buffer (140 mM NaCl, 1.5 mM KCl, 2.0 mM 
CaCl2, 1.0 mM MgSO4, 20 mM α-D-glucose; pH 7.5) containing 4 µCi of 86Rb+.  86Rb+ 
uptake was terminated by filtration of the synaptosomes onto glass fiber filters (6 mm; 
Type A/E, Gelman Sciences, Ann Arbor, MI) under gentle vacuum (0.2 atm), followed 
by three washes with superfusion buffer (0.5 ml each).  Subsequently, each filter 
containing the 86Rb+-loaded synaptosomes (39 ± 4.8 µg protein/µl) was placed on a 13 
mm glass fiber filter (Type A/E) mounted on a polypropylene platform.  86Rb+ efflux 
assay buffer (125 mM NaCl, 5 mM CsCl, 1.5 mM KCl; 2 mM CaCl2, 1 mM MgSO4, 25 
mM HEPES, 20 mM α-D-glucose, 0.1 µM TTX, 1.0 g/l bovine serum albumin; pH 7.5) 
was superfused onto the synaptosomes at a rate of 2.5 ml/min.  TTX and CsCl were 
included in the buffer to block voltage-gated Na+ and K+ channels, respectively, and to 
reduce the rate of basal 86Rb+ efflux (Marks et al. 1995). 
 
The intrinsic activity of the quaternary ammonium analog as well as the ability to inhibit 
86Rb+ efflux evoked by 1 µM NIC was determined.  After 8 min of superfusion, samples 
were collected (sample/18 s) for 5 min to determine basal 86Rb+ efflux.  Subsequently, 
synaptosomes were superfused for 3 min with the quaternary ammonium analog to 
determine the intrinsic properties of the analog.  The exposure to the analog was followed 
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by superfusion with buffer containing both the quaternary ammonium analog and NIC for 
an additional 3 min, to determine the ability of the analog to inhibit NIC-evoked 86Rb+ 
efflux.  Each aliquot part of thalamic synaptosomes was exposed to only one 
concentration of quaternary ammonium analog.  In each experiment, one synaptosomal 
aliquot part was superfused in the absence of either compound to determine basal 86Rb+ 
efflux over the course of the superfusion period, and another aliquot was superfused with 
NIC (1 µM) to determine the effect of NIC on 86Rb+ efflux in the absence of the 
quaternary ammonium analog.  Samples were analyzed by liquid scintillation 
spectroscopy (Packard model B1600 TR Scintillation Counter). 
 
3.2.7. Data Analysis 
For analog induced inhibition of [3H]NIC and [3H]MLA binding, data were expressed as 
specific [3H]NIC or [3H]MLA bound as a percentage of control and plotted as a function 
of log analog concentration.  The concentration (IC50) of analog that inhibited specific 
[3H]NIC or [3H]MLA binding by 50% were fit by a one-site binding competition model, 
using nonlinear least-squares regression, such that Y = Bt + (Tp – Bt)/[1 + 10(logIC50 – X)•n], 
where Y is the specific [3H]NIC or [3H]MLA binding expressed as a percentage, X is the 
logarithm of analog concentration, Bt and Tp are the minimum and maximum specific 
[3H]NIC and [3H]MLA binding densities, respectively, and n is the pseudo-Hill 
coefficient.  The inhibition constant (Ki) for each analog was calculated from IC50 values 
using the Cheng-Prusoff equation [Ki  = IC50/(1 + ligand/Kd)], where c is the 
concentration of free radioligand and Kd is the equilibrium dissociation constant of the 
ligand. 
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In [3H]DA overflow assays, fractional release of each superfusate sample was calculated 
by dividing the total [3H] collected in each sample by the total [3H] present in the tissue at 
the time of sample collection and was expressed as a percentage of total tissue tritium.  
Basal [3H]outflow was calculated from the average of the fractional release in three five 
minute samples collected prior to the addition of analog to the superfusion buffer.  Total 
[3H]overflow was calculated by summing the increases of [3H] above the basal 
[3H]outflow, resulting from exposure to the analog, NIC, or both and subtracting the 
basal [3H]outflow for an equivalent period of analog exposure.  The data were expressed 
as percent of control and were fitted by non- linear, non-weighted least-squares regression 
using the sigmoidal function, Y = Bt + (Tp – Bt)/[1 + 10(logIC50 – X)], where Y is the total 
[3H]overflow expressed as a percentage of NIC-evoked response, X is the logarithm of 
analog concentration, Bt and Tp are the minimum response (held constant at 0%) and 
maximum response (held constant at 100%), respectively, and log IC50 value represents 
the logarithm of analog concentration required to decrease NIC (10 µM)-evoked [3H]DA 
overflow by 50% of control levels.  The effect of each analog on [3H]DA overflow 
(intrinsic activity) and its ability to inhibit NIC-evoked [3H]DA overflow (inhibition 
effect) was analyzed by one-way repeated-measure analysis of variance (ANOVA), 
where analog concentration was a within subject factor (SPSS version 9.0, Chicago, IL); 
where appropriate, Dunnett’s post hoc tests were performed to determine the 
concentration of analog that significantly evoked or inhibited [3H]DA overflow relative 
to the control (buffer or NIC-evoked [3H]DA overflow, respectively).  A two-way 
repeated-measures ANOVA was performed to analyze the time course of the NIC-
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induced increase in the fractional release (within-subjects factor) for different 
concentrations of the analog (within-subject factor).  IC50 values for analog- induced 
inhibition of NIC-evoked [3H]DA overflow were determined using an iterative non-linear 
least squares curve-fitting program, (PRISM version 3.0, Graph PAD Software, Inc., San 
Diego, CA). 
 
3.3. Results and Discussion 
Chemistry 
Several N-n-alkyl quaternized ammonium salts were successfully synthesized.  mono-
Substituted N-n-alkylpyridinium, N-n-alkylpicolinium, and N-n-alkylnicotinamide salts 
were prepared in similar manners, however, their purification work-up varied.  All three 
precipitated from solution upon reaction and were filtered to afford the crude salts.  The 
N-n-alkylpyridinium and N-n-alkylpicolinium salts were triturated with diethyl ether to 
afford the pure quaternary ammonium salts.  The nicotinamide series were isolated 
differently, due to the low solubility of the nicotinamide starting material in the diethyl 
ether.  These salts were isolated using both an initial diethyl ether wash, followed by an 
aqueous dissolution and subsequent extraction with chloroform.  The N-n-
alkylnicotinium salts were synthesized in a different manner to ensure that the pyridino 
nitrogen was selectively alkylated over the pyrrolidino nitrogen.  Previous research by 
Menshutkin demonstrated that tertiary amines react with alkyl halides resulting in 
quaternary ammonium salt (Figure 3.3a) (Menshutkin 1890).  In the nicotine molecule, 
the pyrrolidine nitrogen is more reactive than the pyridine nitrogen.  Therefore, the 
pyridine nitrogen would be quaternized only after, or at the same time as, the pyrrolidine 
nitrogen, causing a doubly quaternized species (Figure 3.3b).  Due to the reactive nature 
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of both nitrogens and to avoid the double quaternization, a protection of the pyrrolidino 
nitrogen was necessary.  Using the higher reactivity of the pyrrolidino nitrogen, a simple 
acid protection step may be utilized to direct the Menshutkin towards the pyridine 
nitrogen.  Acetic acid was used by Crooks et al. (1995) to achieve this selective 
alkylation of the pyridino nitrogen with excellent results (Figure 3.3c). 
 
Figure 3.3  The Menshutkin reaction and its use in quaternizing nicotine 
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However, the resulting work-up was modified in the current synthesis to increase the 
yield and decrease the labor-intensive work-up.  The existing synthetic route called for 
the protonated NIC molecule and the iodoalkane reactant to be stirred for three days at 
room temperature.  The increase in the reaction temperature due to the refluxing 
increased the yield of the reaction in the present synthesis.  The previous synthesis also 
involved a time-consuming basification and subsequent removal of water at increased 
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temperature followed by a 24-hour reflux in chloroform to remove the excess NIC.  This 
resulted in a loss of the N-n-alkylnicotinium salt due to the salt having some solubility in 
chloroform.  In the current synthesis, after the basification step, the mixture was 
sequentially treated with diethyl ether and chloroform to remove the excess NIC and the 
corresponding N-n-alkylnicotinium salt, respectively, without evaporating the aqueous 
layer.  This procedure removed the two previous time-consuming steps, and increased the 
overall yield of the product. 
 
The bis-N,N’-alkyl quaternary ammonium salts were prepared similarly to their 
corresponding mono-alkyl quaternized ammonium salts.  bis-N,N’-Alkylpyridinium salts 
and bis-N,N’-alkylpicolinium salts, as well as bis-N,N’-alkylquinolinium salts and bis-
N,N’-alkylisoquinolinium salts, were isolated in high yields when diethyl ether was 
utilized to remove the excess reactant.  The bis-N,N’-alkylnicotinium salts were 
synthesized via a similar synthetic route to that utilized for the corresponding mono-
alkylnicotinium salts, although the final purification step was modified.  The diethyl ether 
extraction step removed the unreacted NIC, but the subsequent chloroform extraction 
revealed the presence of a product from an unexpected side reaction; a mono-substituted 
N-alkylnicotinium salt with an acetate terminating the carbon chain instead of another 
NIC molecule was synthesized and had greater solubility than the bis-N,N’-
alkylnicotinium salt in chloroform.  During the reaction, it is possible that the acetate ion 
displaced the iodide or bromide causing the impurity.  Alternatively, the bis-N,N’-
alkylnicotinium salt may have formed but over the course of the reaction the a carbon to 
the quaternized pyridine nitrogen could have been attacked by the acetate ion, resulting in 
 102 
the mono-substituted N-alkylnicotinium salt with the terminal acetate moiety (Figure 3.4).  
The aqueous layer containing the bis-N,N’-alkylnicotinium salt was evaporated under 
reduced pressure and chloroform was added to extract the bis-N,N’-alkylnicotinium salt.  
The chloroform layer was dried using magnesium sulfate, filtered, and evaporated under 
reduced pressure to afford the final product. 
 
Figure 3.4 Formation of the acetate impurity 
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It is important to note, that despite several different functionalities and charges on the 
molecules, the mono- and bis-quaternary ammonium salts all demonstrated chloroform 
solubility. 
 
Pharmacology of the  mono-Substituted Quaternary Ammonium Salts  
N-n-Alkylpyridinium salts  
N-n-Alkylpyridinium salts with chain lengths ranging from one to twenty carbon units 
weakly inhibited [3H]NIC binding to rat striatal membranes (see Table 3.1  for  affinity 
values).  Salts with chain lengths less than 15 carbons completely inhibited [3H]NIC 
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binding.  The C20 analog NEcPB inhibited binding by only 25%.  The binding affinities 
(Ki) at the a4ß2* nAChR subtypes ranged from 9-20 µM for the C1-C11 and C15 analogs.  
The C12 and C20 chain length salts were not active (Ki > 100).  No significant linear 
relationship was found between compound affinity and carbon chain length.  The N-n-
alkylpyridinium salts did not inhibit [3H]MLA binding, and thus had no significant 
affinity at the α7* nAChR subtype (Table 3.1).  
 
Initial screens at two concentrations, i.e. 0.1 and 1.0 µM, of analog, C1-C12, were 
determined for the N-n-alkylpyridinium series in the [3H]DA overflow assay.  Chain 
lengths of nine or less carbons were  not active; however, carbon chain lengths greater 
than nine were found to significantly inhibit NIC-evoked [3H]DA overflow by 70-90%.  
Evaluation of the activities of these compounds, for both intrinsic and inhibitory activity, 
over the full concentration range (0.01-100 µM) was performed.  NUPI (C11), NDDPI 
(C12), and NPDPB (C15) increased [3H]DA overflow at 10 µM and NDPI (C10), NEcPB 
(C20) increase overflow at 100 µM.  Concentrations that elicited intrinsic activity were 
not included in the analysis of inhibition of NIC-evoked DA overflow.  Carbon chain 
lengths greater than nine carbons, i.e. NDPI, NUPI, NDDPI, NPDPB, and NEcPB all 
inhibited NIC-evoked [3H]DA overflow in the high nanomolar concentration range (IC50 
values = 120 – 490 nM, Table 3.1).  For each analog, repeated measures one-way 
ANOVA revealed significant concentration-dependent inhibition of nicotine-evoked 
[3H]DA overflow: NDPI (C10), F5,35 = 29.44, p < 0.0001; NUPI (C11), F4,29 = 24.58, p < 
0.0001; NDDPI (C12), F3,23 = 11.07, p < 001; NPDPB (C15), F5,18 = 24.31, p < 0.001; 
NEcPB (C20), F5,15 = 9.29, p < 0.001.  NDPI, NUPI, and NDDPI all inhibited overflow 
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completely (Imax = 100%), whereas NPDPB and NEcPB only inhibited overflow by a 
maximum of 45-55%.   
 
N-n-Alkylpicolinium salts 
N-n-Alkylpicolinium salts exhibited similar properties to the N-n-alkylpyridinium salts in 
their binding affinities at α4β2* and α7* nAChR subtypes.  Analogs with chain lengths 
of C8-C12 had weak or no affinity in the [3H]NIC binding assay, and had no affinity in the 
[3H]MLA binding assay (Table 3.2).  In the NIC-evoked [3H]DA overflow assay, NOPiI 
(C8) and NDPiI (C10) did not exhibit intrinsic activity up to 1.0 µM, but NDDPiI (C12) did 
evoke overflow at > 1.0 µM.  Due to the intrinsic activity, the concentration 1.0 µM of 
NDDPiI was not used in determining the inhibitory concentration of the compound.  In 
this series of compounds, NDDPiI was the most potent of the N-n-alkylpicolinium salts 
tested at the nAChR subtypes mediating NIC-evoked DA overflow (IC50 = 30 nM) and 
there was an increase of inhibitory activity in this series as the carbon chain increased 
(Table 3.2).  Interestingly, NDDPiI only inhibited overflow by 63%. 
 
N-n-alkylnicotinamide salts 
N-n-alkylnicotinamide salts were not active in either of the binding assays and were not 
tested in the NIC-evoked DA release assay (Table 3.3). 
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N-n-Alkylnicotinium salts  
N-n-Alkylnicotinium salts demonstrated a wide range of affinities in the [3H]NIC binding 
assay (90 nM –20 µM, Table 3.4).  The C10 and C12 analogs (NDNI and NDDNI) had the 
highest affinities, Ki = 90 nm and 140 nm, respectively.  A linear relationship between N-
n-alkyl chain length and analog affinity was determined, with the exception of the N-n-
octyl compound, NONI, which had one of the lowest affinities in the series.  The N-n-
alkylnicotinium salts all demonstrated low affinity in the [3H]MLA binding assay (Table 
3.4). 
 
In the evaluation of the N-n-alkylnicotinium salts to inhibit NIC-evoked [3H]DA 
overflow, analogs with chain lengths greater than six carbons demonstrated intrinsic 
activity at concentrations greater than 1 µM.  Longer chain compounds were more likely 
to evoke significant amounts of [3H]overflow.  NDNI (C10) had the lowest concentration 
necessary for evoking [3H]overflow at 1 µM, followed by NDDNI (C12) at 10 µM, and 
NONI (C8), NHpNI (C7), and NHxNI (C6) at 100 µM.  NNNI (C9) did not evoke 
[3H]overflow at any concentration tested.  For each analog, repeated measures one-way 
ANOVA revealed significant concentration-dependent inhibition of nicotine-evoked 
[3H]DA overflow: NMNI (C1), F3,15 = 5.02, p < 0.05; NPNI (C3), F6,38 = 4.33, p < 0.005; 
NnBNI (C4), F3,19 = 8.83, p < 0.005; NHxNI (C6), F5,20 = 3.81, p < 0.05; NHpNI (C7), 
F5,24 = 26.3, p < 0.0001; NONI (C8), F5,27 = 10.5, p < 0.0001; NNNI (C9), F5,23 = 4.58, p 
< 0.01; and NDDNI (C12), F4,18 = 9.00, p < 0.001.  Evaluation of the inhibition of NIC-
evoked [3H]DA overflow by the N-n-alkylnicotinium salts revealed that NPNI was the 
least potent of the N-n-alkylnicotinium analogs (IC50 = 37 µM), while NnBNI and 
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NHxNI also exhibited low micromolar activity (IC50 = 9 and 3 µM, respectively).  
NHpNI, NONI, and NNNI had IC50 values in the range 0.2 - 0.8 µM.  NDDNI, the C12 
analog, had the highest inhibitory potency with an IC50 value of 9 nM (Table 3.4).   
 
Structure Activity Relationship of the  mono-Substituted Quaternary Ammonium 
Salts 
The affinities of N-n-alkylnicotinium compounds in the [3H]NIC binding assay revealed 
that as the carbon chain was increased so was the affinity for the α4β2* receptor.  
Subsequent evaluation of these compounds in the functional Rb86+ efflux assay 
demonstrated that N-n-alkylnicotinium compounds with good affinity in the [3H]NIC 
binding assay, were receptor antagonists at the α4β2* nAChR subtype.  Analogs with 
longer n-alkyl chain lengths of nine, ten, and twelve all had nanomolar affinities for the 
α4β2* nAChR subtype, with the N-n-decylnicotinium (NDNI) and N-n-
dodecylnicotinium (NDDNI) having the highest affinities for the receptor with Ki values 
of 90 nM and 140 nM, respectively.  These Ki values are comparable to that of the 
classical nAChR antagonist DHβE, which has a Ki value of 149 nM at the α4β2* 
receptor subtype (Wilkins et al. 2003).  Interestingly, a one-carbon deletion from the 
nine-carbon chain analog, to afford the N-n-nonylnicotinium salt (NNNI), results in a 
twenty-fold decrease in affinity for the α4β2* receptor subtype.  Therefore, a subtle 
change to the length of the carbon chain may cause a large difference in activity.  This is 
further supported by the inactivity of the C8 compound, N-n-octylnicotinium, which had 
low affinity in the [3H]NIC binding assay.  The higher affinities in the longer chain 
compounds may be due to an increase in the lipophilic interaction of the carbon chain and 
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the hydrophobic regions of the binding site.  This interaction may have a stabilizing 
effect on the compound-receptor complex, increasing the affinity for the C9-C12 
compounds of this series of compounds. 
 
In addition to the carbon chain length, the pyrrolidine ring of this series of compounds 
also appears to play an important role in the interaction at the binding site.  The N-n-
alkylnicotinium salts with increased numbers of carbon units all demonstrated a greater 
affinity for the α4β2* binding site over their corresponding N-n-alkylpyridinium, N-n-
alkylpicolinium, and N-n-alkylnicotinamide salts.  Complete removal of the pyrrolidine 
ring in the N-n-alkylpyridinium series resulted in a complete loss in affinity for the 
α4β2* receptor.  In the N-n-alkylpicolinium series, the importance of a 3-substituent was 
explored.  However, the low affinity of these salts in the [3H]NIC binding assay indicates 
that a simple methyl group in the three position of the pyridine ring does not afford 
compounds with high affinity for the α4β2* binding site.  The nicotinamide moiety is a 
somewhat larger and more polar substituent that incorporates a second nitrogen atom into 
the receptor-ligand model.  Due to the lack of activity of these molecules at the α4β2* 
binding site, and since the nicotinamide nitrogen is not basic in nature, it can be assumed 
that it is not necessarily the size of the 3-substituent that promotes interaction with the 
receptor but rather the incorporation of an appropriate functional moiety.  Therefore, a 
basic nitrogen, such as that in the pyrrolidine ring may be important for recognition by 
the high affinity [3H]NIC binding site on the α4β2* receptor subtype. 
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Several of the quaternized ammonium salts were potent antagonists in the NIC-evoked 
[3H]DA overflow assay, with the N-n-dodecylnicotinium analog (NDDNI) exhibiting the 
greatest activity at the nAChR subtypes mediating DA release (IC50 = 9 nM); this 
inhibition is significantly greater than that exhibited by DHβE (IC50 = 1.6 µM).  
However, the N-n-alkylpyridinium and N-n-alkylpicolinium salts with similar N-n-alkyl 
chain lengths also antagonized the receptor subtype at higher nanomolar concentrations, 
with IC50 values of 260 nM (NNDPI) and 30 nM (NDDPiI).  The N-n-alkylpicolinium 
and N-n-alkylnicotinium salts both demonstrate a linear relationship between antagonist 
activity and carbon chain length at the nAChR subtypes that mediate DA release.  The 
removal of the pyrrolidine ring did not completely eliminate the ability of these N-n-
alkylpyridinium salts to interact with this class of nAChR subtypes 
 
The quaternary ammonium salts demonstrated low activities in the [3H]MLA binding 
assay.  The N-n-alkylnicotinium molecules only inhibited binding with carbon chain 
lengths of C6, C7, C8 (Ki = 28.3-92.4 µM).  These values are at least ten fold less active at 
the receptor than NIC, a weak agonist.  The N-n-alkylpyridinium compounds also did not 
exhibit affinity for α7* nAChRs, with only two compounds, NPePI (C6) and NNPI (C9), 
having Ki values below 100 µM (67.7 and 61.8 µM, respectively).  Therefore, these 
compounds are not active at the α7* receptor subtype.   
 
Pharmacology of the  bis-Substituted Quaternary Ammonium Salts 
N,N’-bis-Alkylpyridinium salts 
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N,N’-bis-Alkylpyridinium salts with n-alkyl chain lengths ranging from six to twelve 
carbon atoms were evaluated in the [3H]NIC binding assay and had weak affinities for the 
α4β2* nAChR subtype binding site (Table 3.5).  These compounds did show a general 
trend of increasing affinity as the n-alkyl carbon chain length was increased.  Compound 
bPDDB, had the highest affinity for the α4β2* receptor subtype with a Ki value of 9.15 
µM.  The N,N’-bis-alkylpyridinium salts with cha in lengths ranging from C6-C12 
demonstrated low affinity or no affinity with respect to [3H]MLA binding, and thus 
exhibited no significant interaction with the α7* nAChR subtype (Table 3.5).  
 
The C12 analog, bPDDB, had no intrinsic activity at any of the concentrations tested 
(0.001-10 µM) in the [3H]DA overflow assay.  bPDDB inhibited NIC-evoked [3H]DA 
overflow with an IC50 value of 1.0 µM.  No other N,N’-bis-alkylpyridinium compounds 
were evaluated at nAChR subtypes mediating DA release (Table 3.5). 
 
N,N’-bis-Alkylnicotinium salts 
N,N’-bis-Alkylnicotinium salts were also evaluated in the [3H]NIC binding assay.  The 
C10 (bNDI) and C11 (bNUB) analogs had the highest affinities for the α4β2* receptor 
subtype, with Ki values of 330 and 430 nM, respectively (Table 3.6).  Moreover, bNDI 
and bNUB inhibited NIC-evoked 86Rb+ efflux from rat thalamic synaptosomes (IC50 = 
3.76 + 1.1 µM and 5.22 + 1.4 µM, respectively), without producing intrinsic activity.  
Several other compounds, i.e. the C6-C9 and C12 analogs, had low micromolar affinities 
(Ki = 1.54 - 20.0 µM).  None of the N,N’-bis-alkylnicotinium salts were active in the 
[3H]MLA binding assay (Table 3.6). 
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In addition to the α4β2* and α7 receptor subtype assays, the N,N’-bis-alkylnicotinium 
C12 analog, bNDDB, was evaluated for both intrinsic and inhibitory activity in the 
[3H]DA overflow assay.  bNDDB had intrinsic activity at 10 µM.  The C12 salt afforded 
an IC50 value of 3.30 µM in the NIC-evoked [3H]DA overflow assay (Table 3.6). 
 
N,N’-bis-Alkylpicolinium salts 
N,N’-bis-Alkylpicolinium salts generally did not exhibit high affinities at the α4β2* 
nAChR subtype, with Ki values for the C9, C11, C12 analogs in the high micromolar range 
(48.6-79.9 µM) and the C6, C10 and C11 compounds had no affinity at this nAChR subtype 
(>100 µM).  The N,N’-bis-alkylpicolinium salts were not active in the [3H]MLA binding 
assay (Table 3.7). 
 
The C12 N,N’-bis-alkylpicolinium analog, bPiDDB, was evaluated for its intrinsic and 
inhibitory behavior in the [3H]DA overflow assay.  bPiDDB had no intrinsic activity in 
[3H]DA overflow assay at any of the concentrations tested (0.001-10 µM).  The 
compound was very potent in inhibiting NIC-evoked [3H]DA overflow.  With an IC50 
value of 2 nM, this compound is one of the most potent compounds in inhibiting NIC-
evoked DA release (Table 3.7).  Interestingly, bPiDDB inhibited NIC-evoked [3H]DA 
overflow by a maximum of only 50%. 
 
Due to the high potency of bPiDDB to inhibit NIC-evoked [3H]DA overflow, all the 
N,N’-bis-alkylpicolinium analogs were tested for intrinsic activity and for their ability to 
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inhibit [3H]DA overflow.  Generally, N,N’-bis-alkylpicolinium analogs did not exhibit 
intrinsic activity in this assay.  One-way ANOVAs revealed significant concentration-
dependent inhibition for each analog: bPiOI (C8), F5,19 = 4.441, p = 0.007; bPiNB (C9), F 
5,19 = 4.053, p = 0.011; bPiDI (C10), F5,23 = 7.346, p < 0.001; bPiUB (C11), F5,28 = 11.750, 
p < 0.001, bPiDDB (C12), F5,23 = 13.282, p < 0.001.  Contrary to what was observed in 
the pyridinium series, the shorter chain length compounds, i.e. C8 and C10, were potent 
antagonists at the nAChR subtype responsible for mediating DA release.  However, the 
antagonism pattern did not seem to increase as carbon chain length increased, as has been 
observed in several of the other series.  The C8 (bPiOI) and C10 (bPiDI), analogs had low 
nanomolar activities (IC50 = 10 and 30 nM, respectively), while the C9 (bPiNB) and C11 
(bPiUB), analogs had low micromolar activities (IC50 = 1.5 - 1.6 µM) and the C6 analog 
(bPiHxI), was inactive (Table 3.7).  All the active N,N’-bis-alkylpicolinium salts 
inhibited NIC-evoked [3H]DA overflow similar to bPiDDB, with a maximum of ~50% 
(Imax = 50%). 
 
N,N’-bis-Alkylisoquinolinium and N,N’-bis-alkylquinolinium salts 
N,N’-bis-Alkylisoquinolinium and N,N’-bis-alkylquinolinium salts were evaluated in the 
[3H]NIC binding assay and generally had low affinities for the α4β2* nAChR (Tables 3.8 
and 3.9).  The C6, C8, C9, C11, and C12 N,N’-bis-alkylisoquinolinium analogs had low to 
moderate micromolar affinities (Ki = 6.10-65.5 µM) for the α4β2* nAChR subtype, 
while the C10 analog had no affinity (Ki > 100 µM).  The pharmacological profile of the 
N,N’-bis-alkylquinolinium salts was similar to that of the N,N’-bis-alkylisoquinolinium 
salts in the [3H]NIC binding assay, with the C6,  C9, and C11 analogs exhibiting only 
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moderate micromolar affinities (Ki = 22.5-39.3 µM) for the α4β2* nAChR subtype, 
while the C8, C10, and C12 analogs had no affinity (Ki > 100 µM).  Interestingly, analogs 
in both the N,N’-bis-alkylisoquinolinium series and the N,N’-bis-alkylquinolinium series 
were all active in the [3H]MLA binding assay, with Ki values in the low micromolar 
range (1.61-16.0 µM, Tables 3.8 and 3.9); the two most potent analogs in these two 
groups were the C12 analogs, bQDDB and bIQDDB  
(Ki = 1.61 and 2.21 µM, respectively). 
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The compounds in the N,N’-bis-alkylisoquinolinium and N,N’-bis-alkylquinolinium 
series were evaluated for both intrinsic activity and their ability to inhibit NIC-evoked 
[3H]DA overflow.  The C8 and C12 N,N’-bis-alkylquinolinium salts, bQOI and bQDDB,  
and the C10 N,N’-bis-alkylisoquinolinium salt, bIQDDB, elicited [3H]DA overflow at 10 
µM.  The other N,N’-bis-alkylquinolinium and N,N’-bis-alkylisoquinolinium salts, did 
not exhibit intrinsic activity at any concentration tested N,N’-bis-alkylquinolinium.  One-
way ANOVA revealed significant concentration-dependent inhibition for bQHxI (C6), 
F5,24 = 5.055, p = 0.002; bIQOI (C8), F4,14 = 6.428, p = 0.003; bQNB (C9), F5,19 = 4.872, 
p = 0.004; bQDI (C10), F4,14 = 3.294, p = 0.033; bQUB (C11), F5,19 = 7.873, p < 0.001; 
bQDDB (C12), F5,24 = 9.16, p < 0.001; bIQOI (C8), F5,20 = 4.141, p = 0.01; bIQDI (C10), 
F4,16 = 4.835, p < 0.001, bIQUB (C11), F5,20 = 4.157, p < 0.001; bIQDDB (C12), F5,22 = 
3.827, p < 0.05.  N,N’-bis-alkylisoquinolinium salts exhibited antagonist activity at 
nAChR subtypes that mediate DA release (IC50 = 20-90 nM).  In addition, the analogs 
only partially inhibited NIC-evoked [3H]DA overflow (Imax = 62-78%). 
, F5,19 = 4.441, p = 0.007; bPiNB (C9), F 5,19 = 4.053, p = 0.011; bPiDI (C10), F5,23 = 
7.346, p < 0.001; bPiUB (C11), F5,28 = 11.750, p < 0.001, bPiDDB (C12), 
 
Structure Activity Relationship of the  bis-Substituted Quaternary Ammonium Salts 
At muscle-type peripheral receptors, the compounds with only a trimethylammonium 
headgroup, were found to require an optimum chain length of ten carbon units (DEC).  
Although DEC had three orders of magnitude lower affinity for the α4β2* subtype 
compared to NIC (Ki = 5.73 + 0.76 µM versus 0.0014 + 0.0001 µM) for the α4β2* 
subtype and had no affinity for the α7* subtype, it is apparent that replacing the N,N’-
 125 
trimethylammonium moieties of DEC with azaaromatic moieties, such as nicotinium 
moieties (α4β2*) and quinolinium and isoquinolinium moieties (α7*), affords molecules 
with good affinity for nAChR subtypes. 
 
Of particular interest is the finding that two compounds in this study exhibited high 
selectivity at the α4β2* nAChR subtype.  In this respect, the N,N’-bis-alkylnicotinium 
analogs, bNDI and bNUB exhibit low nanomolar affinities (330 and 430 nM, 
respectively) for the α4β2* nAChR subtype, and functionally inhibited NIC-evoked 
86Rb+ efflux, while demonstrating no affinity for the α7* nAChR subtype, these data 
indicate that these two analogs are selective α4β2* nAChR subtype antagonists.  As seen 
in the mono-quaternary ammonium series, the importance of the pyrrolidino moiety to 
achieve activity at the α4β2* subtype is also seen in the bis-quaternary ammonium series.  
The N,N’-bis-alkylnicotinium series, when compared to the N,N’-bis-alkylpyridinium and  
N,N’-bis-alkylpicolinium series, demonstrates a two-fold decrease in affinity in the 
[3H]NIC binding assay for the most potent compounds.  Additionally, the N,N’-bis-
alkylisoquinolinium and N,N’-bis-alkylquinolinium series had low affinity for the α4β2* 
subtype, indicating that increased aromaticity, i.e. 6π  system to 10π  system, is not 
necessarily an important requirement for binding. 
 
In contrast, replacing the bis-nicotinium headgroups with bis-quinolinium and bis-
isoquinolinium moieties afforded compounds with no affinity for the α4β2* nAChR, but 
which had similar affinity to NIC and d-TBC (Ki values = 0.45 + 0.09 µM and 4.79 + 
0.20 µM, respectively) at the α7* nAChR subtype.  Although no correlation between 
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carbon chain length and affinity was observed in either series, the C12 analogs in the 
N,N’-bis-alkylisoquinolinium (bIQDDB) and N,N’-bis-alkylquinolinium (bQDDB) series 
had the highest affinities, and when the bis-quinolinium and bis- isoquinolinium 
headgroups were replaced with simple bis-pyridinium moieties, only the longer chain 
molecules were active (C11 and C12 analogs).  The presence of a 3-position methyl 
substituent in the pyridinium ring in the N,N’-bis-alkylpicolinium series appears to 
decrease the affinity for the α7* nAChR subtype, as is seen in the loss of α7* affinity in 
the bis-nicotinium and bis-picolinium series.  The bis-quinolinium analog, bQDDB 
exhibited a Ki value of 1.61 µM for the α7* nAChR subtype and this compound had no 
affinity for the α4β2* nAChR subtype.  Therefore, it appears that increased aromaticity is 
an important structural requirements for the α7* nAChR subtype and not for the α4β2* 
nAChR subtype.  The N,N’-bis-alkylisoquinolinium and N,N’-bis-alkylquinolinium series 
is the first active compound in both the mono- and bis-azaaromatic series for the a7* 
nAChR subtype. 
 
In initial experiments, the C12 analogs of the bis- azaaromatic series were evaluated in the 
NIC-evoked [3H]DA overflow, because the C12 N-n-alkylnicotinium analog, NDDNI, 
was the most potent antagonist at the nAChR subtypes mediating DA release.  In all of 
the bis-azaaromatic series, the C12 analogs were able to inhibit NIC-evoked [3H]DA 
overflow at low micromolar or low nanomolar concentrations.  The most potent 
antagonist in the series was the C12 analog in the N,N’-bis-alkylpicolinium series.  Taken 
together with the data from the α4β2* and α7* assays, this compound is highly selective 
as an antagonist at the nAChR subtype mediating DA release.  Four to five orders of 
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magnitude separate the affinity for the nAChR subtypes mediating DA release with those 
for the α4β2* and α7* nAChR subtypes.  Additionally, other analogs in the N,N’-bis-
alkylpicolinium series of compounds were evaluated and all were found to have 
inhibitory activity in the NIC-evoked [3H]DA overflow assay, although none were as 
potent as bPiDDB.  The simple C8 and C10 analogs N,N’-bis-alkylpyridinium series were 
also tested to determine their activity and surprisingly, none of the N,N’-bis-
alkylpyridinium analogs had any activity at concentrations below 1 µM.  This represents 
a 10-fold decrease in potency for the corresponding C8 and C10 N,N’-bis-alkylpicolinium 
analogs and a 1000-fold decrease for the C12 analogs.  Surprisingly, the C12 N,N’-bis-
alkylnicotinium analog was not as active as bPiDDB, indicating that the bulky 
pyrrolidino moiety maybe hindering binding at the nAChR subtypes mediating DA 
release and therefore decreasing the activity.  The increased aromaticity of the N,N’-bis-
alkylisoquinolinium and N,N’-bis-alkylquinolinium series also led to an increase in 
antagonist activity at nAChR subtypes mediating NIC-evoked DA release but none of the 
analogs in these series of compounds approached the inhibitory activity of bPiDDB.  
Thus, the 3-methyl substituent on the picolinium ring is important for determining NIC-
evoked [3H]DA overflow at these receptor subtypes. 
 
As stated previously, there is currently considerable debate as to the exact subunit 
composition of nAChR subtypes mediating NIC-evoked DA release (Klink et al. 2001; 
Azam et al. 2002; Champtiaux et al. 2002; Whiteaker et al. 2002; Zoli et al. 2002).  The 
discovery and use of the α-conotoxins (α-ctx), particularly the α-ctx MII, has greatly 
increased our understanding of this receptor class.  Two receptor subtypes, α-ctx MII 
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sensitive and α-ctx MII resistant, have been determined as the nAChR subtypes 
responsible for NIC-evoked DA release.  Using knockout mice data coupled with the α-
ctx MII data, Luetje (2004) has identified four distinct DA releasing subtypes, α-ctx MII 
sensitive subtypes, α6β2β3 and α6α4β2β3, where α6 and α4 form with the β2 subunit to 
form a functional receptor; and α-ctx MII resistant subtypes consist of α4β2 and α4α5β2 
with the α4 and β2 subunits forming the agonist binding sites (Luetje 2004).  
Interestingly, bPiDDB only partially blocks the effects of NIC-evoked [3H]DA overflow 
(Imax~50%), indicating that it is only antagonizing select subtypes that mediate DA 
release, similar to α-ctx MII.  The observed low affinity of bPiDDB for the α4β2* 
nAChR subtype, in addition to the partial antagonism activity demonstrated by bPiDDB 
in the NIC-evoked [3H]DA overflow assay, indicates that bPiDDB most likely 
antagonizes the α-ctx MII sensitive subtypes, α6β2β3 and α6α4β2β3 and not the ctx MII 
resistant subtypes, α4β2 and α4α5β2. 
 
Binding Model of Quaternized Azaaromatic Compounds at the nAChR subtypes 
mediating DA release 
In order to propose a binding model for these quaternary ammonium compounds, it is 
important to identify if these antagonists are competing for the same receptor binding 
site.  It was determined that the C8 N-n-alkylnicotinium salt, NONI, was a competitive 
antagonist in the NIC-evoked [3H]DA overflow assay (Wilkins et al. 2002).  Crooks et al. 
(1995) reported that N-n-alkylation of the pyridyl nitrogen of NIC resulted in a change in 
the physical properties of both the pyridyl nitrogen atom as well as the pyrrolidine 
nitrogen atom of the molecule.  The pyridyl alkylation caused the pKa of the pyrrolidine 
 129 
nitrogen to fall 2 pH units, resulting in it being mostly unprotonated at physiological pH.  
Therefore, a nAChR binding model was hypothesized for the nAChR subtypes mediating 
DA release, wherein the nAChR recognition points of the quaternized molecule were 
reversed from those in the protonated NIC molecule, resulting in a novel interaction of 
such molecules at the nAChR binding site (Crooks et al. 1995).  In this model, the 
cationic binding area of the nAChR receptor recognizes the quaternary ammonium 
moiety of the N-n-alkylnicotinium compound, while the hydrogen-bonding site 
accommodates the unprotonated pyrrolidine nitrogen (lone pair) (Figure 3.5). 
 
Figure 3.5 Illustration of the different modes of interaction of protonated NIC and 
NDDNI at the nAChR 
 
 
Many compounds belonging to the mono- and  bis-azaaromatic series were active in the 
NIC-evoked [3H]DA release assay.  Therefore, a flexible model should be examined for 
the nAChR subtypes mediating DA release.  Because of the fact that the quaternized 
pyridinium moiety is a constant structural feature in many compounds of the mono-
azaaromatic series, there must still be a cationic binding site that interacts with these 
types of molecules.  This interaction is not sufficient to inhibit release, as evidenced by 
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the lack inhibition exhibited by the smaller chain N-n-alkyl analogs; therefore, the carbon 
chain length is also an important structural feature.  The length of the carbon chain in 
active molecules is found to be variable, depending on the substituent in the three 
position of the pyridyl moiety.  It is hypothesized that the N-n-alkylnicotinium molecules 
fit into the receptor binding site at a unique angle, which allows the pyrrolidino moiety to 
interact with a nearby H-bonding site, and an n-alkyl moiety with critical carbon chain 
length is necessary to complete the strong interaction of the molecule with the DA-
releasing nAChR at the N-n-alkyl binding site.  The n-alkyl chain would likely interact 
with residues adjacent to the binding site itself that are of a hydrophobic nature.  This 
hydrophobic interaction may also explain the observed decrease in activity seen with C10 
N-n-alkylnicotinium salt, NDNI.  In this case, the ten-carbon alkyl chain may not fit the 
binding area due to a negative interaction of the chain with the receptor protein, leading 
to a decrease in affinity.  The C12 n-alkyl analog was a potent antagonist in the NIC-
evoked DA release assay.  This may be due to an interaction that overcomes the 
disruption that NDNI encounters.  The longer alkyl chain may be able to bend to a 
conformation that minimizes the interaction or that moves around the amino acid causing 
the issue. 
 
The recognition site also allows the N-n-alkylpyridinium and N-n-alkylpicolinium 
molecules to interact with the binding site.  However, the N-n-alkylpyridinium and N-n-
alkylpicolinium molecules still have a decreased affinity when compared to the N-n-
alkylnicotinium series.  This points to the importance of the absence of the pyrrolidine 
ring, decreasing the strength of the interaction with the binding site.  Without the 
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pyrrolidine ring, these series of compounds may lack the ability to seat into the cationic 
binding site as strongly as the N-n-alkylnicotinium molecules.  Therefore, they require 
longer chain lengths to create a more favorable ionic interaction at the cationic site while 
maintaining the ability to interact at the N-n-alkyl binding site.  However, the effect of 
the increase in carbon chain length does not fully compensate for the loss of the 
pyrrolidine ring, as the N-n-alkylpyridinium and N-n-alkylpicolinium series demonstrated 
at least 10 fold decreased affinities (0.12 and 0.03 µM, respectively) when compared to 
the N-n-alkylnicotinium series (0.009 µM).  Taken overall, these data underline the 
importance of the N-n-alkyl binding site, the H-binding site, and the cationic binding site 
in the binding of this series of compounds. 
 
The activity of compounds in the bis-azaaromatic series provides additional information 
on the interaction of these quaternary ammonium compounds with nAChR subtypes 
mediating DA release.  Due to the presence of the second quaternized headgroup, the 
carbon chain length and the quaternary ammonium center are not the only factors in 
determining interaction between the molecule and the receptor.  The inclusion of a 
second quaternary ammonium headgroup increases antagonist activity at the nAChR 
subtypes mediating DA release for the N,N’-bis-alkylpicolinium series.  This increased 
activity is likely due to interaction of these molecules with a second quaternary 
ammonium binding area remote from the first quaternary ammonium binding site.  Due 
to the poor activity of the C12 N,N’-bis-alkylnicotinium analog in the DA release assay, 
the second quaternary ammonium binding site may be different than the first quaternary 
ammonium binding site.  It is possible that site has a smaller area that cannot 
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accommodate the entire nicotine molecule, but a smaller 3-position substituent may be fit 
into the second binding site (Figure 3.6C). 
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Figure 3.6 Potential binding pocket of the α6β2β3 nAChR subtype with NDDPiI, 
NDDNI, bPiDDB, and bNDDB 
 
 
Even though the exact sub-unit composition is not known, the heterologously assembled 
DA-releasing nAChR subtype binding sites utilize an α-β  interface (Kuo et al. 2005).  
The main binding pocket of the mostly resides in the α subunit of the receptor site 
(Karlin 2002; Unwin 2005).  Recently, it was determined that the ß subunits may play a 
dominant role in receptor inactivation (Fenster et al. 1997; Gentry et al. 2003).  
Therefore, the β-subunit must be integral to the strong inhibitory activity of this series of 
compounds at the nAChR subtypes mediating DA release.  If the second binding pocket, 
as well as, some of the hydrophobic residues that interact with the carbon chain of 
quaternized molecule, resides on the β-subunit interface, the interaction of the molecule 
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could prevent a conformational shift of the binding pocket and not allow the ionic pore to 
open, inactivating the receptor. 
 
3.4. Conclusions  
Several interesting mono- and bis-azaaromatic quaternary ammonium compounds have 
emerged from this structure-activity study.  bPiDDB was found to be a potent and 
selective antagonist at the nAChRs mediating DA release, indicating it to be a possible 
α6β2β3 or α6α4β2β3 nAChR subtype antagonist.  The C10 mono- and bis-nicotinium 
analogs, NDNI and bNDI, both had good antagonist activity and selectivity for α4β2* 
nAChR subtypes.  Additionally, bQDDB and bIQDDB have been shown to be the first 
members of these series of quaternary ammonium molecules that have affinity for α7* 
nAChR subtypes.  The selectivity of these series of compounds for nAChR subtypes 
demonstrates that these agents may be useful for both basic and clinical research aimed at 
determining the pharmacological role of nAChR subtypes and their potential use as 
therapeutic agents. 
 
 
 
 
 
 
 
Copyright © Joshua Thomas Longen Ayers 2006
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Chapter 4: Molecular Modeling of mono- and bis-Quaternary Ammonium Salts at 
α4β2* Receptor Subtypes  
 
4.1. Introduction 
Over the past decade, the nAChR has become a target for drug development.  The most 
prevalent nAChR subtype in the mammalian brain is the heterologously expressed α4β2* 
receptor subtype, which is the primary high affinity [3H]nicotine binding site.  Ligands 
that specifically interact with this nAChR subtype are of interest in a number of 
pathologies, including tobacco dependence and drug addiction, Alzheimer's disease, 
Parkinson's disease, Tourette’s syndrome, schizophrenia, and pain (Lindstrom 1997; 
Dwoskin et al. 2000; Lloyd and Williams 2000; Dwoskin and Crooks 2001; Dani et al. 
2004; Hogg and Bertrand 2004).  NIC and other nAChR agonists (e.g., epibatidine) are 
not selective for α4β2* receptor subtypes, and produce significant side effects, making 
these compounds less attractive as drug candidates.  Consequently, previous studies have 
generated quantitative structure-activity relationships (QSAR) in an attempt to 
understand the interactions of these agonists with their recognition sites on nAChRs 
(Barlow and McLeod 1969; Barlow and Johnson 1989; Dukat et al. 1996; Nielsen et al. 
2000; Nicolotti et al. 2001). 
 
To date, several of these QSAR studies have utilized linear regression analysis of ligand-
receptor binding or function, in order to elucidate the nature of the ligand interactions 
within several nAChR receptor subtypes (Barlow and McLeod 1969; Dukat et al. 1996; 
Nielsen et al. 2000).  Of note, QSAR studies have been used to investigate ligand 
interactions at the α4β2* nAChR subtype (Dukat et al. 1996; Tonder and Olesen 2001; 
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Tonder et al. 2001).  Though generalities for the ligand interactions were drawn from the 
SARs generated, insufficient model validation limited the ability of the previously used 
models to recognize the training set of compounds.  As such, generation of a nAChR 
pharmacophore has proven difficult.  In this respect the earlier pharmacophore model 
generated by Sheridan et al. (1986), despite being based on crude pharmacological data, 
still constitutes an approach worthy of further exploration (Sheridan et al. 1986; Schmitt 
2000; Glennon et al. 2004). 
 
Another model surmises that a water molecule may mediate binding of a ligand to the 
receptor, perhaps through an interaction with the protonated nitrogen atom of the ligand 
or the hydrogen bonding acceptor moiety in the ligand molecule (Glennon et al. 2004).  
The crystallization of an acetylcholine binding protein (AChBP) from snail glia has also 
provided insight into the binding domain of the nAChR.  Brejc et al. (2001) have 
determined that the loop C (Changeux’s nomenclature) of the acetylcholine binding site 
was crystallographically less well resolved than the rest of the binding site (Brejc et al. 
2001), leading to the possibility that part of the binding site may take on different 
conformations, depending on ligand shape and size.  This represents a plausib le challenge 
to the notion of a static pharmacophore.  Due to the complexity of the nAChR molecular 
recognition process and the difficulty in obtaining high-resolution (e.g. microscopic 
kinetics) data for specific receptor subtypes, unambiguous models defining specific 
nAChR subtype pharmacophores do not yet exist. 
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It has been established previously that QSAR descriptor data has non-linear 
characteristics (Zupan and Gasteiger 1993; Rogers and Hopfinger 1994; Kohonen 2001).  
Therefore, alternative approaches such as self-organizing maps (SOMs) and the genetic 
functional approximation (GFA) algorithm have been utilized to generate QSAR for 
several biological systems (Gokhale and Kulkarni 2000; So et al. 2000; Yuan and Parrill 
2002; Schneider and Nettekoven 2003; von Korff and Steger 2004), and may be better 
suited for analysis of ligand interactions with α4β2* nAChRs.  Regression analysis 
typically employed in QSAR, such as Partial Least Squares (PLS) or Multiple Least 
Squares (MLS) are limited to relating linear descriptor trends to a given activity or 
property.  Considering the complexity in the modeling of the mono- and bis-quaternary 
ammonium salt interactions with nAChRs described in this study, we elected to use 
SOMs and GFAs in the QSAR analysis described below as one valid modeling approach. 
 
4.2. Experimental 
 
4.2.1. Biological Data 
Biological data were obtained from the [3H]NIC binding assay using rat striatal 
membranes, a well established  assay reported to identify the α4β2* subtype (Xu et al. 
2001; Ayers et al. 2002; Grinevich et al. 2003; Wilkins  et al. 2003).  The data set 
consisted of ninety-three mono- and bis-substituted quaternary ammonium compounds 
together with other related compounds developed in the Crooks laboratory, many of 
which are described in earlier section of this dissertation.  The chemical structures are 
presented in Figure 1.  Activities (e.g. α4β2* receptor affinities) are expressed as 
experimentally determined Ki values as explained in Chapter three. 
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4.2.2. Descriptor Generation 
Descriptors were generated using the chemical modeling program Cerius2 (Accelrys, Inc. 
San Diego CA) and QSARIS (MDL Information Systems Inc., San Liandro CA).  
Descriptors were divided into one of several physical property categories: 
conformational, electronic, information, molecular shape analysis (MSA), quantum 
mechanical, receptor, spatial, structural, thermodynamic, and topological.  The 
descriptors were used for the generation of both the SOMs and GFAs. 
 
4.2.3. Self-Organizing Maps with Descriptor Selection 
In order to relate bioactivity and molecular features, a set of computational models were 
developed using a custom-built stepwise descriptor selection algorithm coupled to a 
supervised SOM (Bayram et al. 2004).  The algorithm was developed using Matlab 6.1 
with the SOM Toolbox 2.0 (http://www.cis.hut.fi/projects/somtoolbox/).  Table 4.1 
contains a description of the descriptors employed in the various models. 
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Table 4.1 Descriptors utilized in the generation of SOM and GFA models 
Descriptors Description 
Area Molecular area 
CIC Complementary informational content 
E-DIST-mag Entropy of the matrix 
Fh2o Desolvation free energy for water 
Foct Desolvation free energy for octanol 
IC Informational content 
Jurs-FNSA-3 Fractional negatively charged partial surface areas 
Jurs-PNSA-1 Partial negative surface area 
Jurs-RASA Relative hydrophobic surface area 
Jurs-RPCS Relative positive charge surface area  
Jurs-WNSA-2 Surface weighted, partial negative charge  
Jurs-WNSA-3 Partial weighting of the surface accessible portions of the molecule 
Jurs-WPSA-1 Surface-weighted charged partial surface areas 
LogP Octanol/water partition coefficient 
Log Z Logarithm of the Hosoya index 
MW Molecular weight 
PHI Kier flexibility index 
S_aaCH Energy states of aromatic CH bonds 
S_aasC Energy states of the C bonds 
S_dCH2 Energy states of all CH2 groups 
S_dO Energy states of all carbonyl moieties 
S_sCH3 Energy states of all CH3 
S_ssCH2 Energy states of the CH2 bonds 
S_sssNH Energy states of all NH bonds 
S_tCH Energy states of total CH bonds 
SC-3_P Molecular connectivity index of longer chain lengths 
SIC Structural informational content 
Vm Molecular volume 
 
Datasets 
Three data sets were created: (1) both mono- and bis-salts (92 molecules; the ‘ALL’ data 
set); (2) mono-quaternary ammonium salts (69 molecules; the ‘MONO’ data set); and (3) 
bis-quaternary ammonium salts (23 molecules; the ‘BIS’ data set).  A binning scheme 
was created to convert the numerical bioactivity into categorical data since our 
implementation of SOMs works on categorical data.  The scheme assigned roughly the 
same number of molecules to each of three bins.  
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Figure 4.1 N-Alkyl quaternary ammonium salts and their affinities (Ki) at α4β2* 
nAChRs used in SOM and GFA studies 
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17.4
11.1
28.9
25.4
23.8
9.52
12.3
8.57
N
I R
N
I R
CH3
NH2
O
R= Octyl
R= Dodecyl
R= Octyl
R= Nonyl
R= Decyl
R= Undecyl
NOPiI
NDDPiI
NONAI
NNNAI
NDNAI
NUNAI
54a
54e
55a
55b
55c
55d
Ki
>100
>100
Ki
>100
>100
>100
>100
N-Alkylpicolinium Salts
N-Alkylnicotinamide Salts
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R= Methyl
R= Ethyl
R= Propyl
R= Butyl
R= Hexyl
R= Heptyl
R= Octyl
R= Nonyl
R= Decyl
R= Dodecyl
NMNI
NENI
NPNI
NnBNI
NHxNI
NHpNI
NONI
NNNI
NDNI
NDDNI
N
I R
N
CH3
H
56a
56b
56c
56d
56f
56g
56h
56i
56j
56l
R= 7-Methyloctyl
R= Octyl-cyclobutyl
R= Octyl-cyclopentyl
R= Octyl-cyclohexyl
R= Benzyl
R= Allyl
R= cis-Oct-3-enyl
R= trans-Oct-3-enyl
R= Oct-7-enyl
R= Oct-3-ynyl
R= 7-Methyl-oct-6-enyl
R= cis-Dec-4-enyl
R= trans-Dec-4-enyl
R= Dec-9-enyl
R= Dec-3-ynyl
R= Undec-10-enyl
NONB-7M
NCyNB-4
NCyNB-5
NCyNB-6
NBzNB
NANI
NONB-3c
NONB-3t
NONB-7e
NONB-3y
NONB-6e7M
NDNB-4c
NDNB-4t
NDNB-9e
NDNB-3y
NUNB-10e
63a
63b
63c
63d
63e
63f
63g
63h
63i
63j
63k
63l
63m
63n
63o
63p
Ki
0.44
4.56
5.54
7.20
2.67
2.1
0.075
3.97
0.45
0.20
0.45
7.39
0.32
0.049
0.49
0.54
Ki
3.5
1.0
22
10.9
0.53
2.1
20
0.84
0.093
0.14
N-Alkylnicotinium Salts
N
N
H
H
H3C
N
N
CH3
H
H
CH3 CH3I
I
26a   ACO    R= Octyl
26b   ACN    R= Nonyl
26c   ACD     R= Decyl
26d   ACUD  R= Undecyl
26e   ACDD  R= Dodecyl
Ki
>100
>100
>100
>100
>100
Ki
>100
>100
>100
>100
>100
Conformationally Restricted N-Alkylnicotinium Salts
25a   BCO     R= Octyl
25b   BCN     R= Nonyl
25c   BCD     R= Decyl
25d   BCUD  R= Undecyl
25e   BCDD  R= Dodecyl  
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N
N N
N
H3C
CH3
CH3
H3C
CH3
H3C
CH3
CH3
CH3
CH3
CH3
CH3
45  HEX   Ki = 31.9 63  DEC   Ki = 4.27
N
N
N
N
N
N
CH3
H3C
n = 1; X = I
n = 4; X = I
n = 5; X = Br
n = 6; X = I
n = 7; X = Br
n = 8; X = Br
n = 4; X = I
n = 5; X = Br
n = 6; X = I
n = 7; X = Br
n = 8; X = Br
n = 4; X = I
n = 5; X = Br
n = 6; X = I
n = 7; X = Br
n = 8; X = Br
bPPeI
bPOI
bPNB
bPDI
bPUB
bPDDB
bPiOI
bPiNB
bPiDI
bPiUB
bPiDDB
bQOI
bQNB
bQDI
bQUB
bQDDB
56a
56c
56d
56e
56f
56g
57b
57c
57d
57e
57f
58b
58c
58d
58e
58f
N
N
N
N
H3C
CH3
H
H
n = 4; X = I
n = 5; X = Br
n = 6; X = I
n = 7; X = Br
n = 8; X = Br
bNOI
bNNB
bNDI
bNUB
bNDDB
60b
60c
60d
60e
60f
Ki
1.50
4.31
0.28
0.37
1.43
Ki
>100
20.1
>100
38.3
>100
Ki
>100
66.7
>100
82.0
33.0
Ki
>100
33.9
24.1
18.6
14.4
9.14
bis-N,N'-Alkylpicolinium Salts
bis-Quaternary Ammonium Salts
bis-N,N'-Alkylquinolinium Salts
bis-N,N'-Alkylnicotinium Salts
 n n
bis-N,N'-Alkylpyridinium Salts
nn
2X 2X
2X2X
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In using the supervised SOM learning algorithm provided in the toolbox, this binning 
scheme allowed for a more accurate clustering of the data sets and for extracting the 
underlying commonalities of the molecules.  
Bin 1: 0 < x = 5 
Bin 2: 5 < x = 50 
Bin 3: 50 < x = 100 
The data set being modeled was partitioned into a set of test molecules (20%) and 
training molecules (80%).  Membership in the test or training set was random, with the 
one requirement that the proportion of molecular population in each bin be identical in 
both test and training sets.  The descriptor blocks for each data set were normalized to 
unit variance and mapped to a logistic function.  Descriptors with zero variance were 
removed, as were pairs with linear correlation above 0.90, retaining the most 
representative of the pair. 
 
The SOM-Stepwise Feature Reduction Algorithm 
Finally, a SOM-oriented variation of a forward entry stepwise regression algorithm was 
employed, to select a small number of independent variables from which the SOM model 
was constructed.  The algorithm used is identical to the forward entry stepwise method 
with the following variations: 
(1) the entry statistic was defined to be the percent of training set molecules 
correctly classified by the model, any increase of which resulted in the inclusion 
of the descriptors being tested;  
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(2) the entry statistic was calculated by constructing a SOM using a supervised 
learning algorithm; and, 
(3) descriptors to be entered into the model were chosen in pairs, one from each of 
two randomized lists of the full set of descriptors. 
 
Algorithm training was conducted iteratively until some convergence criteria were met. 
 
Experimental Design 
For each of the three data sets, ten independent runs were conducted, each with distinct 
training set/test set samplings.  At the end of each training process, the test set molecules 
were predicted with the trained SOM model, providing the benchmark statistic, e.g., 
‘percentage correctly classified’.  Averaging these statistics over the ten runs produced an 
estimate of the algorithm’s success in both learning the training data and generalizing to 
the test data.  Conducting multiple runs to some extent minimizes sampling bias, as well 
as bias arising from the stochastic SOM initialization process.  The best model for each of 
the three data sets was further examined using custom visualization tools, as shown in the 
Figures 4.2-4.4. 
 
4.2.4. Genetic Functional Activity Algorithms  
Genetic functional algorithms (GFAs) as described by Rogers and Hopfinger (Rogers and 
Hopfinger 1994) were implemented using Cerius2 (version 4.6) software (Accelrys Inc., 
San Diego, CA).  GFAs were conducted using static 100 member populations; linear, 
quadratic, and offset quadratic basis functions; the mutation probability for both additions 
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and deletions was set at 0.2%.  Lack of fit criterion was set at 1.0 and initial equation 
length was set to three.  Models were evolved over 50,000-80,000 generations using 
standard convergence criterion. 
 
4.3. Results and Discussion 
 
Self-Organizing Maps  
U-matrix maps represent the descriptor-based relationships of the training set of 
molecules by the SOM, and are constructed by projecting all selected descriptor’s 
contributions to the mapping.  
 
D-matrix maps  indicate the classification mapping of the SOM, as learned from the 
corresponding training sets.  All three maps illustrate strong clustering. 
 
The color level, in all the maps seen below (see Figures 4.2-4.4) describes the rela tive 
clustering in the data; the darker areas indicate small distances, while the lighter areas 
indicate larger distances.  The colored hexagons indicate the points on the map 
corresponding to training molecules, and are colored by the affinity classification and 
labeled with the corresponding training molecule names. 
 
SOM models of the ALL data set 
The ten models learned the training set with high classification accuracy (93% + 0.02) 
and were able to correctly classify the test compounds with a percent accuracy of 68% + 
0.08.  The average number of descriptors chosen via the stepwise SOM was 11, which 
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were selected from a total number of 47 descriptors.  False negative values, where the 
model placed the compound two bins removed from its actual value, were low, 
accounting for less than 2% of the failures generated by the model.  There were no false 
positives reported for any of the models.  Figure 4.2 is a graphical representation of the 
best model of the ten models generated from the ALL data set.  The descriptors selected 
by the best model were, S_dO, S_aaCH, IC, S_sCH3, S_sssNH, S_tCH, and PHI. 
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Figure 4.2 (A) D-matrix generated from the ALL data set, red numbers indicate the 
classification mapping of each node;  (B) U-matrix SOM generated from the ALL data 
set.  Key: red- class 1, green- class 2, blue- class 3.  Inter-node distances are shown in 
grey-scale coloring, the closer the distance the darker the shading. 
A)                      
B)                
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The D-matrix (Figure 4.2A) shows that there are three general clusters for the full 
complement of compounds in the ALL data set.  The descriptor, IC (informational 
content), is an information-theoretic topological index and may be identifying steric 
qualities of the molecules.  The descriptors utilized, S_dO, S_aaCH, IC, S_sCH3, 
S_sssNH, S_tCH, and PHI, by the model mostly correspond to the electrotopological (E-
Top) indices.  S_dO describes the sum of the energies of carbonyl moieties in the set 
from the N-n-alkylnicotinamide series.  As the carbonyl-containing compounds of this 
family are inactive, S_dO may be acting largely as a binary classifier.  Additionally, the 
best model used descriptors for the energy states of all CH3, aromatic CH, total CH, and 
NH bonds, e.g. S_sCH3, S_aaCH, S_tCH, and S_sssNH, respectively.  These descriptors 
may differentiate the C3-functionality of the pyridine ring; the S_dO and S_sssNH 
descriptors together likely map the SAR relative to the inclusion of the amide 
functionality at the C3-position of the pyridine ring, leading to a decrease in affinity.  
Another descriptor that may demonstrate the importance of the C3-position functionality 
is the Kier flexibility index, PHI.  The compounds in the N-n-alkylpicolinium series, 
which contain a methyl group at the C3-position of the pyridine ring, were also inactive 
and grouped with the N-n-alkylnicotinamide salts.  The active N-n-alkylnicotinium salts, 
with a 2-N-methylpyrrolidino functionality at the C3-position of the pyridine ring, 
however, were separated from the inactive compounds.  The rigidity of the methyl and 
amide functionalities when compared to the more flexible pyrrolidine ring may also be 
key to the observed affinity of these compounds at the a4ß2* nAChR. 
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The U-matrix (Figure 4.2B) reflects chemically intuitive trends; the longer saturated N-n-
alkylnicotinium salts were clustered together.  Additionally, the unsaturated N-n-
alkylnicotinium compounds, NONB-3y, NDNB-4t, and NDNB-3y, were similar in 
bioactivity and clustered near the saturated N-n-alkylnicotinium compound NNNI.  
However, NONI, the less active eight-carbon analog, was clustered among the active 
compounds, pointing to a limitation in the SOM or the descriptors.  Shorter carbon chain 
N-n-alkylnicotinium compounds and N-n-alkylpyridinium compounds were likewise 
clustered together.  Interestingly, rotationally restricted analogs were not found in the 
freely rotating N-n-alkylnicotinium compound cluster.  This reflects a bias toward their 
different affinities, as the model does not recognize the two classes as structurally similar, 
but actually classifies the restricted rotation analogs as being structurally similar to the 
longer chain N-n-alkylpyridinium analogs (NEcPB and NDDPI). 
 
A strong distinction is observed between the different structural classes of bis-substituted 
quaternary ammonium compounds.  The active bis-quaternary ammonium salts are 
closely associated with the N-n-alkylnicotinium compounds, as well as the classical 
muscle nAChR antagonist, decamethonium bromide (DEC).  The bis-quaternary 
ammonium compounds were clustered nearer to the mono-substituted N-n-
alkylpyridinium salts.  This clustering may indicate that the bis-quaternary ammonium 
compounds bind to the receptor in similar fashion as the N-n-alkylnicotinium compounds. 
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SOM models of the MONO data set 
The ten models learned the training set with high accuracy (95% ± 0.03) and were able to 
predict test compound affinities with 72% ± 0.10 accuracy.  The average number of 
descriptors chosen via the stepwise SOM regression method was 7.8 descriptors, selected 
from a total number of 42.  A 7.2 percentile of the missed assignments by the model were 
false positives.  False negatives accounted for less than 1% of the failures generated by 
the model.  Figure 4.3 is a graphical demonstration of the best model generated from the 
mono-substituted series of compounds.  From the model generated, the descriptors used 
to create the model were S_aaCH, Jurs-RASA, Jurs-PNSA-1, Foct, S_dCH2, Fh2o, and 
LogP. 
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Figure 4.3 (A) D-matrix generated from the MONO data set; (B) the U-matrix 
representation. 
A)                      
B)                       
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The mono-substituted quaternary ammonium salt model based on the MONO data set 
also demonstrated three distinct areas of clustering (Figure 4.3A) and used different 
descriptors, S_aaCH, Jurs-RASA, Jurs-PNSA-1, Foct, S_dCH2, Fh2o, and LogP, than 
those used in the ALL compound set, with only one similar descriptor, e.g. S_aaCH.  The 
model did use a similar descriptor, S_dCH2, to describe the importance of the energy 
states of all of the CH2 groups in the molecule.  One of the new descriptors, Jurs-PNSA-1 
describes the partial negative surface area (e.g. the sum of the solvent-accessible surface 
areas of all negatively charged atoms).  Also included in the model is the related Jurs-
RASA descriptor, which indicates the relative hydrophobic surface area, defined as the 
total hydrophobic surface area divided by the total molecular solvent-accessible surface 
area.  The hydrophobic character of compounds in this series appears to be a major 
determining factor for their affinity, and is supported by the three additional related 
descriptors, e.g. Foct, Fh2o, and LogP.  These descriptors are thermodynamic descriptors 
that estimate the desolvation free energy for octanol, water, and the octanol/water 
partition coefficient, respectively. 
 
The long chain N-n-alkylnicotinium salts and the unsaturated N-n-alkenylnicotinium salts 
were clustered together in the SOM model (Figure 4.3B).  These compounds share 
similar structures and similar a4ß2* nAChR affinities.  The unsaturated and saturated N-
alkylpyridinium salts were grouped together with the shorter chained N-n-
alkylnicotinium compounds, which indicates, according to the descriptors chosen, that 
both the N-alkyl chain and the pyridine C3-position substituent are important for 
determining a4ß2* nAChR affinity.  The longer chain N-n-alkylnicotinium salts 
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exhibited the highest affinities, which correlate with a larger number of lipophilic group 
(e.g. CH2 groups in the alkyl chains and in the N-methylpyrrolidine ring), whereas the 
longer chain N-n-alkylpyridinium salts and the shorter chain N-n-alkylnicotinium salts 
have fewer numbers of CH2 groups and therefore, lower affinities for the a4ß2* nAChR 
receptor. 
 
The third cluster contains two interesting compound families: N-n-alkylnicotinamide 
salts, which were inactive in the [3H]NIC binding assay, and the conformationally 
restricted N-n-alkylnicotinium analogs, which were also inactive.  The N-n-
alkylnicotinamide salts possess a hydrophilic moiety at the 3-position of the pyridinium 
ring.  Similar to many nAChR ligands, affinity at the α4β2* nAChR subtype is positively 
influenced by a hydrophobic interaction, whereas a hydrophilic moiety at the 3-position 
of the pyridinium ring serves to decrease affinity.  The low-affinity, conformationally-
restricted N-n-alkylnicotinium analogs have a high degree of hydrophobicity, and the 
model was able to differentiate them from other nicotinium molecules.  Although it is 
unclear exactly which descriptor or descriptors may map this phenomenon, it is clear that 
the SOMs can differentiate in a manner that takes into account both distributed 
(hydropathy) and localized (functional groups) determinants of the observed SAR. 
 
SOM models of the BIS data set 
The ten models learned the training set with high accuracy (98% ± 0.03) and predicted 
the test compounds with a percentage accuracy of 58% ± 0.15.  The average number of 
descriptors chosen via the stepwise SOM was 4.8 selected from a total number of 30 
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descriptors.  False positive and negative values were not observed in this model.  Figure 
4.4 is a graphical representation of the best model generated from the bis-substituted 
series of compounds.  From the model generated, the descriptors used to create the model 
were S_ssCH2, CIC, S_aasC, Jurs-RPCS, and Jurs-WNSA-3. 
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Figure 4.4 (A) D-matrix generated from the BIS dataset; (B) the U-matrix representation. 
A)                        
B)                        
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The model developed for the bis-quaternary ammonium salts based on the BIS data set 
also shows three distinct clustering areas (Figure 4.4A and 4.4B).  This model contains 
the descriptors S_ssCH2 (energy states of the CH2 bonds) and S_aasC (energy states of 
the C bonds), again stressing the importance of the lipophilic nature of these compounds.  
The model also contained the descriptor, CIC (complementary informational content), 
which is an information-theoretic topological index similar to IC and may be identifying 
steric interactions of the molecules.  The bis-quaternary ammonium salt model utilized 
the Jurs spatial descriptors to generate the model.  However, unlike the mono-N-n-
alkylated quaternary ammonium salt model, which uses a hydrophobic interaction 
descriptor, the bis-quaternary ammonium salt SOM used a positive charge surface area 
descriptor, Jurs-RPCS.  This descriptor represents the most positively charged atom and 
its relative accessible surface area.  Since these bis-molecules possess two positive 
charges, the selected descriptors may indicate an increased importance of charge 
distribution within the series.  The model also uses the Jurs-WNSA-3 descriptor, which is 
similar to the Jurs-PNSA-1 descriptor used in the mono-N-n-alkylated quaternary 
ammonium salt model, except that it represents only a partial weighting of the surface 
accessible portions of the molecule.  The highest affinity members of this data set, the 
bis-quaternary ammonium salts, were clustered together.  DEC was also clustered in the 
high affinity bin, whereas the classical ganglionic nAChR antagonist, hexamethonium 
bromide (HEX), was clustered with the lower affinity compounds, viz. the bis-
quinolinium and the bis-pyridinium salts.  Additionally, the bis-picolinium compounds 
were grouped with two of the bis-quinolinium salts in the weakest affinity set.  Therefore, 
the presence of the 2-N-methylpyrrolidine ring of the bis-nicotinium salts plays an 
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important role in determining the affinities of this series of compounds for the a4ß2* 
nAChR receptor.  It was demonstrated that a pKa shift occurs in the pyrrolidino nitrogen 
when the pyridino functionality in the NIC molecule is quaternized (Crooks et al. 1995).  
Therefore, the importance of the 2-N-methylpyrrolidine may be due to increased 
lipophilicity and/or to the possibility that the less basic nitrogen may act as a hydrogen 
bond acceptor. 
 
Genetic Functional Activity Algorithms  
Genetic Functional Algorithm Models 
 
N-Alkylpyridinium and N-Alkyl-3-substituted pyridinium salts 
The resulting equation was derived using the GFA methods: 
Ki = 161.582 + 0.004244 (Area)2 – 2.7e-5 (E-DIST-mag)2 – 5.12623 (Vm) + 36.4862 
(SC-3_P) + 0.001581 (Jurs-WPSA-1)2                                                                 (1) 
r2: 0.835734 
q2: 0.720 
The GFA methodology was applied to generate three equations for the prediction of the 
quaternary ammonium compound’s affinity at the α4β2* nAChR subtype.  Equation (1) 
was generated to correlate the descriptors to the bioactivity of all of the N-n-
alkylpyridinium salts, N-n-alkylpicolinium salts and N-n-alkylnicotinamide salts (MONO 
dataset).  The equation reveals a positive correlation with increased molecular volume 
(Vm) and area (Area), while the molecular connectivity index of longer chain lengths 
(SC-3_P) has a negative correlation.  Interestingly, the compounds in the N-n-
alkylnicotinamide series, which have larger molecular volumes than their corresponding 
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pyridinium cousins, possess less affinity toward this nAChR subtype.  Additionally, the 
affinities of the N-n-alkylnicotinamide salts were also decreased when compared to the 
simpler N-n-alkylpyridinium salts.  The GFA also had a negative correlation with the E-
DIST-mag descriptor, which describes the entropy of the matrix.  The Jurs-WPSA-1 
descriptor describes the surface-weighted charged partial surface areas; an indication that 
the positive charge distribution plays a role in receptor recognition (note that the converse 
descriptor, Jurs-PNSA-1 was used in the corresponding SOM model). 
 
N-Alkylnicotinium salts 
The resulting equation was derived using the GFA methods: 
Ki = 43.5762 + 1.0e-6 (E-DIST-mag)2 – 3.03532 (Jurs-RPCS)2 – 6862.5 (Jurs-FNSA-3)2 
+ 0.000602 (MW)2                                                                              (2) 
r2: 0.592152 
q2: 0.369 
Equation (2) models the SAR of the N-n-alkylnicotinium salts only.  As can be seen in 
equation (1), the E-DIST-mag descriptor was utilized, however, a positive correlation 
was found with this set of data.  Jurs-RPCS, a measurement of the relative positive 
surface charge, and Jurs-FNSA-3, fractional negatively charged partial surface areas, 
positively correlate with affinity for the α4β2* nAChR binding site, with the latter 
descriptor having the most weight.  Interestingly, molecular weight (MW) is also 
negatively correlated.  Since the highest affinity analogs NDDNI and NDNI (C12 and the 
C10 N-n-alkylnicotinium compounds, respectively) possess the highest molecular weight, 
the spatial partial charge interactions described by the Jurs descriptors must be more 
 159 
heavily weighted in this case.  Additionally, this data set did not include NONI, the C8 N-
n-alkylnicotinium analog.  The GFA was unable to generate a reliable model with NONI 
included, indicating that the descriptor set was likely insufficient to fully describe the 
SAR of this series. 
 
bis-Quaternary Ammonium salts 
The resulting equation was derived using the GFA methods: 
Ki = -141.363 + 1449.55 (SIC)2 + 0.000602 (Jurs-WNSA-2)2 – 47.5526 (IC)2 + 2.43134 
(Log Z)                                                                       (3) 
r2: 0.810622 
q2: 0.657 
The affinity of the bis-quaternary ammonium compounds is modeled by equation (3).  
Similar to the N-n-alkylnicotinium salts and the SOM maps, the bis-quaternary 
ammonium salts utilized a surface weighted, partial charge descriptor.  Again, the 
information-theoretic topological indices are found in the model equation.  IC and SIC 
(structural informational content) are present and may be identifying steric qualities of 
the molecules and Log Z (logarithm of the Hosoya index), which deals with connectivity 
of the molecule.  It also appears that the Jurs descriptors are effective in describing the 
SAR of the quaternary ammonium salts.  The GFA selected a surface weighted, partial 
negative charge descriptor, Jurs-WNSA, which is most likely related to a portion of the 
molecule, possibly the aromatic pyridinium ring. 
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It is important to note that although the SOM and GFA methodologies were provided the 
same set of descriptors at the outset of training, not surprisingly, models resulting from 
the two methods utilize different subsets of these descriptors.  A combination of three 
factors is thought to underlie this observation: 1) GFAs and SOMs model nonlineararity 
in fundamentally different ways; 2) each method approaches descriptor selection in 
fundamentally different ways and; 3) each have different susceptibilities to getting stuck 
in local minima. 
 
4.4. Conclusion 
Two different computational modeling methodologies were used to model the SAR of the 
interaction of quaternary ammonium compounds with the α4β2* nAChR subtype.  The 
SOM methodology was effective in appropriately grouping compounds with diverse 
structures and activities.  GFAs were also able to predict compound activities from a set 
of physical descriptions.  Taken together, the charge distribution and the hydrophobic 
free energies seem to be important indicators of bioactivity for this particular class of 
molecules.  However, both methodologies exhibited limitations when compounds with 
similar physical properties, but vastly different biological activities were evaluated.  
Nevertheless, the current work demonstrates that non- linear in silico methodologies can 
be used to screen large series of compounds, and successful models can be generated to 
aide in the selection of active compounds from larger compound libraries to be further 
evaluated. 
Copyright © Joshua Thomas Longen Ayers 2006 
 
 161 
Chapter 5: Enantioselective Synthesis of Nicotine Analogs as Precursors for the 
Preparation of Novel Quaternary Ammonium Analogs 
 
5.1. Introduction 
The principal tobacco alkaloid, NIC, is a potent agonist at nAChRs, and interacts with all 
known nAChR subtypes.  nAChR ligands modulate a number of functions within both 
the peripheral and the central nervous systems, mediated by a diversity of nAChR 
subtypes containing a2-a10 and ß2-ß4 subunits.  Interestingly, leaves from Nicotiana 
tobaccum contain a number of other minor alkaloids structurally related to nicotine, e.g., 
nornicotine, anabasine, and anatabine.  S-(-)-Nicotine is biosynthesized in the tobacco 
plant from nicotinic acid and L-ornithine or L-arginine.  Nornicotine, the second most 
abundant tobacco alkaloid, is biosynthesized via enzymatic N-demethylation of S-(-)-
nicotine; the minor alkaloid, anabasine, is generally believed to be biosynthesized from 
nicotinic acid and lysine, via a similar pathway to that described above for nicotine (Bush 
et al. 1999).  Anatabine is derived biosynthetically solely from nicotinic acid, which is 
decarboxylated to 1, 2-dihydropyridine and 2, 5-dihydropyridine followed by 
condensation of these two molecules to form 3, 6-dihydroanatabine (Bush et al. 1999).  
Aromatization of 3, 6-dihydroanatabine then affords anatabine. 
 
While nicotine in tobacco is found almost exclusively in the S-(-)-enantiomeric form 
(Crooks et al. 1992; Armstrong et al. 1999), the minor tobacco alkaloids are present as 
mixtures of their respective optical isomers (Armstrong et al. 1999).  In this respect, 
unlike nicotine, nornicotine exists as a mixture of its S-(-)- and R-(+)-enantiomeric forms 
in various ratios, depending on the species of Nicotiana from which it was isolated.  Even 
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different sources of tobacco, e.g. Burley, Turkish, or Virginia, contain different ratios of 
nornicotine enantiomers (Armstrong et al. 1999).  The presence of both enantiomeric 
forms of nornicotine in the tobacco plant results from the enzymatic N-demethylation of 
S-(-)-nicotine in the plant.  Biosynthetic studies with 2’-[3H]-nicotine have shown that the 
2’-[3H]-label is lost during formation of R-(+)-nornicotine, but is retained in the 
formation of S-(-)-nornicotine (Bush et al. 1999).  These observations suggest the 
formation of a planar intermediate in the formation of the R-(+)- isomer, and the likely 
existence of two distinct N-demethylase enzymes. 
 
The minor tobacco alkaloids are also known to possess nAChR agonist activity, and may 
contribute to the neuropharmacological effects of smoking, although they are generally 
relatively less pharmacologically active than S-(-)-nicotine (Crooks and Dwoskin 1997).  
Pharmacological investigations and structure-activity studies with these minor tobacco 
alkaloids have been somewhat limited, due to the lack of availability of their optically 
pure forms.  Previous structure-activity studies have demonstrated that the optical 
isomers of nornicotine show significant differences in their ability to bind to nicotinic 
receptors in rat brain and generally are less potent compared with nicotine (Reavill et al. 
1988; Copeland et al. 1991).  For example, S-(-)-nornicotine inhibits [3H]-nicotine 
binding to rat brain membranes with a 50-fold lower affinity (Ki = 47 nM) compared with 
nicotine (Ki = 1.0 nM) (Xu et al. 2001).  In contrast, S-(-)-nicotine and S-(-)-nornicotine 
exhibit similar affinities for the [3H]methyllycaconitine binding site (Ki = 770 nM and 
1340 nM, respectively) in brain (Xu et al. 2001).  These results indicate interaction of 
nornicotine with both a4ß2* and a7* nAChR subtypes.  Evidence has also accumulated 
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demonstrating that nornicotine enantiomers differ in their neurochemical and behavioral 
effects (Bardo et al. 1997; Crooks and Dwoskin 1997; Green et al. 2000; Green et al. 
2001).  Similar to nicotine, both enantiomers of nornicotine evoke a concentration-
dependent, Ca2+-dependent and mecamylamine-sensitive increase in DA release from rat 
striatal and nucleus accumbens slices (Dwoskin et al. 1993; Teng et al. 1997; Green et al. 
2001), indicating that nornicotine acts as an agonist at nAChR subtypes modulating DA 
release.  Interestingly, R-(+)-nornicotine was more potent than the S-(-)-enantiomer in 
evoking [3H]dopamine overflow from rat nucleus accumbens slices, whereas both 
isomers were equipotent in this respect in experiments with rat striatal slices, suggesting 
the involvement of different nicotinic receptor subtypes in these brain regions.  Whereas, 
S-(-)-nicotine and S-(-)-nornicotine were equipotent in releasing DA from striatal slices, 
nicotine was 43-fold more potent than nornicotine (EC50 = 70 nM and 3.0 µM, 
respectively) in releasing DA from nucleus accumbens slices (Green et al. 2001).  
Interestingly, nornicotine has a longer half- life than nicotine in both rodent and non-
human primate plasma and brain (Kyerematen et al. 1990; Crooks et al. 1997; Ghosheh 
et al. 1999; Valette et al. 2003); and following chronic treatment with S-(-)-nicotine, 
nornicotine (of unknown chirality) accumulates in rodent brain reaching 
pharmacologically relevant concentrations (Ghosheh et al. 2001). 
 
Behavioral studies using animal models also provide support for the use of nornicotine as 
a tobacco use cessation agent.  Nornicotine produces nicotine- like discriminative 
stimulus effects (Bardo et al. 1997), as well as nicotine- like effects on schedule-
controlled operant responding (Risner et al. 1988).  Recent results indicate that 
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nornicotine functions as a positive reinforcer (Bardo et al. 1999); however, under similar 
experimental conditions, nornicotine is associated with a lower rate of responding in 
comparison with nicotine (Corrigall and Coen 1989; Bardo et al. 1999), suggesting that 
nornicotine has a lower reinforcing efficacy.  Moreover, nornicotine has been shown to 
decrease nicotine self-administration in rats (Green et al. 2000).  Furthermore, across 
repeated nornicotine pretreatments, tolerance did not develop to nornicotine- induced 
decrease in nicotine self-administration.  Importantly, nornicotine has been recently 
found to inhibit dopamine transporter (DAT) function (Middleton et al. 2005), and thus, 
acts similarly to bupropion, which is a currently available smoking cessation agent.  In 
summary, nornicotine increases DA release and inhibits DAT function, both mechanisms 
being beneficial in the treatment of tobacco use.  Thus, a simple structural change, e.g., 
removal of the N-methyl moiety from the pyrrolidine ring of nicotine, which affords 
nornicotine, may be beneficial with respect to its pharmacological profile.  Taken 
together, these current preclinical neurochemical and behavioral results suggest that 
nornicotine could be a promising candidate for development as a tobacco cessation agent 
(Middleton et al. 2005).  In this respect, it should be noted that R-(+)-nornicotine is 
currently being investigated as a potential smoking cessation agent (Crooks et al. 1998). 
 
Dwoskin et al. (1995) have shown that S-(-)-anabasine increases fractional [3H] release in 
a concentration-dependent manner from rat striatal slices preloaded with [3H]-dopamine 
(EC50 = 19.3 ± 3.2 µM), but was less potent than S-(-)-nicotine (EC50 = 3.0 ± 2.2 µM) 
(Dwoskin et al. 1995).  Similar results have been reported by Grady et al. (1992), who 
demonstrated that (±)-anabasine stimulates [3H]-dopamine release from mouse striatal 
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synaptosomes, and (±)-anabasine has been reported to inhibit high affinity binding of 
[3H]-S-(-)-nicotine to rat and mouse striatal membranes (Reavill et al. 1988; Grady et al. 
1992).  Thus far, direct comparisons of these pharmacological properties between the 
enantiomers of anabasine and anatabine have not been determined due to difficulties in 
obtaining the pure optical isomers of each compound. 
 
Early efforts to develop synthetic routes to racemic minor tobacco alkaloids have utilized 
a variety of methods (for a comprehensive review, see Crooks, 1999).  However, few 
examples of general preparative methods for these alkaloids have been reported.  Deo and 
Crooks (1996) have utilized a benzophenone imine intermediate for the general synthesis 
of racemic nornicotine, anabasine, and anatabine, while a number of strategies have been 
developed for the enantioselective synthesis of nornicotine, anabasine and anatabine 
optical isomers (Deo and Crooks 1996; Crooks 1999; Loh et al. 1999; Yus et al. 2001), 
few of these are of general utility.  Recently, the S-(-)-isomers of nornicotine, anabasine 
and anatabine have been synthesized via a 5-step enantioselective synthesis that utilizes a 
ring-closing metathesis route (Felpin et al. 2001); also, Amat et al. (2002) have reported 
a chiral synthesis of S-(-)-anabasine from a chiral lactam intermediate (Amat et al. 2002).  
Additionally, S-(-)-anatabine has been synthesized by reacting an allylsulfone with an 
azaaromatic chiral sulfinimine (Balasubramanian and Hassner 1998). 
 
Aiqiao et al. (1991) have reported a rapid and convenient use of a 2-hydroxy-3-pinanone 
intermediate for the enantioselective synthesis of 2-pyridyl methylamines; this method 
was subsequently adapted by Swango et al. (1999) for the efficient synthesis of S-(-)- and 
R-(+)-nornicotine isomers in three steps, with a reported ee of 91% and 81%, respectively 
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(Aiqiao et al. 1991; Swango  et al. 1999).  This current study describes a general synthetic 
procedure for the facile preparation of the optical isomers of nornicotine, anabasine, and 
anatabine, utilizing modifications of the Swango et al. (1999) synthetic methodology 
(Figure 5.1), and more importantly, establishes this synthetic route as a convenient 
method for the preparation of the enantiomerically pure minor tobacco alkaloids. 
 
5.2. Experimental 
 
5.2.1. Materials 
The chemicals utilized in the synthesis of the enantiomers of nornicotine, anabasine, and 
anatabine were obtained from Aldrich Chemical Company (Milwaukee, WI), or from 
Acros Organics (Somerville, NJ), and were used without further purification.  Flash 
column chromatography was carried out using ICN SILITECH 32-63, 60Å silica gel.  
Melting points were determined on a Fisher Scientific melting point apparatus and are 
uncorrected.  1H-NMR and 13C-NMR spectra were recorded on a Varian 300 MHz NMR.  
All Spectra were referenced, and chemical shifts were determined using tetramethylsilane 
(TMS) as the internal standard.  Mass spectra were recorded on a JEOL JMS-700T 
Mstation, or on a Bruker Autoflex MALDI-TOF mass spectrometer.  Specific rotation 
measurements were carried out on a Perkin-Elmer Model 241 Polarimeter.  
Microanalyses were carried out by Atlantic Microlabs, Inc. (Atlanta, GE). 
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5.2.2. Synthetic Procedures 
Enantioselective NIC Alkaloid Synthesis 
(1R,2R,5R)- and (1S,2S,5S)- 2,6,6-Trimethyl-3-(pyridin-3-ylmethylimino)-
bicyclo[3.1.1]heptan-2-ol (67 and 67R) 
Boron trifluoride diethyl etherate (0.3 mL) was added to a solution of 3-(aminomethyl) 
pyridine (3.30 g, 30.6 mmol) and 1R,  2R,  5R-(+)-2-hydroxy-3-pinanone (5.00 g, 29.8 
mmol).  The reaction mixture was refluxed for 2.5 h under N2 using a Dean-Stark 
apparatus.  After cooling, the solvent was evaporated under reduced pressure.  The 
residue was purified by flash silica gel column chromatography us ing 
CHCl3 :hexane:methanol, 12:2:1 as the elution solvent to afford the (+)-2-hydroxy-3-
pinanone ketimine 67 (6.24 g, 81%) as white crystals after removal of solvent: [aD] = 
+3.8o (c = 1.0, methanol); 1H NMR (300 MHz, CDCl3) δ 8.58 (1H, d, J = 2.4 Hz), 8.48 
(1H, dd, J = 4.8, 1.8 Hz), 7.70 (1H, d, J = 7.8 Hz), 7.25 (1H, dd, J = 7.8, 4.8 Hz), 4.48 
(2H, s), 2.80 (1H, br s), 2.58 (2H, m), 2.34 (1H, m), 2.06 (2H, m), 1.56 (1H, d, J = 10.8 
Hz), 1.50 (3H, s), 1.31 (3H, s), 0.84 (3H, s) ppm.; 13C NMR (75 MHz, CDCl3) δ 178.19, 
149.33, 148.28, 135.81, 135.52, 123.60, 51.83, 50.46, 38.75, 38.50, 34.12, 28.56, 28.37, 
27.51, 23.11 ppm. m/z 258 (M+, base peak). 
 
The same procedure was utilized for the synthesis of 1S, 2S, 5S-(-)-2-hydroxy-3-pinanone 
ketimine (6.58 g, 85%), which was obtained as white crystals from the reaction of 1S, 2S, 
5S-(-)-2-hydroxy-3-pinanone with 3-(aminomethyl)pyridine; [aD] = -3.6o (c = 1.0, 
methanol). 
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Figure 5.1 Enantioselective Synthesis of S-(-)-Nornicotine, S-(-)-Anabasine, and S-(-)-
Anatabine 
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(S)-(-)-Nornicotine and (R)-nornicotine (3 and 3R) 
To a stirred solution of ketimine 67 (258 mg, 1.00 mmol) in THF (8 mL) was added 
dropwise LDA (1.50 mL, 2.0 M solution in THF, 3.00 mmol) at 0°C.  The purple 
solution was stirred at 0°C for 15 min then cooled to –78°C.  1-Chloro-3-iodopropane 
(0.32 mL, 3.00 mmol) in THF (2 mL) was then added dropwise.  The reaction mixture 
was stirred for an additional 30 min at –78°C, and then quenched with saturated aqueous 
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NH4Cl solution.  The solution was extracted with diethyl ether (3x10 mL).  The 
combined organic layers were washed with brine, dried over anhydrous magnesium 
sulfate, filtered, and the solvent evaporated.  The residue was passed through a short 
silica gel column, eluting with hexane, followed by CHCl3:MeOH (20:1) to give the C-
alkylated intermediate as a yellow oil.  The crude product was not purified, but 
immediately added to a mixture of 95% EtOH (6 mL), hydrazine monohydrate (4 mL) 
and acetic acid (2 mL).  The mixture was stirred overnight at room temperature and 10% 
aqueous NaOH solution (10 mL) was added.  The solution was then extracted with 
CHCl3 (3x20 mL), the combined organic liquors were dried over anhydrous magnesium 
sulfate, filtered, and the solvent evaporated.  The residue was purified by flash column 
chromatography on silica gel, eluting with CHCl3 :MeOH:Et3N (100:10:1) to afford S-(-)-
nornicotine (3) (118 mg, 79% overall) as a pale yellow oil; [aD] = -32.6o (c = 1.0, 
methanol); 1H NMR (300 MHz, CDCl3) δ  8.60 (1H, d, J = 1.8 Hz), 8.45 (1H, dd, J = 4.8, 
1,7 Hz), 7.74 (1H, “dt”, J = 7.8, 1.9 Hz), 7.25 (1H, dd, J = 7.8, 4.8 Hz), 4.14 (1H, dd, 
J=7.3, 2.1 Hz), 3.11 (2H, m), 2.20 (1H, m), 2.11 (1H, m), 1.91 (2H, m), 1.66 (1H, m) 
ppm.; 13C NMR (75 MHz, CDCl3) δ 148.3, 148.0, 140.1, 134.2, 123.2, 59.7, 46.7, 34.0, 
25.2 ppm; m/z 148 (M+). 
 
The same procedure was utilized for the synthesis of R-(+)-nornicotine (110 mg, 76% 
overall) from 1S, 2S, 5S-(-)-2-hydroxy-3-pinanone ketimine and 1-chloro-3-iodopropane, 
and the product was obtained as a pale yellow oil; [aD] = +32.8o (c = 1.0, methanol). 
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(S)-(-)-Anabasine and (R)-(+)-anabasine (5 and 5R) 
A similar procedure used to synthesize 3 was also utilized for the synthesis of S-(-)-
anabasine (5), which was obtained in 72% yield from 1R,  2R,  5R-(-)-2-hydroxy-3-
pinanone ketimine (67) using 1-chloro-4- iodobutane as the alkylating agent instead of 1-
chloro-3-iodopropane.  The product was obtained as a light-yellow oil; [aD] = -79.8o (c = 
0.9, methanol); 1H NMR (300 MHz, CDCl3) δ  8.60 (1H, s), 8.50 (1H, dt, J = 4.8, 1,7 
Hz), 7.74 (1H, dm, J = 7.8, 1.8 Hz), 7.25 (1H, dd, J = 7.8, 4.8 Hz), 3.65 (2H, dd, J=11, 
2.2 Hz), 3.22 (1H, dm, J= 11 Hz), 2.75-2.85 (1H, m), 2.00 (1H, s), 1.46-1.95 (6H, m) 
ppm.; 13C NMR (75 MHz, CDCl3) δ 148.0, 148.2, 139.9 133.7, 122.8, 59.2, 47.0, 34.00, 
24.9, 24.6 ppm.  m/z 163 (M+). 
 
Additionally, R-(+)-anabasine was synthesized in a similar manner, utilizing 1S, 2S, 5S- 
(-)-2-hydroxy-3-pinanone ketimine as the chiral intermediate, and was obtained as a pale 
yellow oil (75% yield); [aD] = +80.2 o (c = 1.0, methanol). 
 
S-(-)-Anatabine and R-(+)-anatabine  
cis-2-(4-Bromobut-2-enyloxy)tetrahydropyran (68) 
p-Toluenesulfonic acid monohydrate (0.13 g) was added to a stirred solution of cis-but-2-
ene-1,4-diol (2.64 g, 30.0 mmol) and THP (2.53 g, 30.0 mmol) in CH2Cl2 (10 mL) and 
THF (25 mL) at 0°C.  After stirring at 0 °C for 2 h, the reaction mixture was stirred at 
room temperature for a further 20 min.  Water was added, and the aqueous phase was 
extracted with diethyl ether (3x20 mL).  The combined organic layers were dried over 
anhydrous magnesium sulfate, filtered, and the solvent evaporated.  The residue was 
purified by flash column chromatography on silica gel, eluting with hexane:EtOAc, (2:1) 
 171 
to give cis-4-(tetrahydropyran-2-yloxy)but-2-en-1-ol (2.66 g, 52%) as a colorless oil: 1H 
NMR (300 MHz, CDCl3) δ 5.81 (1H, m), 5.67 (1H, m), 4.64 (1H, m), 4.15 (4H, m), 3.82 
(1H, m), 3.49 (1H, m), 1.42-1.84 (6H, m) ppm; 13C NMR (75 MHz, CDCl3) δ 132.54, 
128.11, 97.68, 62.63, 62.31, 58.50, 30.71, 25.59, 19.49 ppm. 
 
To a solution of cis-4-(tetrahydropyran-2-yloxy)but-2-en-1-ol (2.44 g, 14.2 mmol) in 
DMF (40 mL) was added triphenylphosphine (4.17 g, 15.9 mmol).  The solution was 
cooled to 0°C and NBS (2.73 g, 15.5 mmol) was added in portions.  After stirring for 30 
min at room temperature, the reaction was quenched with methanol (2 mL).  The solution 
was diluted with diethyl ether (200 mL), and washed with water, saturated aqueous 
NaHCO3, and brine, successively.  The organic layer was dried over anhydrous 
magnesium sulfate, filtered, and concentrated.  The residue was purified by flash 
chromatography on silica gel, eluting with hexane to afford the bromide 68 (2.24 g, 67%) 
as a colorless oil: 1H NMR (300 MHz, CDCl3) δ 5.86 (1H, m), 5.69 (1H, m), 4.61 (1H, 
dd, J = 4.2, 3.0 Hz), 4.31 (1H, m), 4.14 (1H, m), 4.01 (2H, d, J = 7.8 Hz), 3.84 (1H, m), 
3.51 (1H, m), 1.40-1.90 (6H, m) ppm; 13C NMR (75 MHz, CDCl3) δ 130.95, 128.41, 
98.15, 62.49, 62.08, 30.80, 26.84, 25.65, 19.67 ppm. m/z: 155 (M+-81), 133/135, 85, 53. 
 
1R, 1’S, 2R, 5R-2,6,6-Trimethyl-3-[1’-pyridin-3’’-yl-5’-(tetrahydro-pyran-2’’-
yloxy)pent-3’-enylimino]bicyclo[3.1.1]heptan-2-ol (69) 
To a stirred solution of ketimine 67 (1.94 g, 7.50 mmol) in THF (60 mL) was added 
dropwise LDA (11.3 mL, 2.0 M solution in THF, 22.6 mmol) at 0°C.  The purple 
solution was stirred at 0°C for 15 min then cooled to –78°C.  The bromide 68 (2.12 g, 
 172 
9.00 mmol) in THF (8 mL) was added dropwise.  The reaction mixture was stirred for an 
additional 30 min at –78°C, and then quenched with saturated aqueous NH4Cl solution.  
The aqueous phase was extracted with diethyl ether (3x20 mL).  The combined organic 
layers were washed with brine, dried over anhydrous magnesium sulfate, filtered, and 
evaporated.  The residue was flash chromatographed on silica gel, eluting with 
CHCl3 :hexane:MeOH (100:20:2) to give 69 (2.80 g, 91%) as a colorless oil: 1H NMR 
(300 MHz, CDCl3) δ 8.56 (1H, d, J = 2.1 Hz), 8.48 (1H, dd, J = 5.1, 1.8 Hz), 7.72 (1H, d, 
J = 7.5 Hz), 7.25 (1H, dd, J = 7.5, 4.8 Hz), 5.61 (1H, m), 5.50 (1H, m), 4.59 (2H, m), 4.19 
(1H, m), 4.01 (1H, m), 3.84 (1H, m), 3.49 (1H, m),  2.63 (3H, m), 2.44 (1H, m), 2.26 
(1H, m), 2.06 (1H, t, J = 6.3 Hz), 1.99 (1H, m), 1.62-1.88 (2H, m), 1.52 (3H, s), 1.44-1.60 
(4H, m), 1.39 (1H, d, J = 10.5 Hz), 1.31 (3H, s), 0.90 (3H, s) ppm; 13C NMR (75 MHz, 
CDCl3) shows signals for two diastereomers δ 176.13, 148.77, 148.53, 138.73 (138.70), 
134.69, 129.13 (128.98), 128.80 (128.74), 123.70, 98.17 (97.99), 62.94 (62.85), 62.46, 
61.10 (61.06), 50.26, 38.63, 37.08, 33.91, 30.90, 28.79, 28.26, 27.60, 25.71, 23.32, 19.77 
ppm. m/z: 412 (M+), 327, 311, 257, 162, 144, 85; Anal. Calcd for C25H36N2O3⋅H2O: C, 
69.74; H, 8.90; N, 6.51. Found: C, 69.80; H, 8.58; N, 6.33. 
 
1R, 1’S, 2R, 5R-3-(5’-Hydroxy-1’-pyridin-3’’-yl-pent-3’-enylimino)-2,6,6-trimethyl-
bicyclo[3.1.1]heptan-2-ol (70) 
To a solution of THP ether 69 (1.45 g, 3.52 mmol) in MeOH (90 mL) was added p-
toluenesulfonic acid (1.37 g, 7.04 mmol).  The mixture was stirred at room temperature 
for 3 h and then concentrated.  Saturated aqueous NaHCO3 solution (20 mL) was added, 
and the aqueous phase was extracted with diethyl ether (3x20 mL).  The combined 
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organic layers were washed with brine, dried over anhydrous magnesium sulfate, and 
evaporated.  The residue was flash chromatographed on silica gel, eluting with 
CHCl3 :MeOH (25:1) to give 70 (1.05 g, 90%) as a colorless oil: [aD] = –33.1° (c = 1.0, 
MeOH); 1H NMR (200 MHz, CDCl3) δ 8.51 (1H, br s), 8.44 (1H, d, J = 4.0 Hz), 7.66 
(1H, dt, J = 8.0, 2.0 Hz), 7.22 (1H, dd, J = 8.0, 5.0 Hz), 5.71 (1H, m), 5.42 (1H, m), 4.55 
(1H, dd, J = 8.4, 4.8 Hz), 4.08 (2H, m), 2.42-2.84 (4H, m), 2.16-2.38 (2H, m), 20.1 (1H, 
t, J = 6.0 Hz), 1.94 (1H, m), 1.50 (3H, s), 1.33 (1H, d, J = 11.4 Hz), 1.27 (3H, s), 0.85 
(3H, s) ppm; 13C NMR (75 MHz, CDCl3) δ 177.81, 148.78, 148.69, 138.69, 134.68, 
131.98, 128.25, 123.85, 76.79, 60.45, 58.64, 50.55, 38.52, 38.46, 37.23, 34.15, 28.52, 
28.13, 27.41, 23.13 ppm. m/z: 329 (M++1); Anal. Calcd for C20H28N2O2⋅0.3CHCl3: C, 
66.93; H, 7.83; N, 7.69.  Found: C, 67.16; H, 7.94; N, 7.77. 
 
S-5-Amino-5-pyridin-3-yl-pent-2-en-1-ol (71) 
To a solution of 70 (0.86 g, 2.6 mmol) in MeOH (40 mL) was added hydroxylamine 
hydrochloride (1.39 g, 20.0 mmol).  The mixture was stirred at room temperature for  
18 h. Ammonia gas was bubbled into the solution to adjust the pH to 9.  The MeOH was 
then evaporated and CHCl3 (15 mL) was added to the residue.  The resulting mixture was 
filtered and the filtrate was concentrated.  The resulting residue was flash 
chromatographed on silica gel, eluting with CHCl3 :MeOH:Et3N (100:10:1) to give 71 
(0.34 g, 74%) as a colorless oil: [aD] =  –44.3° (c = 1.0, MeOH); 1H NMR (200 MHz, 
CDCl3) δ 8.53 (1H, d, J = 2.4 Hz), 8.46 (1H, dd, J = 4.8, 1.6 Hz), 7.68 (1H, dt, J = 7.6, 
1.8 Hz), 7.24 (1H, dd, J = 7.4, 5.0 Hz), 5.85 (1H, m), 5.47 (1H, m), 3.90-4.20 (3H, m), 
2.30-2.60 (5H, m) ppm; 13C NMR (50 MHz, CDCl3) δ 149.00, 148.65, 140.70, 134.10, 
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133.01, 128.43, 123.80, 57.84, 52.73, 37.42 ppm. m/z: 179 (M++1); Anal. Calcd for 
C10H14N2O⋅0.2H2O: C, 66.05; H, 7.98; N, 15.41.  Found: C, 66.23; H, 7.91; N, 15.37. 
 
S-(-)-Anatabine and R-(+)-anatabine (6 and 6R) 
Diethyl azodicarboxylate (DEAD, 0.23 mL, 1.40 mmol) was added dropwise to a stirred 
solution of triphenyl phosphine (365 mg, 1.40 mmol) in THF (6 mL) at 0°C under N2.  
The reaction mixture was stirred at 0°C for 20 min.  A solution of 71 (178 mg, 1.00 
mmol) in THF (3 mL) was then added dropwise.  The mixture was stirred at 0°C for 30 
min, and then at room temperature for 2 h.  Evaporation of the solvent followed by 
purification of the residue by flash column chromatography on silica gel (CHCl3 :MeOH, 
20:1) gave S-(-)-anatabine (6) (124 mg, 77%) as a colorless oil: [aD] = -180o (c = 1.0, 
methanol); 1H NMR (300 MHz, CDCl3) δ 8.56 (1H, d, J = 1.6 Hz), 8.46 (1H, dd, J = 4.8, 
1.6 Hz), 7.68 (1H, dt, J = 8.0, 1.8 Hz), 7.23 (1H, dd, J = 4.0, 2.8 Hz), 5.79 (2H, m), 3.84 
(1H, t, J = 7.0 Hz), 3.33-3.65 (2H, m), 2.21 (2H, m), 2.00 (1H, br s) ppm; 13C NMR (75 
MHz, CDCl3) δ 148.93, 148.82, 140.05, 134.29, 126.46, 125.26, 123.71, 55.44, 46.12, 
34.01 ppm. m/z: 160 (M+, base peak), 159, 145, 131, 118, 105, 80, 54. 
 
The same procedure was utilized for the synthesis of R-(+)-anatabine from 1S, 2S, 5S-(-)-
2-hydroxy-3-pinanone ketimine and cis-2-(4-bromobut-2-enyloxy)tetrahydropyran, 
which was obtained as a pale yellow oil (70% yield); [aD] = +177o (c = 1.0, methanol). 
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5.3. Results and Discussion 
The R- and S-enantiomers of nornicotine, anabasine, and anatabine were successfully 
synthesized in good to moderate yields, and in good enantiomeric purity.  The stereo-
controlled C-alkylation of the 2-hydroxy-3-pinanone-3-(aminomethyl)pyridine ketimine 
intermediate is the key step in the reaction sequence.  Experimental evidence from the 
crystal structure of the ketimine (Ayers et al., 2005) formed during the C-alkylation step 
supports the findings that the (+)-ketimine is C-alkylated from the re face of the (-)-
ketimine- lithium complex.  This alkylation affords the S- isomer exclusively, while the C-
alkylated product with the R-configuration is generated from the (-)-ketimine-lithium 
complex.  LDA was chosen from a number of possible catalytic bases, including 
KtBuOH, due to the higher yields obtained, and because of the improvement in purity of 
the isolated products when using this base.  As determined by Aiqiao et al., the base 
(LDA) forms a stable complex with the ketimine, effectively blocking the si face of the 
molecule and opening the re face of the molecule to addition of an alkyl halide (Figure 
5.2) (Aiqiao et al. 1991).   
 
Figure 5.2 Stable carbanion (+)-ketimine intermediate. 
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An advantage in the above procedure over previously reported literature syntheses of R-
(+)- and S-(-)-nornicotine, and R-(+)- and S-(-)-anabasine isomers is the small number of 
overall steps to achieve the formation of the desired alkaloids.  In an earlier approach to 
that outlined above, Swango et al. (1999) utilized the 2-hydroxy-3-pinanone-3-
(aminomethyl)pyridine ketimine reagent in the synthesis of nornicotine isomers, but C-
alkylation was carried out with a halogenoalcohol, to afford an intermediate  N-
alkylhydroxy analog, which had to be isolated and converted to the corresponding N-
alkylbromo analog, prior to cyclization to afford the final product.  The current synthesis 
outlined in this paper constitutes a two-step, general procedure for the synthesis of the 
optical isomers of both nornicotine and anabasine, by utilizing a 1, 4-dihalogeno alkane 
instead of a halogenoalcohol in the C-alkylation of the ketimine.  This change reduces the 
number of steps in the reaction sequence from three to two, and significantly simplifies 
the work-up procedure for obtaining the final chiral product.  Attempts at utilizing 
diiodopropane or diiodobutane in the reaction resulted in lower yields of reaction 
products.  The use of a chloroiodoalkane reactant affords rapid and more efficient C-
alkylation of the ketimine, but slow solvolytic degradation at the chloro-terminus.  This 
allows for flash silica gel column purification to be performed, thereby obtaining a stable 
intermediate for the final cyclization event of the reaction sequence in the presence of 
hydrazine and water. 
 
In addition to Swango et al., other groups have successfully synthesized nornicotine and 
anabasine enantiomerically pure (Felpin et al. 2001; Amat et al. 2002).  However, both 
these syntheses are five steps and result in lower overall yields.  Felpin et al., utilize a 
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novel approach, employing ring closuring metathesis.  Though this synthesis resulted in 
high enantioselective yields the metal used in the final cyclization step is expensive and 
the final step is significantly longer than the ketimine synthesis. 
 
The above procedure can also be utilized for the synthesis of anatabine enantiomers.  
However, three steps are required to introduce the C-hydroxy-cis-alkene substituent at the 
α-carbon of the 2-hydroxy-3-pinanone-3-(aminomethyl)pyridine ketimine, followed by a 
final cyclization step using a Mitsunobu reaction.  Nevertheless, this synthetic route is 
very favorably comparable to previously reported enantioselective syntheses of anatabine 
described by Balasubramanian and Hassner (1998), and by Mehmandoust et al. (1989), 
both of which involve five steps overall (Mehmandoust et al. 1989; Balasubramanian and 
Hassner 1998).  The methodology outlined by Balasubramanian and Hassner could not 
definitively rule out the presence of an enantiomer in the final steps.  The resulting 
enantiomeric yields were only 70% and the overall yield was 60%.   
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5.4. Conclusions  
Successful adaptation and improvement of an existing methodology has allowed for a 
streamlined approach in the stereoselective synthesis of the enantiomers of the nicotinic 
analogs, nornicotine, anabasine, and anatabine.  A two-step synthetic procedure for the 
enantioselective synthesis of the optical isomers of nornicotine and anabasine, and a 
modified procedure for the synthesis of anatabine enantiomers have been successfully 
developed, and all compounds were synthesized in good yields and high enantiomeric 
purity.  Due to this purity, these compounds are ideal to use as precursors for another 
generation of quaternary ammonium analogs.  
 
 
 
 
 
 
 
 
 
 
 
 
Copyright © Joshua Thomas Longen Ayers 2006 
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Chapter 6: Summary and Future Directions  
 
6.1. Summary 
This research project successfully utilized the introductory phases of the drug discovery 
process in order to explore neuronal nAChR subtypes.  Previous research indicated that 
NONI and NDNI were selective and potent antagonists for the nAChRs that mediate DA 
release and for α4β2* nAChR subtypes, respectively.  Synthetic analogs of NONI and 
NDNI were synthesized and evaluated at a4ß2*, a7* and nAChRs that mediate DA 
release to create a structure activity relationship and afforded potent and selective 
antagonists.  The [3H]NIC binding data were also used to create predictive models for the 
binding of these series of compounds to a4ß2* receptor subtypes.  Additionally, new 
enantioselective synthetic routes were developed to afford optically pure NIC analogs. 
 
6.1.1. Quaternary Ammonium Analogs 
In order to begin the drug discovery process, a series of compounds were designed based 
on initial work on NONI and NDNI and synthesized.  Many of the compounds were 
isolated in high yields, and all were obtained in high purity and fully characterized.  In 
the N-n-alkylnicotinium series, in order to selectively N-alkylate the pyridyl N-atom of  
S-(-)-nicotine, a protonation of the pyrrolidine N-atom, using an adaptation on the 
Menshutkin reaction using acetic acid, was necessary.  Purification of the resulting 
compounds was especially important, due to the need to eliminate nicotine completely 
from the product, as it would interfere with pharmacological evaluation in the binding 
and release assays.  Additionally, the N-N-bis-compounds, although similar in structure, 
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proved difficult to isolate and purify, and several different work-up techniques had to be 
developed. 
 
The mono-quaternary ammonium compounds evaluated had a variety of nAChR 
antagonist activities, depending on the length of the chain, as well as the nature of the 3-
pyridyl substituent.  N-n-Alkylnicotinium salts exhibited antagonist activity at both 
α4β2* receptor subtypes and nAChR subtypes that mediate DA release depending on 
alkyl chain length, while having little to no affinity for the α7* receptor subtype.  From 
these studies, NDDNI has emerged as a potential tool for antagonism of the α4β2* 
receptor subtype.  The activities of the N-n-alkylpyridinium, N-n-alkylpicolinium, and N-
n-alkylnicotinamide salts have also led to a better understanding of how the N-n-
nicotinium series of compounds may be interacting with the α4β2* binding site, and has 
highlighted the importance of the pyrrolidine ring as a necessary component to obtain 
antagonist activity.  The length of the N-n-alkyl substituent is also an important 
determinant of the antagonist activity of these molecules, as evidenced by the increased 
activities when the chain length increased for the N-n-alkylpicolinium and N-n-
alkylnicotinium salts. 
 
In contrast to the α4β2* receptor subtype, the pyrrolidine ring of the NONI molecule was 
found not to be critical for binding to and inactivation of nAChR subtypes that mediate 
DA release.  However, the presence of the pyrrolidine ring did afford the most potent 
antagonist, NDDNI.  In addition to the N-n-alkylnicotinium compounds, the N-n-alkyl 
pyridinium and N-n-alkylpicolinium compounds were generally active in inhibiting NIC-
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evoked DA release from rat striatal slices, and had relatively lower affinity for α4β2* and 
α7* nAChR subtypes.  Thus, removal of the pyrrolidine ring from the N-n-
alkylnicotinium series afforded a series of compounds which exhibited an increase in 
antagonist potency for the nAChR subtypes that mediate DA release, while having little 
or no activity in α4β2* and α7* nAChR subtypes.  This supports the idea that there is a 
difference in the binding domains of α4β2* nAChR subtypes, α7* nAChR subtypes, and 
certain nAChRs that mediate DA release. 
 
The bis-quaternary ammonium compounds also demonstrated activity at the various 
nAChR subtypes.  N,N-bis-alkylnicotinium compounds were found to be selective 
antagonists at a4ß2* receptor subtypes, similar to the N-n-alkylnicotinium series.  
However, unlike the N-n-alkylnicotinium series, the N,N-bis-alkylnicotinium compounds 
were not the most potent antagonists at the receptors that mediate NIC-evoked DA 
release.  N,N-bis-Dodecylpicolinium (bPiDDB) proved to be the most potent antagonist 
at the receptors that mediate NIC-evoked DA release.  That, coupled with it inactivity at 
a4ß2* and a7* receptor subtypes, make this compound the most potent and selective 
compound in the all the series tested.  Furthermore, the lack of a4ß2* activity and the 
partial antagonist effect of bPiDDB in the NIC-evoked DA overflow assay, allows for a 
putative assignment of the antagonist activity occurring at α6β2β3 and α6α4β2β3 
nAChR subtypes.  bPiDDB is an excellent lead candidate for exploring the these nAChR 
subtypes due to it pharmacological profile.  In addition to its laboratory utility, acute 
dosing of bPiDDB has recently been shown to decrease nicotine self-administration in 
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rats and may be used as a lead compound for clinical development (Neugebauer et al. 
2006). 
 
The only compounds that were found to be active in the α7* MLA binding assay were 
the heteroaromatic analogs (i.e. N,N-bis-isoquinolinium and N,N-bis-quinolinium salts).  
Within these series of compounds, the most potent analog was bQDDB, the twelve-
carbon quinoline analog, suggesting that the position of the extended aromatic ring is an 
important aspect to the binding of these compounds. 
 
6.1.2. Modeling 
Using several different classes of quaternary ammonium salts, two different established 
molecular modeling techniques were applied to create a novel approach to SAR studies.  
Three self-organizing map (SOMs) models were generated from three different sets of 
compounds.  The groups consisted of the mono-substituted compounds, the bis-
substituted compounds, and both sets combined.  The models were able to successfully 
"bin" the test set of compounds after developing a model from a similar set of training 
compounds.  Additionally, using genetic functional activity (GFA) algorithms an 
evolutionary approach to generating predictive model equations was applied to the 
compounds.  Three separate equations were generated in order to form a predictive 
method for evaluating affinities at the α4β2* receptor subtype. 
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6.1.3. Synthesis of Enantiomerically Pure Nicotinic Analogs 
In addition to the modeling and SAR work of the quaternary ammonium compounds, 
novel synthetic methods were also employed to develop enantiomerically pure nicotine 
analogs.  Efficient enantioselective syntheses of (S)- and R-(+)-nornicotine, (S)-and R-
(+)-anabasine, and (S)-and R-(+)-anatabine have been developed, affording isomers in 
high enantiomeric excess.  
 
6.2. Future Directions 
The three areas of focus of this project can all be expanded.  Evaluation of the quaternary 
ammonium pyridinium analogs in the functional [3H]DA release assay, as well as in the 
86Rb+ efflux assay, is necessary for a complete functional profile to be obtained on each 
compound in each of these series.  Additionally, those compounds that had affinity for 
the α7* nAChR subtype should be tested for their functional activities.  Once the 
functional profile was complete for these compounds, further study of their mode of 
action would be important.  Of considerable interest would also be the functional activity 
of the nicotinamide analogs at nAChRs that mediate DA release.  The compounds 
provide a different functional 3-position substituent with different electronic properties.  
This would allow probing the H-bonding binding area of the nAChRs that mediate DA 
release. 
 
In addition to further testing, novel pyridinium compounds could also be preformed on 
those compounds that were synthesized in Chapter 5.  S-(-)- and R-(+)-Nornicotine (3 
and 3R), S-(-)- and R-(+)-anabasine (5 and 5R), S-(-)- and R-(+)-anatabine (6 and 6R), as 
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well as their N-methylated derivatives, could be quaternized with various chain lengths, 
(Figure 6.1).   
 
Figure 6.1 N-Alkylated quaternary ammonium salts of S-(-)- and R-(+)-Nornicotine (72 
and 73), S-(-)- and R-(+)-anabasine (74 and 75), S-(-)- and R-(+)- anatabine (76 and 77), 
and their methylated derivatives (78, 79, 80, 81, and 82). 
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Novel synthetic compounds may also be synthesized using the techniques outlined in 
Chapter 5.  Although the racemic forms of azetidine and azepine NIC analogs have been 
synthesized, no enantioselective syntheses of these compounds have so far been reported.  
Using the enantioselective synthetic route developed for nornicotine, anabasine, and 
anatabine, synthesis of enantiomerically pure forms of these compounds may be possible. 
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To better direct the next generation of compounds in these series, the computational 
models developed from the initial SAR study of the α4β2* may be used predictively to 
determine active compounds in silico.  Additionally, predictive models could be 
developed for nAChR subtypes that mediate DA release and α7* nAChR subtypes, as 
more data become available. 
 
One of the advantages of the peripheral antagonists, DEC and HEX, is that their 
quaternary ammonium cationic nature does not allow for their passage into the central 
nervous system (CNS), therefore isolating their antagonist activity to nAChRs in the 
periphery.  Although several of these compounds have excellent chloroform solubility 
and could theoretically pass into the CNS, it is not certain if a quaternary ammonium 
molecule can passively enter the blood-brain barrier (BBB).  Active transport into the 
CNS, via the choline transporter may allow the passage of such quaternary ammonium 
molecules.  Allen et al. (2003) have investigated NONI, NDNI, NOPI, binding to the 
BBB choline transporter and found that these salts do have affinity (27 – 49 µM) for the  
transporter binding site.  Research on the bis-azaaromatic quaternary ammonium analogs, 
revealed that bPiDDB also had affinity for the BBB choline transporter (1.57 µM).  
Furthermore, it was determined that radiolabeled NONI and bPiDDB are both transported 
via the BBB choline transporter into the CNS (Allen et al. 2003; Geldenhuys et al. 2005).  
Another possible strategy for delivery of these pyridinium compounds across the BBB 
into the CNS involves the synthesis of a pyridinium head group designed to be a 
bioprecursor of these compounds.  Bodor et al. (1990) have designed uncharged stable 
dihydropyridine analogs that do not rearomatize due to the presence of a C3 or C5 
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electron withdrawing substitution.  Once the reduced product passes the BBB, the CNS 
enzyme monoamine oxidase-B (MAO-B) oxidizes the dihydropyridine analog to the 
quaternary ammonium compound that is active at neuronal nAChRs.  This could be 
important in establishing a delivery method for this class of compounds, and would 
further the potential use of these compounds in nAChR related pathologies. 
 
6.3. Conclusion 
There is much to explore regarding the pharmacology of the neuronal nAChRs and the 
interaction of potential drug molecules with these receptors.  The studies described herein 
have provided initial useful information that may be helpful in determining the functional 
properties of the individual nAChR subtypes, as well as in developing new synthetic 
methods for the preparation of novel compounds to add to the library of ligands available 
for probing the function of the various nAChR subtypes.  Additionally, using established 
modeling techniques, new predictive models could be developed and utilized to increase 
the probability of success in the discovery of biologically active compounds with clinical 
potential.  Using these methodologies allows for the successful identification of potent 
and selective nAChR ligands, of utility in unraveling the complexities of neuronal 
nAChRs, as well as having potential therapeutic uses in the clinic. 
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List of Abbreviations  
 
α-Btx  α-Bungarotoxin 
α-CBT  α-Cobratoxin 
α-ctx α-Conotoxins 
5-HT Serotonin 
ACh  Acetylcholine 
AChBP  Acetylcholine binding protein 
AD  Alzheimer’s disease 
ADME  Absorption, distribution, metabolism, and elimination 
AMPA  α-amino-3-hydroxy-5-methyl-4- isoxazolepropionate 
ANOVA  One-way repeated-measure analysis of variance 
Atx  (+)-Anatoxin-a 
BBB  Blood-brain barrier 
CHCl3  Chloroform 
CNS  Central nervous system 
CoMFA  Comparative molecular field analysis 
Cyt  Cytisine 
DA Dopamine 
DAT Dopamine transporter 
DCEH (R)-descholoroepibatidine 
DEAD  Diethyl azodicarboxylate 
DEC  Decamethonium 
DHβE  Dihydro-β-erythroidine 
DMF   N,N-Dimethylformamide 
d-TC  d-Tubocurarine 
Epi Epibatidine 
Et3N  Triethylamine 
EtOAc  Ethyl acetate 
EtOH  Ethanol 
ETX-a  Erabutoxin-a  
ETX-b Erabutoxin-b 
FDA  Food and Drug Administration 
GABAA  Gamma-aminobutyric acid 
GFA Genetic functional approximation algorithm 
HEK  Human embryonic kidney 
HEPES  N-[2-Hydroxyethyl]piperazine-N’-[2-ethanesulfonic acid] 
HEX  Hexamethonium 
IND  Investigational new drug application 
KtBuOH  Potassium tert- butoxide 
LDA  Lithium diisopropylamide 
L-DOPA L-Dihydroxyphenylanine 
LOB  Lobeline 
LTX  Lophotoxin 
MAO-B  Monoamine oxidase-B 
MEC  Mecamylamine 
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MeOH  Methanol 
MLA  Methyllycaconitine 
MLS  Multiple least squares 
MSA  Molecular shape analysis 
nAChR  Nicotinic acetylcholine receptor 
NaHCO3   Sodium bicarbonate 
NBS N-bromosuccinimide 
n-Btx  Neuronal bungarotoxin 
NDA  New drug application 
NIC Nicotine 
NMDA  N-Methyl-D-aspartate 
NSAID  Nonsteroidal anti- inflammatory drug 
NSTX Neosurugatoxin 
NT Neurotransmitter 
OCB  Open channel blockers 
PD Parkinson’s disease 
PEI  Polyethylenimine 
PLS  Partial least squares  
QSAR Quantitative structure-activity relationship 
R-NIC R-(+)-Nicotine 
SAR  Structure-activity relationship 
SOM  Self-organizing map 
THF   Tetrahydrofuran 
THP   Tetrahydropyran 
Trizma HCl  Tris[hydroxymethyl]-aminomethane hydrochloride 
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